BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hamaguchi M, Kojima T, Takeda N, Nakagawa T, Taniguchi H, Fujii K, Omatsu T, Nakajima T, Sarui H, Shimazaki M, Kato T, Okuda J, Ida K. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med. 2005;143:722-728. [PMID: 16287793 DOI: 10.7326/0003-4819-143-10-200511150-00009] [Cited by in Crossref: 700] [Cited by in F6Publishing: 614] [Article Influence: 43.8] [Reference Citation Analysis]
Number Citing Articles
1 Chen Y, Wu S, Tian Y. Cholecystectomy as a risk factor of metabolic syndrome: from epidemiologic clues to biochemical mechanisms. Lab Invest 2018;98:7-14. [PMID: 28892095 DOI: 10.1038/labinvest.2017.95] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 4.8] [Reference Citation Analysis]
2 Sauerbeck AD, Laws JL, Bandaru VV, Popovich PG, Haughey NJ, McTigue DM. Spinal cord injury causes chronic liver pathology in rats. J Neurotrauma 2015;32:159-69. [PMID: 25036371 DOI: 10.1089/neu.2014.3497] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 6.1] [Reference Citation Analysis]
3 La Carrubba S, Antonini-Canterin F, Fabiani I, Colonna P, Pugliese NR, Caso P, Conte L, Benedetto F, Zito C, Citro R, Carerj S, Di Bello V. Prevalence and Prognostic Impact of Metabolic Syndrome in Asymptomatic (Stage A and B Heart Failure) Patients. Metab Syndr Relat Disord 2016;14:187-94. [PMID: 26866978 DOI: 10.1089/met.2015.0143] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
4 Moscatiello S, Di Luzio R, Sasdelli AS, Marchesini G. Managing the combination of nonalcoholic fatty liver disease and metabolic syndrome. Expert Opin Pharmacother. 2011;12:2657-2672. [PMID: 22043839 DOI: 10.1517/14656566.2011.629188] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
5 Cai XT, Ji LW, Liu SS, Wang MR, Heizhati M, Li NF. Derivation and Validation of a Prediction Model for Predicting the 5-Year Incidence of Type 2 Diabetes in Non-Obese Adults: A Population-Based Cohort Study. Diabetes Metab Syndr Obes 2021;14:2087-101. [PMID: 34007195 DOI: 10.2147/DMSO.S304994] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Kina-tanada M, Sakanashi M, Tanimoto A, Kaname T, Matsuzaki T, Noguchi K, Uchida T, Nakasone J, Kozuka C, Ishida M, Kubota H, Taira Y, Totsuka Y, Kina S, Sunakawa H, Omura J, Satoh K, Shimokawa H, Yanagihara N, Maeda S, Ohya Y, Matsushita M, Masuzaki H, Arasaki A, Tsutsui M. Long-term dietary nitrite and nitrate deficiency causes the metabolic syndrome, endothelial dysfunction and cardiovascular death in mice. Diabetologia 2017;60:1138-51. [DOI: 10.1007/s00125-017-4259-6] [Cited by in Crossref: 42] [Cited by in F6Publishing: 33] [Article Influence: 10.5] [Reference Citation Analysis]
7 van der Voort EA, Koehler EM, Dowlatshahi EA, Hofman A, Stricker BH, Janssen HL, Schouten JN, Nijsten T. Psoriasis is independently associated with nonalcoholic fatty liver disease in patients 55 years old or older: Results from a population-based study. J Am Acad Dermatol. 2014;70:517-524. [PMID: 24373781 DOI: 10.1016/j.jaad.2013.10.044] [Cited by in Crossref: 85] [Cited by in F6Publishing: 68] [Article Influence: 10.6] [Reference Citation Analysis]
8 Liu L, Yu Y, Zhao M, Zheng D, Zhang X, Guan Q, Xu C, Gao L, Zhao J, Zhang H. Benefits of Levothyroxine Replacement Therapy on Nonalcoholic Fatty Liver Disease in Subclinical Hypothyroidism Patients. Int J Endocrinol 2017;2017:5753039. [PMID: 28473851 DOI: 10.1155/2017/5753039] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 5.8] [Reference Citation Analysis]
9 Yoshioka N, Ishigami M, Watanabe Y, Sumi H, Doisaki M, Yamaguchi T, Ito T, Ishizu Y, Kuzuya T, Honda T, Ishikawa T, Haruta JI, Fujishiro M. Effect of weight change and lifestyle modifications on the development or remission of nonalcoholic fatty liver disease: sex-specific analysis. Sci Rep 2020;10:481. [PMID: 31949229 DOI: 10.1038/s41598-019-57369-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
10 Hamaguchi M, Kawahito Y, Takeda N, Kato T, Kojima T. Characteristics of chronic fatigue syndrome in a Japanese community population : chronic fatigue syndrome in Japan. Clin Rheumatol. 2011;30:895-906. [PMID: 21302125 DOI: 10.1007/s10067-011-1702-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
11 Annaloro C, Airaghi L, Saporiti G, Onida F, Cortelezzi A, Deliliers GL. Metabolic syndrome in patients with hematological diseases. Expert Review of Hematology 2014;5:439-58. [DOI: 10.1586/ehm.12.35] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
12 Stephenson K, Kennedy L, Hargrove L, Demieville J, Thomson J, Alpini G, Francis H. Updates on Dietary Models of Nonalcoholic Fatty Liver Disease: Current Studies and Insights. Gene Expr. 2018;18:5-17. [PMID: 29096730 DOI: 10.3727/105221617x15093707969658] [Cited by in Crossref: 40] [Cited by in F6Publishing: 24] [Article Influence: 10.0] [Reference Citation Analysis]
13 Ali R, Cusi K. New diagnostic and treatment approaches in non-alcoholic fatty liver disease (NAFLD). Ann Med. 2009;41:265-278. [PMID: 19353360 DOI: 10.1080/07853890802552437] [Cited by in Crossref: 77] [Cited by in F6Publishing: 66] [Article Influence: 6.4] [Reference Citation Analysis]
14 Graffy PM, Pickhardt PJ. Quantification of hepatic and visceral fat by CT and MR imaging: relevance to the obesity epidemic, metabolic syndrome and NAFLD. Br J Radiol 2016;89:20151024. [PMID: 26876880 DOI: 10.1259/bjr.20151024] [Cited by in Crossref: 46] [Cited by in F6Publishing: 40] [Article Influence: 9.2] [Reference Citation Analysis]
15 Musso G, Bo S, Cassader M, De Michieli F, Gambino R. Impact of sterol regulatory element-binding factor-1c polymorphism on incidence of nonalcoholic fatty liver disease and on the severity of liver disease and of glucose and lipid dysmetabolism. Am J Clin Nutr. 2013;98:895-906. [PMID: 23985808 DOI: 10.3945/ajcn.113.063792] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 3.6] [Reference Citation Analysis]
16 Wenk KS, Arrington KC, Ehrlich A. Psoriasis and non-alcoholic fatty liver disease. J Eur Acad Dermatol Venereol. 2011;25:383-391. [PMID: 20840346 DOI: 10.1111/j.1468-3083.2010.03841.x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 3.1] [Reference Citation Analysis]
17 Sanders FW, Griffin JL. De novo lipogenesis in the liver in health and disease: more than just a shunting yard for glucose. Biol Rev Camb Philos Soc. 2016;91:452-468. [PMID: 25740151 DOI: 10.1111/brv.12178] [Cited by in Crossref: 153] [Cited by in F6Publishing: 127] [Article Influence: 25.5] [Reference Citation Analysis]
18 van Werven JR, Schreuder TC, Aarts EO, Nederveen AJ, Meijer JW, Berends FJ, Janssen IM, Mulder CJ, Jansen PL, Stoker J. Hepatic steatosis in morbidly obese patients undergoing gastric bypass surgery: assessment with open-system 1H-MR spectroscopy. AJR Am J Roentgenol 2011;196:W736-42. [PMID: 21606262 DOI: 10.2214/AJR.10.5215] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
19 Chitturi S, Farrell GC. Fatty liver now, diabetes and heart attack later? The liver as a barometer of metabolic health. J Gastroenterol Hepatol 2007;22:967-9. [DOI: 10.1111/j.1440-1746.2007.04995.x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 2.6] [Reference Citation Analysis]
20 Roberts CK, Sindhu KK. Oxidative stress and metabolic syndrome. Life Sciences 2009;84:705-12. [DOI: 10.1016/j.lfs.2009.02.026] [Cited by in Crossref: 507] [Cited by in F6Publishing: 408] [Article Influence: 42.3] [Reference Citation Analysis]
21 Wong VW, Wong GL, Tsang SW, Hui AY, Chan AW, Choi PC, So WY, Tse AM, Chan FK, Sung JJ. Genetic polymorphisms of adiponectin and tumor necrosis factor-alpha and nonalcoholic fatty liver disease in Chinese people. J Gastroenterol Hepatol. 2008;23:914-921. [PMID: 18565022 DOI: 10.1111/j.1440-1746.2008.05344.x] [Cited by in Crossref: 51] [Cited by in F6Publishing: 46] [Article Influence: 3.9] [Reference Citation Analysis]
22 Uslusoy HS, Nak SG, Gülten M. Noninvasive predictors for liver fibrosis in patients with nonalcoholic steatohepatitis. World J Hepatol 2011;3:219-27. [PMID: 21954411 DOI: 10.4254/wjh.v3.i8.219] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
23 Banderas DZ, Escobedo J, Gonzalez E, Liceaga MG, Ramírez JC, Castro MG. γ-Glutamyl transferase: a marker of nonalcoholic fatty liver disease in patients with the metabolic syndrome. Eur J Gastroenterol Hepatol. 2012;24:805-810. [PMID: 22546752 DOI: 10.1097/meg.0b013e328354044a] [Cited by in Crossref: 29] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
24 Younossi ZM, McCullough AJ. Metabolic syndrome, non-alcoholic fatty liver disease and hepatitis C virus: impact on disease progression and treatment response. Liver Int. 2009;29 Suppl 2:3-12. [PMID: 19187068 DOI: 10.1111/j.1478-3231.2008.01949.x] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 3.3] [Reference Citation Analysis]
25 Farrell GC. The liver and the waistline: Fifty years of growth. J Gastroenterol Hepatol. 2009;24 Suppl 3:S105-S118. [PMID: 19799688 DOI: 10.1111/j.1440-1746.2009.06080.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 2.9] [Reference Citation Analysis]
26 Tarnoki AD, Tarnoki DL, Bata P, Littvay L, Osztovits J, Jermendy G, Karlinger K, Lannert A, Preda I, Kiss RG. Heritability of non-alcoholic fatty liver disease and association with abnormal vascular parameters: a twin study. Liver Int. 2012;32:1287-1293. [PMID: 22651705 DOI: 10.1111/j.1478-3231.2012.02823.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 3.2] [Reference Citation Analysis]
27 El Azeem HA, Khalek el-SA, El-Akabawy H, Naeim H, Khalik HA, Alfifi AA. Association between nonalcoholic fatty liver disease and the incidence of cardiovascular and renal events. J Saudi Heart Assoc. 2013;25:239-246. [PMID: 24198448 DOI: 10.1016/j.jsha.2013.07.004] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 3.4] [Reference Citation Analysis]
28 Yu CS, Chang SS, Lin CH, Lin YJ, Wu JL, Chen RJ. Identify the Characteristics of Metabolic Syndrome and Non-obese Phenotype: Data Visualization and a Machine Learning Approach. Front Med (Lausanne) 2021;8:626580. [PMID: 33898478 DOI: 10.3389/fmed.2021.626580] [Reference Citation Analysis]
29 Hesham A-Kader H. Nonalcoholic fatty liver disease in children living in the obeseogenic society. World J Pediatr. 2009;5:245-254. [PMID: 19911138 DOI: 10.1007/s12519-009-0048-8] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
30 Dunn W, Xu R, Schwimmer JB. Modest wine drinking and decreased prevalence of suspected nonalcoholic fatty liver disease. Hepatology 2008;47:1947-54. [PMID: 18454505 DOI: 10.1002/hep.22292] [Cited by in Crossref: 163] [Cited by in F6Publishing: 141] [Article Influence: 12.5] [Reference Citation Analysis]
31 Daijo K, Nakahara T, Inagaki Y, Nanba M, Nishida Y, Uchikawa S, Kodama K, Oya K, Morio K, Fujino H, Ono A, Murakami E, Yamauchi M, Kawaoka T, Miki D, Tsuge M, Hiramatsu A, Hayes CN, Imamura M, Aikata H, Ochi H, Chayama K. Risk factors for histological progression of non-alcoholic steatohepatitis analyzed from repeated biopsy cases. J Gastroenterol Hepatol 2020;35:1412-9. [PMID: 31896166 DOI: 10.1111/jgh.14968] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
32 Abdeen MB, Chowdhury NA, Hayden MR, Ibdah JA. Nonalcoholic steatohepatitis and the cardiometabolic syndrome. J Cardiometab Syndr. 2006;1:36-40. [PMID: 17675901 DOI: 10.1111/j.0197-3118.2006.05523.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 1.2] [Reference Citation Analysis]
33 Shiralkar K, Johnson S, Bluth EI, Marshall RH, Dornelles A, Gulotta PM. Improved method for calculating hepatic steatosis using the hepatorenal index. J Ultrasound Med. 2015;34:1051-1059. [PMID: 26014325 DOI: 10.7863/ultra.34.6.1051] [Cited by in Crossref: 21] [Cited by in F6Publishing: 11] [Article Influence: 4.2] [Reference Citation Analysis]
34 Flores-Toro JA, Go KL, Leeuwenburgh C, Kim JS. Autophagy in the liver: cell's cannibalism and beyond. Arch Pharm Res. 2016;39:1050-1061. [PMID: 27515049 DOI: 10.1007/s12272-016-0807-8] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.6] [Reference Citation Analysis]
35 Fincher JA, Korte AR, Dyer JE, Yadavilli S, Morris NJ, Jones DR, Shanmugam VK, Pirlo RK, Vertes A. Mass spectrometry imaging of triglycerides in biological tissues by laser desorption ionization from silicon nanopost arrays. J Mass Spectrom 2020;55. [DOI: 10.1002/jms.4443] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
36 Kawamura Y, Arase Y, Ikeda K, Akuta N, Kobayashi M, Saitoh S, Suzuki F, Suzuki Y, Inao M, Mochida S, Kumada H. Effects of Alcohol Consumption on Hepatocarcinogenesis in Japanese Patients With Fatty Liver Disease. Clin Gastroenterol Hepatol 2016;14:597-605. [PMID: 26707683 DOI: 10.1016/j.cgh.2015.11.019] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
37 Moriya A, Iwasaki Y, Ohguchi S, Kayashima E, Mitsumune T, Taniguchi H, Ando M, Yamamoto K. Roles of alcohol consumption in fatty liver: A longitudinal study. Journal of Hepatology 2015;62:921-7. [DOI: 10.1016/j.jhep.2014.11.025] [Cited by in Crossref: 59] [Cited by in F6Publishing: 47] [Article Influence: 9.8] [Reference Citation Analysis]
38 Hashimoto Y, Hamaguchi M, Obora A, Kojima T, Fukui M. Impact of metabolically healthy obesity on the risk of incident gastric cancer: a population-based cohort study. BMC Endocr Disord 2020;20:11. [PMID: 31959179 DOI: 10.1186/s12902-019-0472-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
39 Wu J, He S, Xu H, Chi X, Sun J, Wang X, Gao X, Wu R, Shao M, Zhao H, Jia J, Wang C, Niu J. Non-alcoholic fatty liver disease incidence, remission and risk factors among a general Chinese population with a 6-year follow-up. Sci Rep 2018;8:7557. [PMID: 29765064 DOI: 10.1038/s41598-018-25641-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
40 Ramilli S, Pretolani S, Muscari A, Pacelli B, Arienti V. Carotid lesions in outpatients with nonalcoholic fatty liver disease. World J Gastroenterol. 2009;15:4770-4774. [PMID: 19824109 DOI: 10.3748/wjg.15.4770] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
41 Lin S, Xian Y, Liu Y, Cai W, Song J, Zhang X. Risk factors and community intervention for nonalcoholic fatty liver disease in community residents of Urumqi, China. Medicine (Baltimore) 2018;97:e0021. [PMID: 29489647 DOI: 10.1097/MD.0000000000010021] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
42 Ayonrinde OT, Olynyk JK, Beilin LJ, Mori TA, Pennell CE, de Klerk N, Oddy WH, Shipman P, Adams LA. Gender-specific differences in adipose distribution and adipocytokines influence adolescent nonalcoholic fatty liver disease. Hepatology 2011;53:800-9. [PMID: 21374659 DOI: 10.1002/hep.24097] [Cited by in Crossref: 137] [Cited by in F6Publishing: 115] [Article Influence: 13.7] [Reference Citation Analysis]
43 Zhang H, Shen WJ, Li Y, Bittner A, Bittner S, Tabassum J, Cortez YF, Kraemer FB, Azhar S. Microarray analysis of gene expression in liver, adipose tissue and skeletal muscle in response to chronic dietary administration of NDGA to high-fructose fed dyslipidemic rats. Nutr Metab (Lond) 2016;13:63. [PMID: 27708683 DOI: 10.1186/s12986-016-0121-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
44 Hou J, Zhang X, Wang X, Wei J, Jiao K. Alteration of Liver MMP-9/TIMP-1 and Plasma Type IV Collagen in the Development of Rat Insulin Resistance. In: Li S, Jin Q, Jiang X, Park JJ, editors. Frontier and Future Development of Information Technology in Medicine and Education. Dordrecht: Springer Netherlands; 2014. pp. 531-43. [DOI: 10.1007/978-94-007-7618-0_52] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
45 Bae JC, Kim SK, Han JM, Kwon S, Lee DY, Kim J, Park SE, Park C, Lee W, Oh K, Park S, Rhee EJ. Additive effect of non-alcoholic fatty liver disease on the development of diabetes in individuals with metabolic syndrome. Diabetes Research and Clinical Practice 2017;129:136-43. [DOI: 10.1016/j.diabres.2017.03.037] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
46 Nicolaou VN, Papadakis JE, Karatzis EN, Dermitzaki SI, Tsakiris AK, Skoufas PD. Impact of the Metabolic Syndrome on Atrial Size in Patients With New-Onset Atrial Fibrillation. Angiology 2007;58:21-5. [DOI: 10.1177/0003319706297913] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 6.0] [Reference Citation Analysis]
47 Liu K, Mccaughan GW. Epidemiology and Etiologic Associations of Non-alcoholic Fatty Liver Disease and Associated HCC. In: Yu J, editor. Obesity, Fatty Liver and Liver Cancer. Singapore: Springer; 2018. pp. 3-18. [DOI: 10.1007/978-981-10-8684-7_2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
48 Lin YC, Chang PF, Liu K, Chang MH, Ni YH. Predictors for incidence and remission of nonalcoholic fatty liver disease in obese children and adolescents. J Formos Med Assoc 2021:S0929-6646(21)00021-8. [PMID: 33504463 DOI: 10.1016/j.jfma.2021.01.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
49 Kim SB, Kang OH, Lee YS, Han SH, Ahn YS, Cha SW, Seo YS, Kong R, Kwon DY. Hepatoprotective Effect and Synergism of Bisdemethoycurcumin against MCD Diet-Induced Nonalcoholic Fatty Liver Disease in Mice. PLoS One 2016;11:e0147745. [PMID: 26881746 DOI: 10.1371/journal.pone.0147745] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
50 Cusi K. The Epidemic of Type 2 Diabetes Mellitus: Its Links to Obesity, Insulin Resistance, and Lipotoxicity. In: Regensteiner JG, Reusch JE, Stewart KJ, Veves A, editors. Diabetes and Exercise. Totowa: Humana Press; 2009. pp. 3-54. [DOI: 10.1007/978-1-59745-260-1_1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
51 Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol. 2010;53:372-384. [PMID: 20494470 DOI: 10.1016/j.jhep.2010.04.008] [Cited by in Crossref: 637] [Cited by in F6Publishing: 574] [Article Influence: 57.9] [Reference Citation Analysis]
52 Loria P, Lonardo A, Anania F. Liver and diabetes. A vicious circle. Hepatol Res 2013;43:51-64. [PMID: 23332087 DOI: 10.1111/j.1872-034X.2012.01031.x] [Cited by in Crossref: 114] [Cited by in F6Publishing: 59] [Article Influence: 14.3] [Reference Citation Analysis]
53 Tomita K, Teratani T, Yokoyama H, Suzuki T, Irie R, Ebinuma H, Saito H, Hokari R, Miura S, Hibi T. Serum immunoglobulin a concentration is an independent predictor of liver fibrosis in nonalcoholic steatohepatitis before the cirrhotic stage. Dig Dis Sci. 2011;56:3648-3654. [PMID: 21674175 DOI: 10.1007/s10620-011-1771-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
54 Sato K, Gosho M, Yamamoto T, Kobayashi Y, Ishii N, Ohashi T, Nakade Y, Ito K, Fukuzawa Y, Yoneda M. Vitamin E has a beneficial effect on nonalcoholic fatty liver disease: a meta-analysis of randomized controlled trials. Nutrition. 2015;31:923-930. [PMID: 26059365 DOI: 10.1016/j.nut.2014.11.018] [Cited by in Crossref: 92] [Cited by in F6Publishing: 69] [Article Influence: 13.1] [Reference Citation Analysis]
55 Fontana L, Zhao E, Amir M, Dong H, Tanaka K, Czaja MJ. Aging promotes the development of diet-induced murine steatohepatitis but not steatosis. Hepatology 2013;57:995-1004. [PMID: 23081825 DOI: 10.1002/hep.26099] [Cited by in Crossref: 67] [Cited by in F6Publishing: 62] [Article Influence: 8.4] [Reference Citation Analysis]
56 Liu WY, Huang S, Shi KQ, Zhao CC, Chen LL, Braddock M, Chen YP, Feng WK, Zheng MH. The role of fibroblast growth factor 21 in the pathogenesis of liver disease: a novel predictor and therapeutic target. Expert Opin Ther Targets 2014;18:1305-13. [PMID: 25077735 DOI: 10.1517/14728222.2014.944898] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
57 Hernández-Conde M, Llop E, Carrillo CF, Tormo B, Abad J, Rodriguez L, Perelló C, Gomez ML, Martínez-Porras JL, Puga NF, Trapero-Marugan M, Fraga E, Aracil CF, Panero JLC. Estimation of visceral fat is useful for the diagnosis of significant fibrosis in patients with non-alcoholic fatty liver disease. World J Gastroenterol 2020;26:6658-68. [PMID: 33268953 DOI: 10.3748/wjg.v26.i42.6658] [Reference Citation Analysis]
58 Crum-Cianflone N, Dilay A, Collins G, Asher D, Campin R, Medina S, Goodman Z, Parker R, Lifson A, Capozza T. Nonalcoholic fatty liver disease among HIV-infected persons. J Acquir Immune Defic Syndr. 2009;50:464-473. [PMID: 19225402 DOI: 10.1097/qai.0b013e318198a88a] [Cited by in Crossref: 128] [Cited by in F6Publishing: 60] [Article Influence: 10.7] [Reference Citation Analysis]
59 Kim YS, Lee SH, Park SG, Won BY, Chun H, Cho DY, Kim MJ, Lee JE, Haam JH, Han K. Low levels of total and high-molecular-weight adiponectin may predict non-alcoholic fatty liver in Korean adults. Metabolism 2020;103:154026. [PMID: 31765666 DOI: 10.1016/j.metabol.2019.154026] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
60 Khandelwal R, Dassanayake AS, Conjeevaram HS, Singh SP. Non-alcoholic fatty liver disease in diabetes: When to refer to the hepatologist? WJD 2021;12:1479-93. [DOI: 10.4239/wjd.v12.i9.1479] [Reference Citation Analysis]
61 Tu S, Zhao R, Fang H, Wang L, Shao A, Sheng J. Association between Non-Alcoholic Fatty Liver Disease and Intracerebral Hemorrhage. Cell Transplant 2019;28:1033-8. [PMID: 30922067 DOI: 10.1177/0963689719840025] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
62 Ozawa N, Sato K, Sugimura A, Maki S, Tanaka T, Yamamoto K, Ito T, Ishizu Y, Kuzuya T, Honda T, Ishigami M, Fujishiro M, Ishikawa T, Ando S. Quality of Life in patients with nonalcoholic fatty liver disease: Structure and related factors focusing on illness uncertainty. Jpn J Nurs Sci 2021;:e12415. [PMID: 33709507 DOI: 10.1111/jjns.12415] [Reference Citation Analysis]
63 Kan H, Kimura Y, Hyogo H, Fukuhara T, Fujino H, Naeshiro N, Honda Y, Kawaoka T, Tsuge M, Hiramatsu A, Imamura M, Kawakami Y, Aikata H, Ochi H, Arihiro K, Chayama K. Non-invasive assessment of liver steatosis in non-alcoholic fatty liver disease: L/S ratio of liver steatosis. Hepatol Res 2014;44:E420-7. [DOI: 10.1111/hepr.12330] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
64 Pais R, Pascale A, Fedchuck L, Charlotte F, Poynard T, Ratziu V. Progression from isolated steatosis to steatohepatitis and fibrosis in nonalcoholic fatty liver disease. Clin Res Hepatol Gastroenterol 2011;35:23-8. [PMID: 21634051 DOI: 10.1016/j.gcb.2010.06.004] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 3.8] [Reference Citation Analysis]
65 Setiawan VW, Stram DO, Porcel J, Lu SC, Le Marchand L, Noureddin M. Prevalence of chronic liver disease and cirrhosis by underlying cause in understudied ethnic groups: The multiethnic cohort. Hepatology. 2016;64:1969-1977. [PMID: 27301913 DOI: 10.1002/hep.28677] [Cited by in Crossref: 147] [Cited by in F6Publishing: 109] [Article Influence: 29.4] [Reference Citation Analysis]
66 Perumpail BJ, Khan MA, Yoo ER, Cholankeril G, Kim D, Ahmed A. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease. World J Gastroenterol. 2017;23:8263-8276. [PMID: 29307986 DOI: 10.3748/wjg.v23.i47.8263] [Cited by in CrossRef: 234] [Cited by in F6Publishing: 187] [Article Influence: 78.0] [Reference Citation Analysis]
67 Sogabe M, Okahisa T, Taniguchi T, Tomonari T, Tanaka T, Tanaka H, Nakasono M, Takayama T. Light alcohol consumption plays a protective role against non-alcoholic fatty liver disease in Japanese men with metabolic syndrome. Liver Int. 2015;35:1707-1714. [PMID: 25438866 DOI: 10.1111/liv.12754] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
68 Roberts CK, Hevener AL, Barnard RJ. Metabolic syndrome and insulin resistance: underlying causes and modification by exercise training. Compr Physiol 2013;3:1-58. [PMID: 23720280 DOI: 10.1002/cphy.c110062] [Cited by in Crossref: 74] [Cited by in F6Publishing: 133] [Article Influence: 9.3] [Reference Citation Analysis]
69 Fukuda Y, Hashimoto Y, Hamaguchi M, Fukuda T, Nakamura N, Ohbora A, Kato T, Kojima T, Fukui M. Triglycerides to high-density lipoprotein cholesterol ratio is an independent predictor of incident fatty liver; a population-based cohort study. Liver Int. 2016;36:713-720. [PMID: 26444696 DOI: 10.1111/liv.12977] [Cited by in Crossref: 45] [Cited by in F6Publishing: 37] [Article Influence: 7.5] [Reference Citation Analysis]
70 Rivero-Juárez A, Camacho A, Merchante N, Pérez-Camacho I, Macias J, Ortiz-Garcia C, Cifuentes C, Torre-Cisneros J, Peña J, Pineda JA, Rivero A; Grupo para el estudio de las hepatitis vı´ricas (HEPAVIR) de la Sociedad Andaluza de Enfermedades Infecciosas (SAEI). Incidence of liver damage of uncertain origin in HIV patients not co-infected with HCV/HBV. PLoS One 2013;8:e68953. [PMID: 23874824 DOI: 10.1371/journal.pone.0068953] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 3.6] [Reference Citation Analysis]
71 Cornier MA, Dabelea D, Hernandez TL, Lindstrom RC, Steig AJ, Stob NR, Van Pelt RE, Wang H, Eckel RH. The metabolic syndrome. Endocr Rev. 2008;29:777-822. [PMID: 18971485 DOI: 10.1210/er.2008-0024] [Cited by in Crossref: 951] [Cited by in F6Publishing: 765] [Article Influence: 73.2] [Reference Citation Analysis]
72 Wagenknecht LE, Scherzinger AL, Stamm ER, Hanley AJ, Norris JM, Chen YD, Bryer-Ash M, Haffner SM, Rotter JI. Correlates and heritability of nonalcoholic fatty liver disease in a minority cohort. Obesity (Silver Spring). 2009;17:1240-1246. [PMID: 19584882 DOI: 10.1038/oby.2009.4] [Cited by in Crossref: 33] [Cited by in F6Publishing: 57] [Article Influence: 2.8] [Reference Citation Analysis]
73 Ishii H, Kajihara M. Non-alcoholic fatty liver disease guidelines: An Asian perspective. J Gastroenterol Hepatol 2007;22:769-70. [DOI: 10.1111/j.1440-1746.2007.05015.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
74 Bruschi FV, Tardelli M, Claudel T, Trauner M. PNPLA3 expression and its impact on the liver: current perspectives. Hepat Med. 2017;9:55-66. [PMID: 29158695 DOI: 10.2147/hmer.s125718] [Cited by in Crossref: 37] [Cited by in F6Publishing: 24] [Article Influence: 9.3] [Reference Citation Analysis]
75 Speliotes EK, Massaro JM, Hoffmann U, Vasan RS, Meigs JB, Sahani DV, Hirschhorn JN, O'Donnell CJ, Fox CS. Fatty liver is associated with dyslipidemia and dysglycemia independent of visceral fat: the Framingham Heart Study. Hepatology 2010;51:1979-87. [PMID: 20336705 DOI: 10.1002/hep.23593] [Cited by in Crossref: 241] [Cited by in F6Publishing: 221] [Article Influence: 21.9] [Reference Citation Analysis]
76 Karavia EA, Papachristou DJ, Liopeta K, Triantaphyllidou IE, Dimitrakopoulos O, Kypreos KE. Apolipoprotein A-I modulates processes associated with diet-induced nonalcoholic fatty liver disease in mice. Mol Med 2012;18:901-12. [PMID: 22576368 DOI: 10.2119/molmed.2012.00113] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 3.2] [Reference Citation Analysis]
77 Liu PY, Chen CC, Chin CY, Liu TJ, Tsai WC, Chou JL, Huang CY, Chen YG, Chen YC. E3 ubiquitin ligase Grail promotes hepatic steatosis through Sirt1 inhibition. Cell Death Dis 2021;12:323. [PMID: 33771967 DOI: 10.1038/s41419-021-03608-9] [Reference Citation Analysis]
78 Okamura T, Hashimoto Y, Hamaguchi M, Obora A, Kojima T, Fukui M. Clinical characteristics and longitudinal changes of patients with non-alcoholic fatty liver disease in 2 decades: the NAGALA study. BMC Gastroenterol 2021;21:223. [PMID: 34001028 DOI: 10.1186/s12876-021-01809-2] [Reference Citation Analysis]
79 Wang DQ, Portincasa P, Neuschwander-Tetri BA. Steatosis in the liver. Compr Physiol 2013;3:1493-532. [PMID: 24265237 DOI: 10.1002/cphy.c130001] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 3.4] [Reference Citation Analysis]
80 Takahashi A, Arinaga-Hino T, Ohira H, Abe K, Torimura T, Zeniya M, Abe M, Yoshizawa K, Takaki A, Suzuki Y, Kang JH, Nakamoto N, Fujisawa T, Tanaka A, Takikawa H; Japan AIH Study Group (JAIHSG). Non-alcoholic fatty liver disease in patients with autoimmune hepatitis. JGH Open 2018;2:54-8. [PMID: 30483564 DOI: 10.1002/jgh3.12046] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
81 Hong HC, Hwang SY, Ryu JY, Yoo HJ, Seo J, Kim SG, Kim NH, Baik SH, Choi DS, Choi KM. The synergistic impact of nonalcoholic fatty liver disease and metabolic syndrome on subclinical atherosclerosis. Clin Endocrinol 2016;84:203-9. [DOI: 10.1111/cen.12940] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
82 Zhang T, Zhang C, Zhang Y, Tang F, Li H, Zhang Q, Lin H, Wu S, Liu Y, Xue F. Metabolic syndrome and its components as predictors of nonalcoholic fatty liver disease in a northern urban Han Chinese population: a prospective cohort study. Atherosclerosis. 2015;240:144-148. [PMID: 25785362 DOI: 10.1016/j.atherosclerosis.2015.02.049] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 5.3] [Reference Citation Analysis]
83 Yoshitaka H, Hamaguchi M, Kojima T, Fukuda T, Ohbora A, Fukui M. Nonoverweight nonalcoholic fatty liver disease and incident cardiovascular disease: A post hoc analysis of a cohort study. Medicine (Baltimore). 2017;96:e6712. [PMID: 28471965 DOI: 10.1097/md.0000000000006712] [Cited by in Crossref: 37] [Cited by in F6Publishing: 15] [Article Influence: 9.3] [Reference Citation Analysis]
84 van Eekelen E, Beulens JWJ, Geelen A, Schrauwen-Hinderling VB, Lamb H, de Roos A, Rosendaal F, de Mutsert R. Consumption of Alcoholic and Sugar-Sweetened Beverages is Associated with Increased Liver Fat Content in Middle-Aged Men and Women. J Nutr 2019;149:649-58. [PMID: 30949667 DOI: 10.1093/jn/nxy313] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
85 Tiessen RG, Kennedy CA, Keller BT, Levin N, Acevedo L, Gedulin B, van Vliet AA, Dorenbaum A, Palmer M. Safety, tolerability and pharmacodynamics of apical sodium-dependent bile acid transporter inhibition with volixibat in healthy adults and patients with type 2 diabetes mellitus: a randomised placebo-controlled trial. BMC Gastroenterol 2018;18:3. [PMID: 29304731 DOI: 10.1186/s12876-017-0736-0] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]
86 Scaglioni F, Ciccia S, Marino M, Bedogni G, Bellentani S. ASH and NASH. Dig Dis 2011;29:202-10. [PMID: 21734385 DOI: 10.1159/000323886] [Cited by in Crossref: 49] [Cited by in F6Publishing: 44] [Article Influence: 4.9] [Reference Citation Analysis]
87 Luo J, Xu L, Li J, Zhao S. Nonalcoholic fatty liver disease as a potential risk factor of cardiovascular disease. Eur J Gastroenterol Hepatol. 2015;27:193-199. [PMID: 25563143 DOI: 10.1097/meg.0000000000000254] [Cited by in Crossref: 36] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
88 Kim YW, Kim YM, Yang YM, Kay HY, Kim WD, Lee JW, Hwang SJ, Kim SG. Inhibition of LXRα-dependent steatosis and oxidative injury by liquiritigenin, a licorice flavonoid, as mediated with Nrf2 activation. Antioxid Redox Signal 2011;14:733-45. [PMID: 20677908 DOI: 10.1089/ars.2010.3260] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
89 Hashimoto Y, Okamura T, Hamaguchi M, Obora A, Kojima T, Fukui M. Impact of respiratory function on the progression from metabolically healthy non-overweight to metabolically abnormal phenotype. Nutrition, Metabolism and Cardiovascular Diseases 2018;28:922-8. [DOI: 10.1016/j.numecd.2018.05.016] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
90 Severson TJ, Besur S, Bonkovsky HL. Genetic factors that affect nonalcoholic fatty liver disease: A systematic clinical review. World J Gastroenterol. 2016;22:6742-6756. [PMID: 27547017 DOI: 10.3748/wjg.v22.i29.6742] [Cited by in CrossRef: 48] [Cited by in F6Publishing: 34] [Article Influence: 12.0] [Reference Citation Analysis]
91 Graham RC, Burke A, Stettler N. Ethnic and sex differences in the association between metabolic syndrome and suspected nonalcoholic fatty liver disease in a nationally representative sample of US adolescents. J Pediatr Gastroenterol Nutr. 2009;49:442-449. [PMID: 19644391 DOI: 10.1097/mpg.0b013e31819f73b4] [Cited by in Crossref: 40] [Cited by in F6Publishing: 19] [Article Influence: 3.6] [Reference Citation Analysis]
92 Ott C, Schmieder RE. The role of statins in the treatment of the metabolic syndrome. Current Science Inc 2009;11:143-9. [DOI: 10.1007/s11906-009-0025-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
93 Nishio T, Taura K, Iwaisako K, Koyama Y, Tanabe K, Yamamoto G, Okuda Y, Ikeno Y, Yoshino K, Kasai Y, Okuno M, Seo S, Sakurai T, Asagiri M, Hatano E, Uemoto S. Hepatic vagus nerve regulates Kupffer cell activation via α7 nicotinic acetylcholine receptor in nonalcoholic steatohepatitis. J Gastroenterol 2017;52:965-76. [PMID: 28044208 DOI: 10.1007/s00535-016-1304-z] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis]
94 Huang G, Zhou H, Shen C, Sheng Y, Xue R, Dong C, Zhang S. Bi-directional and temporal relationship between elevated alanine aminotransferase and hypertension in a longitudinal study of Chinese adults. Clin Exp Hypertens 2021;:1-8. [PMID: 34355631 DOI: 10.1080/10641963.2021.1960364] [Reference Citation Analysis]
95 Omagari K, Morikawa S, Nagaoka S, Sadakane Y, Sato M, Hamasaki M, Kato S, Masuda J, Osabe M, Kadota T. Predictive factors for the development or regression of Fatty liver in Japanese adults. J Clin Biochem Nutr. 2009;45:56-67. [PMID: 19590708 DOI: 10.3164/jcbn.08-269] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
96 Ogden CL, Yanovski SZ, Carroll MD, Flegal KM. The epidemiology of obesity. Gastroenterology. 2007;132:2087-2102. [PMID: 17498505 DOI: 10.1053/j.gastro.2007.03.052] [Cited by in Crossref: 952] [Cited by in F6Publishing: 745] [Article Influence: 68.0] [Reference Citation Analysis]
97 Straznicky NE, Lambert EA, Grima MT, Eikelis N, Nestel PJ, Dawood T, Schlaich MP, Masuo K, Chopra R, Sari CI, Dixon JB, Tilbrook AJ, Lambert GW. The effects of dietary weight loss with or without exercise training on liver enzymes in obese metabolic syndrome subjects. Diabetes, Obesity and Metabolism 2012;14:139-48. [DOI: 10.1111/j.1463-1326.2011.01497.x] [Cited by in Crossref: 44] [Cited by in F6Publishing: 34] [Article Influence: 4.4] [Reference Citation Analysis]
98 Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ; American Association for the Study of Liver Diseases; American College of Gastroenterology; American Gastroenterological Association. The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Am J Gastroenterol. 2012;107:811-826. [PMID: 22641309 DOI: 10.1038/ajg.2012.128] [Cited by in Crossref: 245] [Cited by in F6Publishing: 216] [Article Influence: 27.2] [Reference Citation Analysis]
99 Saligram S, Williams EJ, Masding MG. Raised liver enzymes in newly diagnosed Type 2 diabetes are associated with weight and lipids, but not glycaemic control. Indian J Endocrinol Metab 2012;16:1012-4. [PMID: 23226654 DOI: 10.4103/2230-8210.103027] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
100 Ameer F, Scandiuzzi L, Hasnain S, Kalbacher H, Zaidi N. De novo lipogenesis in health and disease. Metabolism 2014;63:895-902. [PMID: 24814684 DOI: 10.1016/j.metabol.2014.04.003] [Cited by in Crossref: 201] [Cited by in F6Publishing: 169] [Article Influence: 28.7] [Reference Citation Analysis]
101 Ishizaka N, Ishizaka Y, Hashimoto H, Toda E, Nagai R, Yamakado M. Metabolic Syndrome May Not Associate With Carotid Plaque in Subjects With Optimal, Normal, or High-Normal Blood Pressure. Hypertension 2006;48:411-7. [DOI: 10.1161/01.hyp.0000233466.24345.2e] [Cited by in Crossref: 15] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
102 Gonzales CA, Bacchetti P, Khalili M. Impact of gender and menopausal status on metabolic parameters in chronic hepatitis C infection. J Viral Hepat 2016;23:232-9. [PMID: 26554398 DOI: 10.1111/jvh.12487] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
103 Ryoo JH, Choi JM, Moon SY, Suh YJ, Shin JY, Shin HC, Park SK. The clinical availability of non alcoholic fatty liver disease as an early predictor of the metabolic syndrome in Korean men: 5-year's prospective cohort study. Atherosclerosis 2013;227:398-403. [PMID: 23390894 DOI: 10.1016/j.atherosclerosis.2013.01.002] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 3.0] [Reference Citation Analysis]
104 Oliveira BMGBD, Medeiros MMDC, Cerqueira JVMD, Quixadá RTDS, Oliveira ÍMXD. Síndrome metabólica em pacientes com diagnóstico de artrite reumatoide acompanhados em um Hospital Universitário do Nordeste brasileiro. Revista Brasileira de Reumatologia 2016;56:117-25. [DOI: 10.1016/j.rbr.2015.05.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
105 Hamano M, Kamada Y, Kiso S, Furuta K, Kizu T, Chatani N, Egawa M, Takemura T, Ezaki H, Yoshida Y. Adiponectin negatively correlates with alcoholic and non-alcoholic liver dysfunction: Health check-up study of Japanese men. Hepatol Res. 2013;43:238-248. [PMID: 22835062 DOI: 10.1111/j.1872-034x.2012.01066.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
106 Yamada T, Fukatsu M, Suzuki S, Yoshida T, Tokudome S, Joh T. Alcohol drinking may not be a major risk factor for fatty liver in Japanese undergoing a health checkup. Dig Dis Sci. 2010;55:176-182. [PMID: 19156520 DOI: 10.1007/s10620-008-0693-0] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 2.0] [Reference Citation Analysis]
107 Morris-Stiff G, Tan YM, Vauthey JN. Hepatic complications following preoperative chemotherapy with oxaliplatin or irinotecan for hepatic colorectal metastases. Eur J Surg Oncol. 2008;34:609-614. [PMID: 17764887 DOI: 10.1016/j.ejso.2007.07.007] [Cited by in Crossref: 81] [Cited by in F6Publishing: 64] [Article Influence: 5.8] [Reference Citation Analysis]
108 Cariou B, Staels B. GFT505 for the treatment of nonalcoholic steatohepatitis and type 2 diabetes. Expert Opin Investig Drugs 2014;23:1441-8. [PMID: 25164277 DOI: 10.1517/13543784.2014.954034] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
109 Noureddin M, Mato JM, Lu SC. Nonalcoholic fatty liver disease: update on pathogenesis, diagnosis, treatment and the role of S-adenosylmethionine. Exp Biol Med (Maywood). 2015;240:809-820. [PMID: 25873078 DOI: 10.1177/1535370215579161] [Cited by in Crossref: 57] [Cited by in F6Publishing: 42] [Article Influence: 9.5] [Reference Citation Analysis]
110 Wu SJ, Zou H, Zhu GQ, Wang LR, Zhang Q, Shi KQ, Han JB, Huang WJ, Braddock M, Chen YP, Zheng MH. Increased levels of systolic blood pressure within the normal range are associated with significantly elevated risks of nonalcoholic fatty liver disease. Medicine (Baltimore) 2015;94:e842. [PMID: 25984671 DOI: 10.1097/MD.0000000000000842] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
111 Loria P, Lonardo A, Targher G. Is liver fat detrimental to vessels?: intersections in the pathogenesis of NAFLD and atherosclerosis. Clin Sci (Lond). 2008;115:1-12. [PMID: 19016656 DOI: 10.1042/cs20070311] [Cited by in Crossref: 47] [Cited by in F6Publishing: 13] [Article Influence: 3.9] [Reference Citation Analysis]
112 Hernaez R. Genetics of non-alcoholic fatty liver disease and associated metabolic disorders. Avances en Diabetología 2011;27:186-97. [DOI: 10.1016/j.avdiab.2011.11.004] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
113 Cui Y, Liu J, Shi H, Hu W, Song L, Zhao Q. Serum uric acid is positively associated with the prevalence of nonalcoholic fatty liver in non-obese type 2 diabetes patients in a Chinese population. J Diabetes Complications 2021;35:107874. [PMID: 33640265 DOI: 10.1016/j.jdiacomp.2021.107874] [Reference Citation Analysis]
114 Madan SA, John F, Pitchumoni CS. Nonalcoholic Fatty Liver Disease and Mean Platelet Volume: A Systemic Review and Meta-analysis. J Clin Gastroenterol. 2016;50:69-74. [PMID: 25984978 DOI: 10.1097/mcg.0000000000000340] [Cited by in Crossref: 14] [Cited by in F6Publishing: 5] [Article Influence: 2.8] [Reference Citation Analysis]
115 Lonardo A, Nascimbeni F, Mantovani A, Targher G. Hypertension, diabetes, atherosclerosis and NASH: Cause or consequence? J Hepatol. 2018;68:335-352. [PMID: 29122390 DOI: 10.1016/j.jhep.2017.09.021] [Cited by in Crossref: 224] [Cited by in F6Publishing: 196] [Article Influence: 56.0] [Reference Citation Analysis]
116 Wong VW, Wong GL, Yeung DK, Abrigo JM, Kong AP, Chan RS, Chim AM, Shen J, Ho CS, Woo J. Fatty pancreas, insulin resistance, and β-cell function: a population study using fat-water magnetic resonance imaging. Am J Gastroenterol. 2014;109:589-597. [PMID: 24492753 DOI: 10.1038/ajg.2014.1] [Cited by in Crossref: 117] [Cited by in F6Publishing: 106] [Article Influence: 16.7] [Reference Citation Analysis]
117 Okamura T, Hashimoto Y, Hamaguchi M, Obora A, Kojima T, Fukui M. Low urine pH is a risk for non-alcoholic fatty liver disease: A population-based longitudinal study. Clinics and Research in Hepatology and Gastroenterology 2018;42:570-6. [DOI: 10.1016/j.clinre.2018.06.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
118 Reha JL, Lee S, Hofmann LJ. Prevalence and Predictors of Nonalcoholic Steatohepatitis in Obese Patients Undergoing Bariatric Surgery: A Department of Defense Experience. The American Surgeon 2014;80:595-9. [DOI: 10.1177/000313481408000624] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 17.0] [Reference Citation Analysis]
119 Regnell SE. Cannabinoid 1 receptor in fatty liver. Hepatol Res. 2013;43:131-138. [PMID: 22994399 DOI: 10.1111/j.1872-034x.2012.01085.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
120 Robberecht H, Hermans N. Biomarkers of Metabolic Syndrome: Biochemical Background and Clinical Significance. Metab Syndr Relat Disord 2016;14:47-93. [PMID: 26808223 DOI: 10.1089/met.2015.0113] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
121 Coccia F, Testa M, Guarisco G, Di Cristofano C, Silecchia G, Leonetti F, Gastaldelli A, Capoccia D. Insulin resistance, but not insulin response, during oral glucose tolerance test (OGTT) is associated to worse histological outcome in obese NAFLD. Nutr Metab Cardiovasc Dis 2020;30:106-13. [PMID: 31677889 DOI: 10.1016/j.numecd.2019.08.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
122 Dallio M, Masarone M, Errico S, Gravina AG, Nicolucci C, Di Sarno R, Gionti L, Tuccillo C, Persico M, Stiuso P, Diano N, Loguercio C, Federico A. Role of bisphenol A as environmental factor in the promotion of non-alcoholic fatty liver disease: in vitro and clinical study. Aliment Pharmacol Ther 2018;47:826-37. [DOI: 10.1111/apt.14499] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 7.7] [Reference Citation Analysis]
123 Harb Z, Deckert V, Bressenot AM, Christov C, Guéant-Rodriguez RM, Raso J, Alberto JM, de Barros JP, Umoret R, Peyrin-Biroulet L, Lagrost L, Bronowicki JP, Guéant JL. The deficit in folate and vitamin B12 triggers liver macrovesicular steatosis and inflammation in rats with dextran sodium sulfate-induced colitis. J Nutr Biochem 2020;84:108415. [PMID: 32645655 DOI: 10.1016/j.jnutbio.2020.108415] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
124 Wang Y, Li YY, Nie YQ, Zhou YJ, Cao CY, Xu L. Association between metabolic syndrome and the development of non-alcoholic fatty liver disease. Exp Ther Med 2013;6:77-84. [PMID: 23935723 DOI: 10.3892/etm.2013.1090] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 3.6] [Reference Citation Analysis]
125 Chang JJ, Chung DJ, Lee YJ, Wen BH, Jao HY, Wang CJ. Solanum nigrum Polyphenol Extracts Inhibit Hepatic Inflammation, Oxidative Stress, and Lipogenesis in High-Fat-Diet-Treated Mice. J Agric Food Chem 2017;65:9255-65. [PMID: 28982243 DOI: 10.1021/acs.jafc.7b03578] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 3.8] [Reference Citation Analysis]
126 Speliotes EK, Butler JL, Palmer CD, Voight BF; GIANT Consortium; MIGen Consortium; NASH CRN, Hirschhorn JN. PNPLA3 variants specifically confer increased risk for histologic nonalcoholic fatty liver disease but not metabolic disease. Hepatology. 2010;52:904-912. [PMID: 20648472 DOI: 10.1002/hep.23768] [Cited by in Crossref: 254] [Cited by in F6Publishing: 231] [Article Influence: 23.1] [Reference Citation Analysis]
127 Diakou MC, Liberopoulos EN, Mikhailidis DP, Tsianos EV, Burroughs AK, Elisaf MS. Pharmacological treatment of non-alcoholic steatohepatitis: the current evidence. Scand J Gastroenterol. 2007;42:139-147. [PMID: 17327932 DOI: 10.1080/00365520601058395] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
128 Zelber-Sagi S, Ben-Assuli O, Rabinowich L, Goldstein A, Magid A, Shalev V, Shibolet O, Chodick G. The association between the serum levels of uric acid and alanine aminotransferase in a population-based cohort. Liver Int. 2015;35:2408-2415. [PMID: 25845417 DOI: 10.1111/liv.12842] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
129 Lidofsky SD. Nonalcoholic fatty liver disease: diagnosis and relation to metabolic syndrome and approach to treatment. Curr Diab Rep. 2008;8:25-30. [PMID: 18366995 DOI: 10.1007/s11892-008-0006-1] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 1.2] [Reference Citation Analysis]
130 Agrawal S, Daruwala C. Metabolic syndrome and hepatic resection: improving outcome. HPB (Oxford). 2011;13:846-859. [PMID: 22081919 DOI: 10.1111/j.1477-2574.2011.00380.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
131 Völzke H. Multicausality in fatty liver disease: is there a rationale to distinguish between alcoholic and non-alcoholic origin? World J Gastroenterol. 2012;18:3492-3501. [PMID: 22826613 DOI: 10.3748/wjg.v18.i27.3492] [Cited by in CrossRef: 43] [Cited by in F6Publishing: 33] [Article Influence: 4.8] [Reference Citation Analysis]
132 Watanabe S, Hashimoto E, Ikejima K, Uto H, Ono M, Sumida Y, Seike M, Takei Y, Takehara T, Tokushige K, Nakajima A, Yoneda M, Saibara T, Shiota G, Sakaida I, Nakamuta M, Mizuta T, Tsubouchi H, Sugano K, Shimosegawa T. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Hepatol Res. 2015;45:363-377. [PMID: 25832328 DOI: 10.1111/hepr.12511] [Cited by in Crossref: 59] [Cited by in F6Publishing: 93] [Article Influence: 9.8] [Reference Citation Analysis]
133 Yilmaz B, Sahin K, Bilen H, Bahcecioglu IH, Bilir B, Ashraf S, Halazun KJ, Kucuk O. Carotenoids and non-alcoholic fatty liver disease. Hepatobiliary Surg Nutr. 2015;4:161-171. [PMID: 26151056 DOI: 10.3978/j.issn.2304-3881.2015.01.11] [Cited by in F6Publishing: 23] [Reference Citation Analysis]
134 . Sex difference in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Hepatology Research 2010;40:108-10. [DOI: 10.1111/j.1872-034x.2009.00611.x] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
135 Iida A, Kuranuki S, Yamamoto R, Uchida M, Ohta M, Ichimura M, Tsuneyama K, Masaki T, Seike M, Nakamura T. Analysis of amino acid profiles of blood over time and biomarkers associated with non-alcoholic steatohepatitis in STAM mice. Exp Anim 2019;68:417-28. [PMID: 31155606 DOI: 10.1538/expanim.18-0152] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
136 Tsuneto A, Hida A, Sera N, Imaizumi M, Ichimaru S, Nakashima E, Seto S, Maemura K, Akahoshi M. Fatty liver incidence and predictive variables. Hypertens Res 2010;33:638-43. [PMID: 20379184 DOI: 10.1038/hr.2010.45] [Cited by in Crossref: 49] [Cited by in F6Publishing: 45] [Article Influence: 4.5] [Reference Citation Analysis]
137 Okamura T, Hashimoto Y, Hamaguchi M, Obora A, Kojima T, Fukui M. The visceral adiposity index is a predictor of incident nonalcoholic fatty liver disease: A population-based longitudinal study. Clinics and Research in Hepatology and Gastroenterology 2020;44:375-83. [DOI: 10.1016/j.clinre.2019.04.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
138 Smith BW, Adams LA. Non-alcoholic fatty liver disease. Crit Rev Clin Lab Sci. 2011;48:97-113. [PMID: 21875310 DOI: 10.3109/10408363.2011.596521] [Cited by in Crossref: 183] [Cited by in F6Publishing: 160] [Article Influence: 18.3] [Reference Citation Analysis]
139 Zelber-Sagi S, Lotan R, Shlomai A, Webb M, Harrari G, Buch A, Nitzan Kaluski D, Halpern Z, Oren R. Predictors for incidence and remission of NAFLD in the general population during a seven-year prospective follow-up. J Hepatol. 2012;56:1145-1151. [PMID: 22245895 DOI: 10.1016/j.jhep.2011.12.011] [Cited by in Crossref: 148] [Cited by in F6Publishing: 127] [Article Influence: 16.4] [Reference Citation Analysis]
140 Venkatesh SK, Hennedige T, Johnson GB, Hough DM, Fletcher JG. Imaging patterns and focal lesions in fatty liver: a pictorial review. Abdom Radiol (NY) 2017;42:1374-92. [PMID: 27999887 DOI: 10.1007/s00261-016-1002-6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
141 Lee YI, Lim YS, Park HS. Colorectal neoplasms in relation to non-alcoholic fatty liver disease in Korean women: a retrospective cohort study. J Gastroenterol Hepatol. 2012;27:91-95. [PMID: 21679251 DOI: 10.1111/j.1440-1746.2011.06816.x] [Cited by in Crossref: 52] [Cited by in F6Publishing: 44] [Article Influence: 5.8] [Reference Citation Analysis]
142 Ma H, Xu C, Xu L, Yu C, Miao M, Li Y. Independent association of HbA1c and nonalcoholic fatty liver disease in an elderly Chinese population. BMC Gastroenterol. 2013;13:3. [PMID: 23294935 DOI: 10.1186/1471-230x-13-3] [Cited by in Crossref: 21] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
143 Konerman MA, Walden P, Joseph M, Jackson EA, Lok AS, Rubenfire M. Impact of a structured lifestyle programme on patients with metabolic syndrome complicated by non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2019;49:296-307. [PMID: 30561027 DOI: 10.1111/apt.15063] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
144 Lonardo A, Carani C, Carulli N, Loria P. ‘Endocrine NAFLD’ a hormonocentric perspective of nonalcoholic fatty liver disease pathogenesis. J Hepatol. 2006;44:1196-1207. [PMID: 16618516 DOI: 10.1016/j.jhep.2006.03.005] [Cited by in Crossref: 83] [Cited by in F6Publishing: 81] [Article Influence: 5.5] [Reference Citation Analysis]
145 Godoy-matos AFD, Guedes EP, Souza LLD, Valério CM. O sistema endocanabinóide: novo paradigma no tratamento da síndrome metabólica. Arq Bras Endocrinol Metab 2006;50:390-9. [DOI: 10.1590/s0004-27302006000200025] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
146 Marchesini G, Mazzotti A. NAFLD incidence and remission: only a matter of weight gain and weight loss? J Hepatol 2015;62:15-7. [PMID: 25450705 DOI: 10.1016/j.jhep.2014.10.023] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 4.1] [Reference Citation Analysis]
147 Park YJ, Lim JH, Kwon ER, Kim HK, Jung MC, Seol KH, Noh WY, Kim NE. Development and validation of a simple index system to predict nonalcoholic fatty liver disease. Korean J Hepatol 2011;17:19-26. [PMID: 21494074 DOI: 10.3350/kjhep.2011.17.1.19] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
148 Toshikuni N, Tsuchishima M, Fukumura A, Arisawa T, Tsutsumi M. Associations of Fatty Liver Disease with Hypertension, Diabetes, and Dyslipidemia: Comparison between Alcoholic and Nonalcoholic Steatohepatitis. Gastroenterol Res Pract 2017;2017:9127847. [PMID: 28912806 DOI: 10.1155/2017/9127847] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
149 Gray B, Steyn F, Davies PSW, Vitetta L. Liver function parameters, cholesterol, and phospholipid α-linoleic acid are associated with adipokine levels in overweight and obese adults. Nutrition Research 2014;34:375-82. [DOI: 10.1016/j.nutres.2014.04.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
150 Misra VL, Khashab M, Chalasani N. Nonalcoholic fatty liver disease and cardiovascular risk. Curr Gastroenterol Rep. 2009;11:50-55. [PMID: 19166659 DOI: 10.1007/s11894-009-0008-4] [Cited by in Crossref: 66] [Cited by in F6Publishing: 53] [Article Influence: 5.5] [Reference Citation Analysis]
151 Warmbrunn MV, Koopen AM, de Clercq NC, de Groot PF, Kootte RS, Bouter KEC, Ter Horst KW, Hartstra AV, Serlie MJ, Ackermans MT, Soeters MR, van Raalte DH, Davids M, Nieuwdorp M, Groen AK. Metabolite Profile of Treatment-Naive Metabolic Syndrome Subjects in Relation to Cardiovascular Disease Risk. Metabolites 2021;11:236. [PMID: 33924347 DOI: 10.3390/metabo11040236] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
152 Zelber-sagi S, Salomone F, Yeshua H, Lotan R, Webb M, Halpern Z, Santo E, Oren R, Shibolet O. Non-high-density lipoprotein cholesterol independently predicts new onset of non-alcoholic fatty liver disease. Liver Int 2014;34:e128-35. [DOI: 10.1111/liv.12318] [Cited by in Crossref: 34] [Cited by in F6Publishing: 27] [Article Influence: 4.3] [Reference Citation Analysis]
153 Eslam M, Sarin SK, Wong VW, Fan JG, Kawaguchi T, Ahn SH, Zheng MH, Shiha G, Yilmaz Y, Gani R, Alam S, Dan YY, Kao JH, Hamid S, Cua IH, Chan WK, Payawal D, Tan SS, Tanwandee T, Adams LA, Kumar M, Omata M, George J. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol Int. 2020;14:889-919. [PMID: 33006093 DOI: 10.1007/s12072-020-10094-2] [Cited by in Crossref: 61] [Cited by in F6Publishing: 54] [Article Influence: 61.0] [Reference Citation Analysis]
154 Hashimoto Y, Tanaka M, Okada H, Senmaru T, Hamaguchi M, Asano M, Yamazaki M, Oda Y, Hasegawa G, Toda H, Nakamura N, Fukui M. Metabolically healthy obesity and risk of incident CKD. Clin J Am Soc Nephrol 2015;10:578-83. [PMID: 25635035 DOI: 10.2215/CJN.08980914] [Cited by in Crossref: 72] [Cited by in F6Publishing: 30] [Article Influence: 12.0] [Reference Citation Analysis]
155 Sumida Y, Yonei Y, Kanemasa K, Hara T, Inada Y, Sakai K, Imai S, Hibino S, Yamaguchi K, Mitsuyoshi H. Lower circulating levels of dehydroepiandrosterone, independent of insulin resistance, is an important determinant of severity of non-alcoholic steatohepatitis in Japanese patients. Hepatol Res. 2010;40:901-910. [PMID: 20887595 DOI: 10.1111/j.1872-034x.2010.00704.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
156 Chang Y, Ryu S, Sung E, Woo HY, Oh E, Cha K, Jung E, Kim WS. Nonalcoholic fatty liver disease predicts chronic kidney disease in nonhypertensive and nondiabetic Korean men. Metabolism. 2008;57:569-576. [PMID: 18328362 DOI: 10.1016/j.metabol.2007.11.022] [Cited by in Crossref: 88] [Cited by in F6Publishing: 80] [Article Influence: 6.8] [Reference Citation Analysis]
157 Khashab M, Chalasani N. Use of insulin sensitizers in NASH. Endocrinol Metab Clin North Am 2007;36:1067-87; xi. [PMID: 17983937 DOI: 10.1016/j.ecl.2007.07.006] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
158 Willemse PM, van der Meer RW, Burggraaf J, van Elderen SG, de Kam ML, de Roos A, Lamb HJ, Osanto S. Abdominal visceral and subcutaneous fat increase, insulin resistance and hyperlipidemia in testicular cancer patients treated with cisplatin-based chemotherapy. Acta Oncol 2014;53:351-60. [PMID: 23957624 DOI: 10.3109/0284186X.2013.819116] [Cited by in Crossref: 22] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
159 Takahashi S, Tanaka M, Furuhashi M, Moniwa N, Koyama M, Higashiura Y, Osanami A, Gocho Y, Ohnishi H, Numata K, Hisasue T, Hanawa N, Miura T. Fatty liver index is independently associated with deterioration of renal function during a 10-year period in healthy subjects. Sci Rep 2021;11:8606. [PMID: 33883636 DOI: 10.1038/s41598-021-88025-w] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
160 Hamaguchi M, Kojima T, Ohbora A, Takeda N, Fukui M, Kato T. Aging is a risk factor of nonalcoholic fatty liver disease in premenopausal women. World J Gastroenterol. 2012;18:237-243. [PMID: 22294826 DOI: 10.3748/wjg.v18.i3.237] [Cited by in CrossRef: 68] [Cited by in F6Publishing: 62] [Article Influence: 7.6] [Reference Citation Analysis]
161 Yuan F, Hou L, Wei L, Quan R, Wang J, Liu H, Liu J. Fowl Adenovirus Serotype 4 Induces Hepatic Steatosis via Activation of Liver X Receptor-α. J Virol 2021;95:e01938-20. [PMID: 33361420 DOI: 10.1128/JVI.01938-20] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
162 Lee JW, Cho YK, Ryan M, Kim H, Lee SW, Chang E, Joo KJ, Kim JT, Kim BS, Sung KC. Serum uric Acid as a predictor for the development of nonalcoholic Fatty liver disease in apparently healthy subjects: a 5-year retrospective cohort study. Gut Liver. 2010;4:378-383. [PMID: 20981217 DOI: 10.5009/gnl.2010.4.3.378] [Cited by in Crossref: 53] [Cited by in F6Publishing: 45] [Article Influence: 4.8] [Reference Citation Analysis]
163 Nakahara T, Hyogo H, Yoneda M, Sumida Y, Eguchi Y, Fujii H, Ono M, Kawaguchi T, Imajo K, Aikata H. Type 2 diabetes mellitus is associated with the fibrosis severity in patients with nonalcoholic fatty liver disease in a large retrospective cohort of Japanese patients. J Gastroenterol. 2014;49:1477-1484. [PMID: 24277052 DOI: 10.1007/s00535-013-0911-1] [Cited by in Crossref: 73] [Cited by in F6Publishing: 59] [Article Influence: 9.1] [Reference Citation Analysis]
164 Lee JH, Baek SY, Jang EJ, Ku SK, Kim KM, Ki SH, Kim CE, Park KI, Kim SC, Kim YW. Oxyresveratrol ameliorates nonalcoholic fatty liver disease by regulating hepatic lipogenesis and fatty acid oxidation through liver kinase B1 and AMP-activated protein kinase. Chem Biol Interact 2018;289:68-74. [PMID: 29702089 DOI: 10.1016/j.cbi.2018.04.023] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 7.3] [Reference Citation Analysis]
165 Park HN, Sinn DH, Gwak GY, Kim JE, Rhee SY, Eo SJ, Kim YJ, Choi MS, Lee JH, Koh KC. Upper normal threshold of serum alanine aminotransferase in identifying individuals at risk for chronic liver disease. Liver Int. 2012;32:937-944. [PMID: 22260521 DOI: 10.1111/j.1478-3231.2011.02749.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
166 Hassanain M, Simoneau E, Doi SA, Aljiffry M, Aloraini A, Madkhali A, Metrakos P. Trends in brain-dead organ donor characteristics: a 13-year analysis. Can J Surg 2016;59:154-60. [PMID: 26999472 DOI: 10.1503/cjs.007415] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
167 Miele L, Forgione A, Gasbarrini G, Grieco A. Noninvasive assessment of fibrosis in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Transl Res. 2007;149:114-125. [PMID: 17320797 DOI: 10.1016/j.trsl.2006.11.011] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 1.7] [Reference Citation Analysis]
168 Wang L, Jiang Z, Lei XG. Knockout of SOD1 alters murine hepatic glycolysis, gluconeogenesis, and lipogenesis. Free Radic Biol Med 2012;53:1689-96. [PMID: 22974764 DOI: 10.1016/j.freeradbiomed.2012.08.570] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 3.3] [Reference Citation Analysis]
169 Lee Y, Lee H, Shim J, Moon B, Lee J, Kim J. Relationship between white blood cell count and nonalcoholic fatty liver disease. Digestive and Liver Disease 2010;42:888-94. [DOI: 10.1016/j.dld.2010.04.005] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 3.5] [Reference Citation Analysis]
170 Nikniaz L, Nikniaz Z, Tabrizi JS, Sadeghi-Bazargani H, Farahbakhsh M. Is within-normal range liver enzymes associated with metabolic syndrome in adults? Clin Res Hepatol Gastroenterol 2018;42:92-8. [PMID: 28866090 DOI: 10.1016/j.clinre.2017.06.006] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
171 Hsieh SD, Muto T, Tsuji H, Arase Y, Murase T. Clustering of other metabolic risk factors in subjects with metabolic syndrome. Metabolism 2010;59:697-702. [PMID: 19913845 DOI: 10.1016/j.metabol.2009.08.026] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
172 Kim S, Lee J, Im J, Hwang H. Increased γ-glutamyltransferase and decreased total bilirubin are associated with metabolic syndrome in Korean postmenopausal women. Clinical Chemistry and Laboratory Medicine 2010;48. [DOI: 10.1515/cclm.2010.302] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
173 Sogabe M, Okahisa T, Tsujigami K, Fukuno H, Hibino S, Yamanoi A. Visceral fat predominance is associated with non-alcoholic fatty liver disease in Japanese women with metabolic syndrome: Distinction between V- and S-type MS. Hepatol Res 2014;44:515-22. [DOI: 10.1111/hepr.12146] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
174 Rodríguez-torres M, Govindarajan S, Solá R, Clumeck N, Lissen E, Pessôa M, Buggisch P, Main J, Depamphilis J, Dieterich DT. Hepatic steatosis in HIV/HCV co-infected patients: Correlates, efficacy and outcomes of anti-HCV therapy: A paired liver biopsy study. Journal of Hepatology 2008;48:756-64. [DOI: 10.1016/j.jhep.2008.01.015] [Cited by in Crossref: 32] [Cited by in F6Publishing: 25] [Article Influence: 2.5] [Reference Citation Analysis]
175 Corey KE, Misdraji J, Gelrud L, Zheng H, Chung RT, Krauss RM. Nonalcoholic steatohepatitis is associated with an atherogenic lipoprotein subfraction profile. Lipids Health Dis. 2014;13:100. [PMID: 24952382 DOI: 10.1186/1476-511x-13-100] [Cited by in Crossref: 18] [Cited by in F6Publishing: 8] [Article Influence: 2.6] [Reference Citation Analysis]
176 Brea A, Puzo J. Non-alcoholic fatty liver disease and cardiovascular risk. Int J Cardiol. 2013;167:1109-1117. [PMID: 23141876 DOI: 10.1016/j.ijcard.2012.09.085] [Cited by in Crossref: 55] [Cited by in F6Publishing: 38] [Article Influence: 6.1] [Reference Citation Analysis]
177 Younossi ZM, Zheng L, Stepanova M, Henry L, Venkatesan C, Mishra A. Trends in outpatient resource utilizations and outcomes for Medicare beneficiaries with nonalcoholic fatty liver disease. J Clin Gastroenterol 2015;49:222-7. [PMID: 24637730 DOI: 10.1097/MCG.0000000000000071] [Cited by in Crossref: 33] [Cited by in F6Publishing: 18] [Article Influence: 5.5] [Reference Citation Analysis]
178 Manjoo P, Joseph L, Dasgupta K. Abdominal adiposity and daily step counts as determinants of glycemic control in a cohort of patients with type 2 diabetes mellitus. Nutr Diabetes 2012;2:e25. [PMID: 23154681 DOI: 10.1038/nutd.2011.22] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
179 Iogna Prat L, Tsochatzis EA. The effect of antidiabetic medications on non-alcoholic fatty liver disease (NAFLD). Hormones 2018;17:219-29. [DOI: 10.1007/s42000-018-0021-9] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 8.0] [Reference Citation Analysis]
180 Issa D, Patel V, Sanyal AJ. Future therapy for non-alcoholic fatty liver disease. Liver Int 2018;38 Suppl 1:56-63. [PMID: 29427492 DOI: 10.1111/liv.13676] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 15.5] [Reference Citation Analysis]
181 Baragetti A, Pisano G, Bertelli C, Garlaschelli K, Grigore L, Fracanzani AL, Fargion S, Norata GD, Catapano AL. Subclinical atherosclerosis is associated with Epicardial Fat Thickness and hepatic steatosis in the general population. Nutr Metab Cardiovasc Dis 2016;26:141-53. [PMID: 26777475 DOI: 10.1016/j.numecd.2015.10.013] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 3.7] [Reference Citation Analysis]
182 Leite NC, Villela-Nogueira CA, Pannain VL, Bottino AC, Rezende GF, Cardoso CR, Salles GF. Histopathological stages of nonalcoholic fatty liver disease in type 2 diabetes: prevalences and correlated factors. Liver Int. 2011;31:700-706. [PMID: 21457442 DOI: 10.1111/j.1478-3231.2011.02482.x] [Cited by in Crossref: 98] [Cited by in F6Publishing: 91] [Article Influence: 9.8] [Reference Citation Analysis]
183 Hashimoto E, Tokushige K. Prevalence, gender, ethnic variations, and prognosis of NASH. J Gastroenterol 2011;46:63-9. [DOI: 10.1007/s00535-010-0311-8] [Cited by in Crossref: 152] [Cited by in F6Publishing: 126] [Article Influence: 13.8] [Reference Citation Analysis]
184 Krakoff J, Clark JM, Crandall JP, Wilson C, Molitch ME, Brancati FL, Edelstein SL, Knowler WC; Diabetes Prevention Program Research Group. Effects of metformin and weight loss on serum alanine aminotransferase activity in the diabetes prevention program. Obesity (Silver Spring) 2010;18:1762-7. [PMID: 20186137 DOI: 10.1038/oby.2010.21] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 3.4] [Reference Citation Analysis]
185 Tamada H, Naito H, Kitamori K, Hayashi Y, Yamagishi N, Kato M, Nakajima T. Efficacy of Dietary Lipid Control in Healing High-Fat and High-Cholesterol Diet-Induced Fibrotic Steatohepatitis in Rats. PLoS One 2016;11:e0145939. [PMID: 26727365 DOI: 10.1371/journal.pone.0145939] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
186 Lim HW, Bernstein DE. Risk Factors for the Development of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis, Including Genetics. Clin Liver Dis 2018;22:39-57. [PMID: 29128060 DOI: 10.1016/j.cld.2017.08.008] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
187 Öztürk H, Gümrükçüoğlu HA, Yaman M, Akyol A, Öztürk Ş, Akdağ S, Şimşek H, Şahin M, Günaydın ZY. Hepatosteatosis and carotid intima-media thickness in patients with myocardial infarction. J Med Ultrason (2001) 2016;43:77-82. [PMID: 26703170 DOI: 10.1007/s10396-015-0649-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
188 Coccia F, Testa M, Guarisco G, Bonci E, Di Cristofano C, Silecchia G, Leonetti F, Gastaldelli A, Capoccia D. Noninvasive assessment of hepatic steatosis and fibrosis in patients with severe obesity. Endocrine 2020;67:569-78. [PMID: 31858390 DOI: 10.1007/s12020-019-02155-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
189 Dajani AI, Popovic B. Essential phospholipids for nonalcoholic fatty liver disease associated with metabolic syndrome: A systematic review and network meta-analysis. World J Clin Cases 2020;8:5235-49. [PMID: 33269259 DOI: 10.12998/wjcc.v8.i21.5235] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
190 Bouchi R, Takeuchi T, Akihisa M, Ohara N, Nakano Y, Nishitani R, Murakami M, Fukuda T, Fujita M, Minami I, Mihara M, Yoshimoto T, Ogawa Y. Increased visceral adiposity with normal weight is associated with the prevalence of non-alcoholic fatty liver disease in Japanese patients with type 2 diabetes. J Diabetes Investig 2016;7:607-14. [PMID: 27182043 DOI: 10.1111/jdi.12443] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
191 Liu ZL, Xie LZ, Zhu J, Li GQ, Grant SJ, Liu JP. Herbal medicines for fatty liver diseases. Cochrane Database Syst Rev. 2013;(8):CD009059. [PMID: 23975682 DOI: 10.1002/14651858.cd009059.pub2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
192 Toshikuni N, Fukumura A, Hayashi N, Nomura T, Tsuchishima M, Arisawa T, Tsutsumi M. Comparison of the relationships of alcoholic and nonalcoholic fatty liver with hypertension, diabetes mellitus, and dyslipidemia. J Clin Biochem Nutr. 2013;52:82-88. [PMID: 23341703 DOI: 10.3164/jcbn.12-55] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
193 Yu AH, Duan-Mu YY, Zhang Y, Wang L, Guo Z, Yu YQ, Wang YS, Cheng XG. Correlation between Non-Alcoholic Fatty Liver Disease and Visceral Adipose Tissue in Non-Obese Chinese Adults: A CT Evaluation. Korean J Radiol. 2018;19:923-929. [PMID: 30174482 DOI: 10.3348/kjr.2018.19.5.923] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
194 Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines: management of nonalcoholic fatty liver disease. Clin Mol Hepatol 2013;19:325-48. [PMID: 24459637 DOI: 10.3350/cmh.2013.19.4.325] [Cited by in Crossref: 75] [Cited by in F6Publishing: 67] [Article Influence: 9.4] [Reference Citation Analysis]
195 Neves YCS, Castro-Lima VAC, Solla DJF, Ogata VSM, Pereira FL, Araujo JM, Ho YL, Chammas MC. Ultrasound Findings and Laboratory Predictors of Early Mortality in Patients With Severe Yellow Fever. AJR Am J Roentgenol 2021;216:1392-9. [PMID: 33703928 DOI: 10.2214/AJR.20.23455] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
196 Alexander MP, Patel TV, Farag YM, Florez A, Rennke HG, Singh AK. Kidney pathological changes in metabolic syndrome: a cross-sectional study. Am J Kidney Dis. 2009;53:751-759. [PMID: 19339092 DOI: 10.1053/j.ajkd.2009.01.255] [Cited by in Crossref: 61] [Cited by in F6Publishing: 43] [Article Influence: 5.1] [Reference Citation Analysis]
197 Hwang AC, Lin YC, Liu PT, Kao YM, Chen JD. Synergistic effect of gamma glutamyltransferase and obesity on metabolic syndrome, independent of hepatic steatosis. Ann Epidemiol 2012;22:876-80. [PMID: 23110960 DOI: 10.1016/j.annepidem.2012.09.012] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
198 Hashimoto Y, Hamaguchi M, Kojima T, Ohshima Y, Ohbora A, Kato T, Nakamura N, Fukui M. Modest alcohol consumption reduces the incidence of fatty liver in men: a population-based large-scale cohort study. J Gastroenterol Hepatol 2015;30:546-52. [PMID: 25238605 DOI: 10.1111/jgh.12786] [Cited by in Crossref: 59] [Cited by in F6Publishing: 45] [Article Influence: 9.8] [Reference Citation Analysis]
199 Yamada T, Fukatsu M, Suzuki S, Wada T, Yoshida T, Joh T. Fatty liver predicts impaired fasting glucose and type 2 diabetes mellitus in Japanese undergoing a health checkup. J Gastroenterol Hepatol. 2010;25:352-356. [PMID: 19817963 DOI: 10.1111/j.1440-1746.2009.05998.x] [Cited by in Crossref: 85] [Cited by in F6Publishing: 84] [Article Influence: 7.1] [Reference Citation Analysis]
200 Maggio M, Lauretani F, Ceda GP, Bandinelli S, Basaria S, Paolisso G, Ble A, Egan JM, Metter EJ, Abbatecola AM, Zuliani G, Ruggiero C, Valenti G, Guralnik JM, Ferrucci L. Association of hormonal dysregulation with metabolic syndrome in older women: data from the InCHIANTI study. Am J Physiol Endocrinol Metab 2007;292:E353-8. [PMID: 16968811 DOI: 10.1152/ajpendo.00339.2006] [Cited by in Crossref: 46] [Cited by in F6Publishing: 43] [Article Influence: 3.1] [Reference Citation Analysis]
201 Yang J, Sáinz N, Félix-Soriano E, Gil-Iturbe E, Castilla-Madrigal R, Fernández-Galilea M, Martínez JA, Moreno-Aliaga MJ. Effects of Long-Term DHA Supplementation and Physical Exercise on Non-Alcoholic Fatty Liver Development in Obese Aged Female Mice. Nutrients 2021;13:501. [PMID: 33546405 DOI: 10.3390/nu13020501] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
202 Carnagarin R, Kiuchi MG, Goh G, Adams L, Cohen N, Kavnoudias H, Gan SK, Van Schie G, Esler MD, Matthews VB, Schlaich MP. Role of the sympathetic nervous system in cardiometabolic control: implications for targeted multiorgan neuromodulation approaches. J Hypertens 2021;39:1478-89. [PMID: 33657580 DOI: 10.1097/HJH.0000000000002839] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
203 Naik RD, Choksi YA, Vaezi MF. Consequences of bariatric surgery on oesophageal function in health and disease. Nat Rev Gastroenterol Hepatol 2016;13:111-9. [DOI: 10.1038/nrgastro.2015.202] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
204 Tominaga K, Fujimoto E, Suzuki K, Hayashi M, Ichikawa M, Inaba Y. Prevalence of non-alcoholic fatty liver disease in children and relationship to metabolic syndrome, insulin resistance, and waist circumference. Environ Health Prev Med 2009;14:142-9. [PMID: 19568858 DOI: 10.1007/s12199-008-0074-5] [Cited by in Crossref: 40] [Cited by in F6Publishing: 34] [Article Influence: 3.3] [Reference Citation Analysis]
205 Mokhayeri Y, Riahi SM, Rahimzadeh S, Pourhoseingholi MA, Hashemi-nazari SS. Metabolic syndrome prevalence in the Iranian adult’s general population and its trend: A systematic review and meta-analysis of observational studies. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 2018;12:441-53. [DOI: 10.1016/j.dsx.2017.12.023] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
206 Tomic D, Kemp WW, Roberts SK. Nonalcoholic fatty liver disease: current concepts, epidemiology and management strategies. Eur J Gastroenterol Hepatol 2018;30:1103-15. [PMID: 30113367 DOI: 10.1097/MEG.0000000000001235] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 12.0] [Reference Citation Analysis]
207 Faran SA, Asghar S, Khalid SH, Khan IU, Asif M, Khalid I, Gohar UF, Hussain T. Hepatoprotective and Renoprotective Properties of Lovastatin-Loaded Ginger and Garlic Oil Nanoemulsomes: Insights into Serum Biological Parameters. Medicina (Kaunas) 2019;55:E579. [PMID: 31505863 DOI: 10.3390/medicina55090579] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
208 Shiraishi M, Tanaka M, Okada H, Hashimoto Y, Nakagawa S, Kumagai M, Yamamoto T, Nishimura H, Oda Y, Fukui M. Potential impact of the joint association of total bilirubin and gamma-glutamyltransferase with metabolic syndrome. Diabetol Metab Syndr 2019;11:12. [PMID: 30740147 DOI: 10.1186/s13098-019-0408-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
209 Caballería L, Pera G, Rodríguez L, Auladell MA, Bernad J, Canut S, Torán P. Metabolic syndrome and nonalcoholic fatty liver disease in a Spanish population: influence of the diagnostic criteria used. Eur J Gastroenterol Hepatol. 2012;24:1007-1011. [PMID: 22668875 DOI: 10.1097/meg.0b013e328355b87f] [Cited by in Crossref: 20] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
210 Takeuchi K, Yokouchi C, Goto H, Umehara K, Yamada H, Ishii Y. Alleviation of fatty liver in a rat model by enhancing N1-methylnicotinamide bioavailability through aldehyde oxidase inhibition. Biochemical and Biophysical Research Communications 2018;507:203-10. [DOI: 10.1016/j.bbrc.2018.11.008] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
211 Petta S, Eslam M, Valenti L, Bugianesi E, Barbara M, Cammà C, Porzio M, Rosso C, Fargion S, George J, Craxì A. Metabolic syndrome and severity of fibrosis in nonalcoholic fatty liver disease: An age-dependent risk profiling study. Liver Int 2017;37:1389-96. [PMID: 28235154 DOI: 10.1111/liv.13397] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
212 Ogawa Y, Imajo K, Yoneda M, Kessoku T, Tomeno W, Shinohara Y, Kato S, Mawatari H, Nozaki Y, Fujita K, Kirikoshi H, Maeda S, Saito S, Wada K, Nakajima A. Soluble CD14 levels reflect liver inflammation in patients with nonalcoholic steatohepatitis. PLoS One 2013;8:e65211. [PMID: 23762319 DOI: 10.1371/journal.pone.0065211] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 3.6] [Reference Citation Analysis]
213 Moriyama K, Urata N, Masuda Y, Oda K, Okuno C, Yamada C, Takashimizu S, Kubo A, Kishimoto N, Nishizaki Y. Usefulness of Triglyceride to High-Density Lipoprotein Ratio and Alanine Aminotransferase for Predicting Insulin Resistance and Metabolic Syndrome in the Japanese Population. Metab Syndr Relat Disord 2021;19:225-32. [PMID: 33577395 DOI: 10.1089/met.2020.0121] [Reference Citation Analysis]
214 Edens MA, Kuipers F, Stolk RP. Non-alcoholic fatty liver disease is associated with cardiovascular disease risk markers. Obesity Reviews 2009;10:412-9. [DOI: 10.1111/j.1467-789x.2009.00594.x] [Cited by in Crossref: 48] [Cited by in F6Publishing: 30] [Article Influence: 4.0] [Reference Citation Analysis]
215 Dassanayake AS, Kasturiratne A, Rajindrajith S, Kalubowila U, Chakrawarthi S, De Silva AP, Makaya M, Mizoue T, Kato N, Wickremasinghe AR. Prevalence and risk factors for non-alcoholic fatty liver disease among adults in an urban Sri Lankan population. J Gastroenterol Hepatol. 2009;24:1284-1288. [PMID: 19476560 DOI: 10.1111/j.1440-1746.2009.05831.x] [Cited by in Crossref: 119] [Cited by in F6Publishing: 80] [Article Influence: 9.9] [Reference Citation Analysis]
216 Masuoka HC, Chalasani N. Nonalcoholic fatty liver disease: an emerging threat to obese and diabetic individuals. Ann N Y Acad Sci. 2013;1281:106-122. [PMID: 23363012 DOI: 10.1111/nyas.12016] [Cited by in Crossref: 159] [Cited by in F6Publishing: 133] [Article Influence: 19.9] [Reference Citation Analysis]
217 Eguchi Y, Wong G, Lee EI, Akhtar O, Lopes R, Sumida Y. Epidemiology of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in Japan: A focused literature review. JGH Open 2020;4:808-17. [PMID: 33102749 DOI: 10.1002/jgh3.12349] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
218 Hobeika C, Cauchy F, Poté N, Rautou PE, Durand F, Farges O, Dokmak S, Vilgrain V, Ronot M, Paradis V, Soubrane O. Short- and Long-Term Outcomes of Liver Resection for Intrahepatic Cholangiocarcinoma Associated with the Metabolic Syndrome. World J Surg 2019;43:2048-60. [PMID: 30949764 DOI: 10.1007/s00268-019-04996-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
219 Tacelli M, Celsa C, Magro B, Giannetti A, Pennisi G, Spatola F, Petta S. Antidiabetic Drugs in NAFLD: The Accomplishment of Two Goals at Once? Pharmaceuticals (Basel). 2018;11:121. [PMID: 30413050 DOI: 10.3390/ph11040121] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 7.0] [Reference Citation Analysis]
220 Caldwell SH, Ikura Y, Iezzoni JC, Liu Z. Has natural selection in human populations produced two types of metabolic syndrome (with and without fatty liver)? J Gastroenterol Hepatol. 2007;22 Suppl 1:S11-S19. [PMID: 17567458 DOI: 10.1111/j.1440-1746.2006.04639.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
221 Sogabe M, Okahisa T, Kurihara T, Takehara M, Kagemoto K, Okazaki J, Kida Y, Hirao A, Tanaka H, Tomonari T, Taniguchi T, Okamoto K, Nakasono M, Takayama T. Differences among patients with and without nonalcoholic fatty liver disease having elevated alanine aminotransferase levels at various stages of metabolic syndrome. PLoS One 2020;15:e0238388. [PMID: 32866186 DOI: 10.1371/journal.pone.0238388] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
222 Luk A, Chan JC. Diabetic nephropathy--what are the unmet needs? Diabetes Res Clin Pract 2008;82 Suppl 1:S15-20. [PMID: 18952313 DOI: 10.1016/j.diabres.2008.09.033] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
223 Sanal MG, Sarin SK. Association of nonalcoholic fatty liver disease with metabolic syndrome in Indian population. Diabetes Metab Syndr 2011;5:76-80. [PMID: 22813407 DOI: 10.1016/j.dsx.2012.02.015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
224 Lee SR, Han Y, Kim JW, Park JY, Kim JM, Suh S, Park MK, Lee HJ, Kim DK. Cardio-metabolic features of type 2 diabetes subjects discordant in the diagnosis of metabolic syndrome. Diabetes Metab J 2012;36:357-63. [PMID: 23130320 DOI: 10.4093/dmj.2012.36.5.357] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
225 Muthiah MD, Sanyal AJ. Burden of Disease due to Nonalcoholic Fatty Liver Disease. Gastroenterol Clin North Am 2020;49:1-23. [PMID: 32033757 DOI: 10.1016/j.gtc.2019.09.007] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 13.0] [Reference Citation Analysis]
226 Amarapurkar DN, Hashimoto E, Lesmana LA, Sollano JD, Chen PJ, Goh KL, Asia-Pacific Working Party on NAFLD. How common is non-alcoholic fatty liver disease in the Asia-Pacific region and are there local differences? J Gastroenterol Hepatol. 2007;22:788-793. [PMID: 17565631 DOI: 10.1111/j.1440-1746.2007.05042.x] [Cited by in Crossref: 251] [Cited by in F6Publishing: 247] [Article Influence: 17.9] [Reference Citation Analysis]
227 Montez P, Vázquez-Medina JP, Rodríguez R, Thorwald MA, Viscarra JA, Lam L, Peti-Peterdi J, Nakano D, Nishiyama A, Ortiz RM. Angiotensin receptor blockade recovers hepatic UCP2 expression and aconitase and SDH activities and ameliorates hepatic oxidative damage in insulin resistant rats. Endocrinology. 2012;153:5746-5759. [PMID: 23087176 DOI: 10.1210/en.2012-1390] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
228 Lin L, Zhang J, Jiang L, Du R, Hu C, Lu J, Wang T, Li M, Zhao Z, Xu Y, Xu M, Bi Y, Ning G, Wang W, Chen Y. Transition of metabolic phenotypes and risk of subclinical atherosclerosis according to BMI: a prospective study. Diabetologia 2020;63:1312-23. [DOI: 10.1007/s00125-020-05116-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 11.0] [Reference Citation Analysis]
229 Hamaguchi M, Hashimoto Y, Obora A, Kojima T, Fukui M. Non-alcoholic fatty liver disease with obesity as an independent predictor for incident gastric and colorectal cancer: a population-based longitudinal study. BMJ Open Gastroenterol 2019;6:e000295. [PMID: 31275587 DOI: 10.1136/bmjgast-2019-000295] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 8.5] [Reference Citation Analysis]
230 Sanal MG. The blind men 'see' the elephant-the many faces of fatty liver disease. World J Gastroenterol 2008;14:831-44. [PMID: 18240340 DOI: 10.3748/wjg.14.831] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 28] [Article Influence: 2.4] [Reference Citation Analysis]
231 Imajo K, Yoneda M, Fujita K, Kessoku T, Tomeno W, Ogawa Y, Shinohara Y, Sekino Y, Mawatari H, Nozaki Y, Kirikoshi H, Taguri M, Toshima G, Takahashi J, Saito S, Wada K, Nakajima A. Oral choline tolerance test as a novel noninvasive method for predicting nonalcoholic steatohepatitis. J Gastroenterol 2014;49:295-304. [PMID: 23503837 DOI: 10.1007/s00535-013-0776-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
232 Olynyk JK, Knuiman MW, Divitini ML, Davis TME, Beilby J, Hung J. Serum Alanine Aminotransferase, Metabolic Syndrome and Cardiovascular Disease in an Australian Population. Am J Gastroenterol 2009;104:1715-22. [DOI: 10.1038/ajg.2009.229] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 2.6] [Reference Citation Analysis]
233 Li L, Liu D-, Yan H-, Wang Z-, Zhao S-, Wang B. Obesity is an independent risk factor for non-alcoholic fatty liver disease: evidence from a meta-analysis of 21 cohort studies: Obesity and non-alcoholic fatty liver disease. Obesity Reviews 2016;17:510-9. [DOI: 10.1111/obr.12407] [Cited by in Crossref: 116] [Cited by in F6Publishing: 97] [Article Influence: 23.2] [Reference Citation Analysis]
234 Koh ZJ, Salgaonkar HP, Lee WJJ, Kim GW, Tan CH, Cheng A, Lomanto D, So JBY, Dan YY, Shabbir A. Improvement in Non-alcoholic Fatty Liver Disease Score Correlates with Weight Loss in Obese Patients Undergoing Laparoscopic Sleeve Gastrectomy: a Two-Centre Study from an Asian Cohort. Obes Surg 2019;29:862-8. [PMID: 30515622 DOI: 10.1007/s11695-018-3581-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
235 Liu W, Qin L, Yu H, Lv F, Wang Y. Apolipoprotein A-I and adenosine triphosphate-binding cassette transporter A1 expression alleviates lipid accumulation in hepatocytes: ApoA-I/ABCA1 expression reduces lipids. J Gastroenterol Hepatol 2014;29:614-22. [DOI: 10.1111/jgh.12430] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 3.1] [Reference Citation Analysis]
236 Lin CY, Lin WY, Lin CC, Shih CM, Jeng LB, Kao CH. The negative impact of fatty liver on maximum standard uptake value of liver on FDG PET. Clin Imaging. 2011;35:437-441. [PMID: 22040787 DOI: 10.1016/j.clinimag.2011.02.005] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 3.2] [Reference Citation Analysis]
237 Dixon JB. Surgical treatment for obesity and its impact on non-alcoholic steatohepatitis. Clin Liver Dis. 2007;11:141-154, ix-x. [PMID: 17544976 DOI: 10.1016/j.cld.2007.02.005] [Cited by in Crossref: 36] [Cited by in F6Publishing: 24] [Article Influence: 2.6] [Reference Citation Analysis]
238 Miyake T, Kumagi T, Hirooka M, Furukawa S, Koizumi M, Tokumoto Y, Ueda T, Yamamoto S, Abe M, Kitai K. Body mass index is the most useful predictive factor for the onset of nonalcoholic fatty liver disease: a community-based retrospective longitudinal cohort study. J Gastroenterol. 2013;48:413-422. [PMID: 22933183 DOI: 10.1007/s00535-012-0650-8] [Cited by in Crossref: 44] [Cited by in F6Publishing: 34] [Article Influence: 4.9] [Reference Citation Analysis]
239 Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Chang AR, Cheng S, Das SR, Delling FN, Djousse L, Elkind MSV, Ferguson JF, Fornage M, Jordan LC, Khan SS, Kissela BM, Knutson KL, Kwan TW, Lackland DT, Lewis TT, Lichtman JH, Longenecker CT, Loop MS, Lutsey PL, Martin SS, Matsushita K, Moran AE, Mussolino ME, O'Flaherty M, Pandey A, Perak AM, Rosamond WD, Roth GA, Sampson UKA, Satou GM, Schroeder EB, Shah SH, Spartano NL, Stokes A, Tirschwell DL, Tsao CW, Turakhia MP, VanWagner LB, Wilkins JT, Wong SS, Virani SS;  American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2019 Update: A Report From the American Heart Association. Circulation. 2019;139:e56-e528. [PMID: 30700139 DOI: 10.1161/cir.0000000000000659] [Cited by in Crossref: 2988] [Cited by in F6Publishing: 1191] [Article Influence: 1494.0] [Reference Citation Analysis]
240 Pei K, Gui T, Kan D, Feng H, Jin Y, Yang Y, Zhang Q, Du Z, Gai Z, Wu J, Li Y. An Overview of Lipid Metabolism and Nonalcoholic Fatty Liver Disease. Biomed Res Int. 2020;2020:4020249. [PMID: 32733940 DOI: 10.1155/2020/4020249] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
241 Mishra A, Younossi ZM. Epidemiology and Natural History of Non-alcoholic Fatty Liver Disease. J Clin Exp Hepatol. 2012;2:135-144. [PMID: 25755422 DOI: 10.1016/s0973-6883(12)60102-9] [Cited by in Crossref: 51] [Cited by in F6Publishing: 25] [Article Influence: 5.7] [Reference Citation Analysis]
242 Tanaka N, Tanaka E, Sheena Y, Komatsu M, Okiyama W, Misawa N, Muto H, Umemura T, Ichijo T, Matsumoto A, Yoshizawa K, Horiuchi A, Kiyosawa K. Useful parameters for distinguishing nonalcoholic steatohepatitis with mild steatosis from cryptogenic chronic hepatitis in the Japanese population. Liver Int. 2006;26:956-963. [PMID: 16953836 DOI: 10.1111/j.1478-3231.2006.01338.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 1.6] [Reference Citation Analysis]
243 Schreuder TC, Verwer BJ, van Nieuwkerk CM, Mulder CJ. Nonalcoholic fatty liver disease: an overview of current insights in pathogenesis, diagnosis and treatment. World J Gastroenterol. 2008;14:2474-2486. [PMID: 18442193 DOI: 10.3748/wjg.14.2474] [Cited by in CrossRef: 111] [Cited by in F6Publishing: 101] [Article Influence: 9.3] [Reference Citation Analysis]
244 Kawamura Y, Arase Y, Ikeda K, Seko Y, Imai N, Hosaka T, Kobayashi M, Saitoh S, Sezaki H, Akuta N, Suzuki F, Suzuki Y, Ohmoto Y, Amakawa K, Tsuji H, Kumada H. Large-scale long-term follow-up study of Japanese patients with non-alcoholic Fatty liver disease for the onset of hepatocellular carcinoma. Am J Gastroenterol. 2012;107:253-261. [PMID: 22008893 DOI: 10.1038/ajg.2011.327] [Cited by in Crossref: 148] [Cited by in F6Publishing: 143] [Article Influence: 14.8] [Reference Citation Analysis]
245 Rosso C, Mezzabotta L, Gaggini M, Salomone F, Gambino R, Marengo A, Saba F, Vanni E, Jouness RI, Saponaro C. Peripheral insulin resistance predicts liver damage in nondiabetic subjects with nonalcoholic fatty liver disease. Hepatology. 2016;63:107-116. [PMID: 26473614 DOI: 10.1002/hep.28287] [Cited by in Crossref: 36] [Cited by in F6Publishing: 29] [Article Influence: 6.0] [Reference Citation Analysis]
246 Ma RC, Liu KH, Lam PM, Cheung LP, Tam WH, Ko GT, Chan MH, Ho CS, Lam CW, Chu WC. Sonographic measurement of mesenteric fat predicts presence of fatty liver among subjects with polycystic ovary syndrome. J Clin Endocrinol Metab. 2011;96:799-807. [PMID: 21190980 DOI: 10.1210/jc.2010-1608] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
247 Fan JG, Saibara T, Chitturi S, Kim BI, Sung JJ, Chutaputti A. What are the risk factors and settings for non-alcoholic fatty liver disease in Asia-Pacific? J Gastroenterol Hepatol. 2007;22:794-800. [PMID: 17498218 DOI: 10.1111/j.1440-1746.2007.04952.x] [Cited by in Crossref: 171] [Cited by in F6Publishing: 168] [Article Influence: 12.2] [Reference Citation Analysis]
248 Lazo M, Zeb I, Nasir K, Tracy RP, Budoff MJ, Ouyang P, Vaidya D. Association Between Endogenous Sex Hormones and Liver Fat in a Multiethnic Study of Atherosclerosis. Clin Gastroenterol Hepatol. 2015;13:1686-1693.e2. [PMID: 25592661 DOI: 10.1016/j.cgh.2014.12.033] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 6.5] [Reference Citation Analysis]
249 Farrell GC, Teoh NC, McCuskey RS. Hepatic microcirculation in fatty liver disease. Anat Rec (Hoboken). 2008;291:684-692. [PMID: 18484615 DOI: 10.1002/ar.20715] [Cited by in Crossref: 166] [Cited by in F6Publishing: 148] [Article Influence: 12.8] [Reference Citation Analysis]
250 Boyce CJ, Pickhardt PJ, Kim DH, Taylor AJ, Winter TC, Bruce RJ, Lindstrom MJ, Hinshaw JL. Hepatic steatosis (fatty liver disease) in asymptomatic adults identified by unenhanced low-dose CT. AJR Am J Roentgenol. 2010;194:623-628. [PMID: 20173137 DOI: 10.2214/ajr.09.2590] [Cited by in Crossref: 132] [Cited by in F6Publishing: 49] [Article Influence: 12.0] [Reference Citation Analysis]
251 Lee K. Metabolic syndrome predicts the incidence of hepatic steatosis in Koreans. Obesity Research & Clinical Practice 2010;4:e217-24. [DOI: 10.1016/j.orcp.2010.02.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
252 Hadi A, Arab A, Khalesi S, Rafie N, Kafeshani M, Kazemi M. Effects of probiotic supplementation on anthropometric and metabolic characteristics in adults with metabolic syndrome: A systematic review and meta-analysis of randomized clinical trials. Clin Nutr 2021;40:4662-73. [PMID: 34237694 DOI: 10.1016/j.clnu.2021.05.027] [Reference Citation Analysis]
253 Symonds ME, Sebert SP, Hyatt MA, Budge H. Nutritional programming of the metabolic syndrome. Nat Rev Endocrinol 2009;5:604-10. [PMID: 19786987 DOI: 10.1038/nrendo.2009.195] [Cited by in Crossref: 258] [Cited by in F6Publishing: 204] [Article Influence: 21.5] [Reference Citation Analysis]
254 Brown TM. Nonalcoholic fatty liver disease and cardiovascular disease risk. Clin Gastroenterol Hepatol. 2012;10:568-569. [PMID: 22387255 DOI: 10.1016/j.cgh.2012.02.023] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
255 Okamoto K, Koda M, Okamoto T, Onoyama T, Miyoshi K, Kishina M, Matono T, Kato J, Tokunaga S, Sugihara T, Hiramatsu A, Hyogo H, Tobita H, Sato S, Kawanaka M, Hara Y, Hino K, Chayama K, Murawaki Y, Isomoto H. Serum miR-379 expression is related to the development and progression of hypercholesterolemia in non-alcoholic fatty liver disease. PLoS One 2020;15:e0219412. [PMID: 32106257 DOI: 10.1371/journal.pone.0219412] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
256 Hamaguchi M, Takeda N, Kojima T, Ohbora A, Kato T, Sarui H, Fukui M, Nagata C, Takeda J. Identification of individuals with non-alcoholic fatty liver disease by the diagnostic criteria for the metabolic syndrome. World J Gastroenterol. 2012;18:1508-1516. [PMID: 22509083 DOI: 10.3748/wjg.v18.i13.1508] [Cited by in CrossRef: 49] [Cited by in F6Publishing: 46] [Article Influence: 5.4] [Reference Citation Analysis]
257 Stein LL, Dong MH, Loomba R. Insulin sensitizers in nonalcoholic fatty liver disease and steatohepatitis: Current status. Adv Ther 2009;26:893-907. [PMID: 19921118 DOI: 10.1007/s12325-009-0072-z] [Cited by in Crossref: 59] [Cited by in F6Publishing: 53] [Article Influence: 4.9] [Reference Citation Analysis]
258 Linhart KB, Glassen K, Peccerella T, Waldherr R, Linhart H, Bartsch H, Seitz HK. The generation of carcinogenic etheno-DNA adducts in the liver of patients with nonalcoholic fatty liver disease. Hepatobiliary Surg Nutr 2015;4:117-23. [PMID: 26005678 DOI: 10.3978/j.issn.2304-3881.2015.01.14] [Cited by in F6Publishing: 13] [Reference Citation Analysis]
259 Tang A, Desai A, Hamilton G, Wolfson T, Gamst A, Lam J, Clark L, Hooker J, Chavez T, Ang BD, Middleton MS, Peterson M, Loomba R, Sirlin CB. Accuracy of MR imaging-estimated proton density fat fraction for classification of dichotomized histologic steatosis grades in nonalcoholic fatty liver disease. Radiology 2015;274:416-25. [PMID: 25247408 DOI: 10.1148/radiol.14140754] [Cited by in Crossref: 131] [Cited by in F6Publishing: 109] [Article Influence: 18.7] [Reference Citation Analysis]
260 Tota-Maharaj R, Blaha MJ, Zeb I, Katz R, Blankstein R, Blumenthal RS, Budoff MJ, Nasir K. Ethnic and sex differences in fatty liver on cardiac computed tomography: the multi-ethnic study of atherosclerosis. Mayo Clin Proc 2014;89:493-503. [PMID: 24613289 DOI: 10.1016/j.mayocp.2013.12.015] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 4.1] [Reference Citation Analysis]
261 Hamaguchi M, Kojima T, Itoh Y, Harano Y, Fujii K, Nakajima T, Kato T, Takeda N, Okuda J, Ida K, Kawahito Y, Yoshikawa T, Okanoue T. The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation. Am J Gastroenterol. 2007;102:2708-2715. [PMID: 17894848 DOI: 10.1111/j.1572-0241.2007.01526.x] [Cited by in Crossref: 414] [Cited by in F6Publishing: 388] [Article Influence: 29.6] [Reference Citation Analysis]
262 Basu Ray S. PNPLA3-I148M: a problem of plenty in non-alcoholic fatty liver disease. Adipocyte 2019;8:201-8. [PMID: 31062641 DOI: 10.1080/21623945.2019.1607423] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 11.0] [Reference Citation Analysis]
263 Sookoian S, Castaño G, Gemma C, Gianotti TF, Pirola CJ. Common genetic variations in CLOCK transcription factor are associated with nonalcoholic fatty liver disease. World J Gastroenterol 2007;13:4242-8. [PMID: 17696255 DOI: 10.3748/wjg.v13.i31.4242] [Cited by in CrossRef: 77] [Cited by in F6Publishing: 71] [Article Influence: 5.5] [Reference Citation Analysis]
264 Kralj D, Virović Jukić L, Stojsavljević S, Duvnjak M, Smolić M, Čurčić IB. Hepatitis C Virus, Insulin Resistance, and Steatosis. J Clin Transl Hepatol 2016;4:66-75. [PMID: 27047774 DOI: 10.14218/JCTH.2015.00051] [Cited by in Crossref: 46] [Cited by in F6Publishing: 26] [Article Influence: 9.2] [Reference Citation Analysis]
265 Corey KE, Vuppalanchi R, Vos M, Kohli R, Molleston JP, Wilson L, Unalp-Arida A, Cummings OW, Lavine JE, Chalasani N. Improvement in liver histology is associated with reduction in dyslipidemia in children with nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr. 2015;60:360-367. [PMID: 25714579 DOI: 10.1097/mpg.0000000000000584] [Cited by in Crossref: 24] [Cited by in F6Publishing: 13] [Article Influence: 4.8] [Reference Citation Analysis]
266 Tajima R, Kimura T, Enomoto A, Yanoshita K, Saito A, Kobayashi S, Masuda K, Iida K. Association between rice, bread, and noodle intake and the prevalence of non-alcoholic fatty liver disease in Japanese middle-aged men and women. Clin Nutr 2017;36:1601-8. [PMID: 27773550 DOI: 10.1016/j.clnu.2016.09.034] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
267 Pati GK, Singh SP. Nonalcoholic Fatty Liver Disease in South Asia. Euroasian J Hepatogastroenterol 2016;6:154-62. [PMID: 29201749 DOI: 10.5005/jp-journals-10018-1189] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
268 Jung S, Kim OY, Kim M, Song J, Lee S, Lee JH. Age-Related Increase in Alanine Aminotransferase Correlates with Elevated Levels of Plasma Amino Acids, Decanoylcarnitine, Lp-PLA 2 Activity, Oxidative Stress, and Arterial Stiffness. J Proteome Res 2014;13:3467-75. [DOI: 10.1021/pr500422z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
269 Deaciuc IV, Song Z, Peng X, Barve SS, Song M, He Q, Knudsen TB, Singh AV, McClain CJ. Genome-wide transcriptome expression in the liver of a mouse model of high carbohydrate diet-induced liver steatosis and its significance for the disease. Hepatol Int 2008;2:39-49. [PMID: 19669278 DOI: 10.1007/s12072-007-9025-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
270 Watanabe S, Yaginuma R, Ikejima K, Miyazaki A. Liver diseases and metabolic syndrome. J Gastroenterol. 2008;43:509-518. [PMID: 18648737 DOI: 10.1007/s00535-008-2193-6] [Cited by in Crossref: 119] [Cited by in F6Publishing: 101] [Article Influence: 9.2] [Reference Citation Analysis]
271 Heianza Y, Arase Y, Tsuji H, Fujihara K, Saito K, Hsieh SD, Tanaka S, Kodama S, Hara S, Sone H. Metabolically healthy obesity, presence or absence of fatty liver, and risk of type 2 diabetes in Japanese individuals: Toranomon Hospital Health Management Center Study 20 (TOPICS 20). J Clin Endocrinol Metab. 2014;99:2952-2960. [PMID: 24823457 DOI: 10.1210/jc.2013-4427] [Cited by in Crossref: 59] [Cited by in F6Publishing: 50] [Article Influence: 8.4] [Reference Citation Analysis]
272 Bhat G, Baba CS, Pandey A, Kumari N, Choudhuri G. Life style modification improves insulin resistance and liver histology in patients with non-alcoholic fatty liver disease. World J Hepatol. 2012;4:209-217. [PMID: 22855696 DOI: 10.4254/wjh.v4.i7.209] [Cited by in Crossref: 33] [Cited by in F6Publishing: 25] [Article Influence: 3.7] [Reference Citation Analysis]
273 Martínez Soriano B, Güemes A, Pola G, Gonzalo A, Palacios Gasós P, Navarro AC, Martínez-Beamonte R, Osada J, García JJ. Effect of Melatonin as an Antioxidant Drug to Reverse Hepatic Steatosis: Experimental Model. Can J Gastroenterol Hepatol 2020;2020:7315253. [PMID: 32566547 DOI: 10.1155/2020/7315253] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
274 Muriel P. The Liver. Liver Pathophysiology. Elsevier; 2017. pp. 3-22. [DOI: 10.1016/b978-0-12-804274-8.00001-1] [Cited by in Crossref: 10] [Article Influence: 2.5] [Reference Citation Analysis]
275 Uslusoy HS, Nak SG, Gülten M, Biyikli Z. Liver histology according to the presence of metabolic syndrome in nonalcoholic fatty liver disease cases. World J Gastroenterol. 2009;15:1093-1098. [PMID: 19266602 DOI: 10.3748/wjg.15.1093] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
276 Nugent C, Younossi ZM. Evaluation and management of obesity-related nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 2007;4:432-41. [DOI: 10.1038/ncpgasthep0879] [Cited by in Crossref: 63] [Cited by in F6Publishing: 55] [Article Influence: 4.5] [Reference Citation Analysis]
277 Thakur ML, Sharma S, Kumar A, Bhatt SP, Luthra K, Guleria R, Pandey RM, Vikram NK. Nonalcoholic fatty liver disease is associated with subclinical atherosclerosis independent of obesity and metabolic syndrome in Asian Indians. Atherosclerosis. 2012;223:507-511. [PMID: 22748277 DOI: 10.1016/j.atherosclerosis.2012.06.005] [Cited by in Crossref: 63] [Cited by in F6Publishing: 55] [Article Influence: 7.0] [Reference Citation Analysis]
278 Prasad GV. Metabolic syndrome and chronic kidney disease: Current status and future directions. World J Nephrol. 2014;3:210-219. [PMID: 25374814 DOI: 10.5527/wjn.v3.i4.210] [Cited by in CrossRef: 61] [Cited by in F6Publishing: 42] [Article Influence: 8.7] [Reference Citation Analysis]
279 Miquilena Colina ME, García Monzón C. [Obesity and liver disease]. Gastroenterol Hepatol 2010;33:591-604. [PMID: 20206411 DOI: 10.1016/j.gastrohep.2009.12.009] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
280 Baumgaertner I, Ratziu V, Vaillant JC, Hannoun L, Poynard T, André T. [Hepatotoxicity of metastatic colorectal cancer chemotherapy: systematic review]. Bull Cancer. 2010;97:559-569. [PMID: 20167564 DOI: 10.1684/bdc.2010.1049] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
281 Parekh S, Anania FA. Abnormal lipid and glucose metabolism in obesity: implications for nonalcoholic fatty liver disease. Gastroenterology. 2007;132:2191-2207. [PMID: 17498512 DOI: 10.1053/j.gastro.2007.03.055] [Cited by in Crossref: 217] [Cited by in F6Publishing: 197] [Article Influence: 15.5] [Reference Citation Analysis]
282 Miyake T, Kumagi T, Furukawa S, Tokumoto Y, Hirooka M, Abe M, Hiasa Y, Matsuura B, Onji M. Non-alcoholic fatty liver disease: factors associated with its presence and onset. J Gastroenterol Hepatol. 2013;28 Suppl 4:71-78. [PMID: 24251708 DOI: 10.1111/jgh.12251] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
283 Chiang PH, Chang TY, Chen JD. Synergistic effect of fatty liver and smoking on metabolic syndrome. World J Gastroenterol 2009;15:5334-9. [PMID: 19908343 DOI: 10.3748/wjg.15.5334] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
284 Ong JP, Younossi ZM. Epidemiology and Natural History of NAFLD and NASH. Clinics in Liver Disease 2007;11:1-16. [DOI: 10.1016/j.cld.2007.02.009] [Cited by in Crossref: 292] [Cited by in F6Publishing: 260] [Article Influence: 20.9] [Reference Citation Analysis]
285 Loria P, Lonardo A, Bellentani S, Day CP, Marchesini G, Carulli N. Non-alcoholic fatty liver disease (NAFLD) and cardiovascular disease: an open question. Nutr Metab Cardiovasc Dis. 2007;17:684-698. [PMID: 17560098 DOI: 10.1016/j.numecd.2007.01.007] [Cited by in Crossref: 55] [Cited by in F6Publishing: 50] [Article Influence: 3.9] [Reference Citation Analysis]
286 Welzel TM, Graubard BI, Zeuzem S, El-Serag HB, Davila JA, McGlynn KA. Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database. Hepatology. 2011;54:463-471. [PMID: 21538440 DOI: 10.1002/hep.24397] [Cited by in Crossref: 338] [Cited by in F6Publishing: 295] [Article Influence: 33.8] [Reference Citation Analysis]
287 Mencarelli A, Cipriani S, Renga B, Bruno A, D'Amore C, Distrutti E, Fiorucci S. VSL#3 resets insulin signaling and protects against NASH and atherosclerosis in a model of genetic dyslipidemia and intestinal inflammation. PLoS One. 2012;7:e45425. [PMID: 23029000 DOI: 10.1371/journal.pone.0045425] [Cited by in Crossref: 62] [Cited by in F6Publishing: 61] [Article Influence: 6.9] [Reference Citation Analysis]
288 Efe D, Aygün F. Assessment of the relationship between non-alcoholic fatty liver disease and CAD using MSCT. Arq Bras Cardiol 2014;102:10-8. [PMID: 24263777 DOI: 10.5935/abc.20130225] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
289 Tang A, Li C, Zou N, Zhang Q, Liu M, Zhang X. Angiotensin-(1-7) improves non-alcoholic steatohepatitis through an adiponectin-independent mechanism: Ang-(1-7) activates AMPK pathway. Hepatol Res 2017;47:116-22. [DOI: 10.1111/hepr.12707] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
290 Chon CW, Kim BS, Cho YK, Sung KC, Bae JC, Kim TW, Won HS, Joo KJ. Effect of nonalcoholic Fatty liver disease on the development of type 2 diabetes in nonobese, nondiabetic korean men. Gut Liver. 2012;6:368-373. [PMID: 22844567 DOI: 10.5009/gnl.2012.6.3.368] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
291 Duseja A, Chalasani N. Epidemiology and risk factors of nonalcoholic fatty liver disease (NAFLD). Hepatol Int 2013;7 Suppl 2:755-64. [PMID: 26202291 DOI: 10.1007/s12072-013-9480-x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
292 Lee SP. Non-Alcoholic Fatty Liver Disease, a Marker of Subclinical Atherosclerosis Applicable Only to Metabolic Syndrome?: Time to Organize the Connection between Metabolism and Atherosclerosis. J Cardiovasc Ultrasound 2012;20:124-5. [PMID: 23185654 DOI: 10.4250/jcu.2012.20.3.124] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
293 Oke SL, Lee K, Papp R, Laviolette SR, Hardy DB. In Utero Exposure to Δ9-Tetrahydrocannabinol Leads to Postnatal Catch-Up Growth and Dysmetabolism in the Adult Rat Liver. Int J Mol Sci 2021;22:7502. [PMID: 34299119 DOI: 10.3390/ijms22147502] [Reference Citation Analysis]
294 Tsai PY, Yen CJ, Li YC, Chiu TY, Chen CY, Jan CF. Association between abnormal liver function and risk factors for metabolic syndrome among freshmen. J Adolesc Health. 2007;41:132-137. [PMID: 17659216 DOI: 10.1016/j.jadohealth.2007.03.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
295 Polyzos SA, Kountouras J, Zavos C, Deretzi G. Nonalcoholic Fatty Liver Disease: Multimodal Treatment Options for a Pathogenetically Multiple-hit Disease. Journal of Clinical Gastroenterology 2012;46:272-84. [DOI: 10.1097/mcg.0b013e31824587e0] [Cited by in Crossref: 80] [Cited by in F6Publishing: 25] [Article Influence: 8.9] [Reference Citation Analysis]
296 Bassi N, Karagodin I, Wang S, Vassallo P, Priyanath A, Massaro E, Stone NJ. Lifestyle modification for metabolic syndrome: a systematic review. Am J Med 2014;127:1242.e1-10. [PMID: 25004456 DOI: 10.1016/j.amjmed.2014.06.035] [Cited by in Crossref: 79] [Cited by in F6Publishing: 61] [Article Influence: 11.3] [Reference Citation Analysis]
297 Khashab MA, Liangpunsakul S, Chalasani N. Nonalcoholic fatty liver disease as a component of the metabolic syndrome. Curr Gastroenterol Rep 2008;10:73-80. [DOI: 10.1007/s11894-008-0012-0] [Cited by in Crossref: 48] [Cited by in F6Publishing: 46] [Article Influence: 3.7] [Reference Citation Analysis]
298 Fracanzani AL, Pisano G, Consonni D, Tiraboschi S, Baragetti A, Bertelli C, Norata GD, Dongiovanni P, Valenti L, Grigore L, Tonella T, Catapano A, Fargion S. Epicardial Adipose Tissue (EAT) Thickness Is Associated with Cardiovascular and Liver Damage in Nonalcoholic Fatty Liver Disease. PLoS One. 2016;11:e0162473. [PMID: 27627804 DOI: 10.1371/journal.pone.0162473] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
299 Pyper SR, Viswakarma N, Yu S, Reddy JK. PPARalpha: energy combustion, hypolipidemia, inflammation and cancer. Nucl Recept Signal. 2010;8:e002. [PMID: 20414453 DOI: 10.1621/nrs.08002] [Cited by in Crossref: 232] [Cited by in F6Publishing: 226] [Article Influence: 21.1] [Reference Citation Analysis]
300 Kan H, Yamagishi SI, Ojima A, Fukami K, Ueda S, Takeuchi M, Hyogo H, Aikata H, Chayama K. Elevation of Serum Levels of Advanced Glycation End Products in Patients With Non-B or Non-C Hepatocellular Carcinoma. J Clin Lab Anal. 2014;Epub ahead of print. [PMID: 25252033 DOI: 10.1002/jcla.21797] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.9] [Reference Citation Analysis]
301 Morita T, Yamazaki Y, Fujiharu C, Ishii T, Seto M, Nishinoue N, Sasaki Y, Kawato T, Motohashi M, Maeno M. Serum γ-glutamyltransferase level is associated with periodontal disease independent of drinking habits in Japanese adults. Med Sci Monit 2014;20:2109-16. [PMID: 25360830 DOI: 10.12659/MSM.891204] [Cited by in Crossref: 16] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
302 Xu C, Yu C, Ma H, Xu L, Miao M, Li Y. Prevalence and risk factors for the development of nonalcoholic fatty liver disease in a nonobese Chinese population: the Zhejiang Zhenhai Study. Am J Gastroenterol. 2013;108:1299-1304. [PMID: 23567356 DOI: 10.1038/ajg.2013.104] [Cited by in Crossref: 97] [Cited by in F6Publishing: 88] [Article Influence: 12.1] [Reference Citation Analysis]
303 Lin HY, Chen CC, Chen YJ, Lin YY, Mersmann HJ, Ding ST. Enhanced amelioration of high-fat diet-induced fatty liver by docosahexaenoic acid and lysine supplementations. Biomed Res Int 2014;2014:310981. [PMID: 24967351 DOI: 10.1155/2014/310981] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
304 Li H, Dong K, Fang Q, Hou X, Zhou M, Bao Y, Xiang K, Xu A, Jia W. High serum level of fibroblast growth factor 21 is an independent predictor of non-alcoholic fatty liver disease: a 3-year prospective study in China. J Hepatol. 2013;58:557-563. [PMID: 23142063 DOI: 10.1016/j.jhep.2012.10.029] [Cited by in Crossref: 63] [Cited by in F6Publishing: 59] [Article Influence: 7.0] [Reference Citation Analysis]
305 Wong C, Yaow CYL, Ng CH, Chin YH, Low YF, Lim AYL, Muthiah MD, Khoo CM. Sodium-Glucose Co-Transporter 2 Inhibitors for Non-Alcoholic Fatty Liver Disease in Asian Patients With Type 2 Diabetes: A Meta-Analysis. Front Endocrinol (Lausanne) 2020;11:609135. [PMID: 33643221 DOI: 10.3389/fendo.2020.609135] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
306 Liao YY, Yang KC, Lee MJ, Huang KC, Chen JD, Yeh CK. Multifeature analysis of an ultrasound quantitative diagnostic index for classifying nonalcoholic fatty liver disease. Sci Rep 2016;6:35083. [PMID: 27734972 DOI: 10.1038/srep35083] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 3.4] [Reference Citation Analysis]
307 Moore JB. Non-alcoholic fatty liver disease: the hepatic consequence of obesity and the metabolic syndrome. Proc Nutr Soc 2010;69:211-20. [DOI: 10.1017/s0029665110000030] [Cited by in Crossref: 141] [Cited by in F6Publishing: 64] [Article Influence: 12.8] [Reference Citation Analysis]
308 Chan HL, de Silva HJ, Leung NW, Lim S, Farrell GC; the Asia–Pacific Working Party on NAFLD. How should we manage patients with non-alcoholic fatty liver disease in 2007? J Gastroenterol Hepatol 2007;22:801-8. [DOI: 10.1111/j.1440-1746.2007.04977.x] [Cited by in Crossref: 57] [Cited by in F6Publishing: 53] [Article Influence: 4.1] [Reference Citation Analysis]
309 Gurka MJ, Mack JA, Chi X, DeBoer MD. Use of metabolic syndrome severity to assess treatment with vitamin E and pioglitazone for non-alcoholic steatohepatitis. J Gastroenterol Hepatol 2021;36:249-56. [PMID: 32506513 DOI: 10.1111/jgh.15131] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
310 Kotronen A, Westerbacka J, Bergholm R, Pietiläinen KH, Yki-Järvinen H. Liver fat in the metabolic syndrome. J Clin Endocrinol Metab. 2007;92:3490-3497. [PMID: 17595248 DOI: 10.1210/jc.2007-0482] [Cited by in Crossref: 280] [Cited by in F6Publishing: 256] [Article Influence: 20.0] [Reference Citation Analysis]
311 Lin L, Peng K, Du R, Huang X, Lu J, Xu Y, Xu M, Chen Y, Bi Y, Wang W. Metabolically healthy obesity and incident chronic kidney disease: The role of systemic inflammation in a prospective study. Obesity (Silver Spring) 2017;25:634-41. [PMID: 28160438 DOI: 10.1002/oby.21768] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
312 Do A, Ilagan-Ying YC, Mehal WZ, Lim JK. Drug development of nonalcoholic fatty liver disease: challenges in research, regulatory pathways, and study endpoints. Expert Opin Drug Discov 2021;16:125-34. [PMID: 33086894 DOI: 10.1080/17460441.2020.1811674] [Reference Citation Analysis]
313 Xiong J, Lu X, Xu W, Bai Y, Huang H, Bian J, Zhang L, Long J, Xu Y, Wang Z, Zhao H. Metabolic syndrome and the risk of cholangiocarcinoma: a hospital-based case-control study in China. Cancer Manag Res 2018;10:3849-55. [PMID: 30288116 DOI: 10.2147/CMAR.S175628] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.7] [Reference Citation Analysis]
314 Fujihara S, Mori H, Kobara H, Nishiyama N, Kobayashi M, Oryu M, Masaki T. Metabolic syndrome, obesity, and gastrointestinal cancer. Gastroenterol Res Pract 2012;2012:483623. [PMID: 23304125 DOI: 10.1155/2012/483623] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
315 Li J, Liu Z, Guo M, Xu K, Jiang M, Lu A, Gao X. Metabolomics profiling to investigate the pharmacologic mechanisms of berberine for the treatment of high-fat diet-induced nonalcoholic steatohepatitis. Evid Based Complement Alternat Med 2015;2015:897914. [PMID: 25977701 DOI: 10.1155/2015/897914] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
316 Baragetti A, Balzarotti G, Grigore L, Pellegatta F, Guerrini U, Pisano G, Fracanzani AL, Fargion S, Norata GD, Catapano AL. PCSK9 deficiency results in increased ectopic fat accumulation in experimental models and in humans. Eur J Prev Cardiolog 2017;24:1870-7. [DOI: 10.1177/2047487317724342] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 7.5] [Reference Citation Analysis]
317 Mori S, Arima N, Ito M, Fujiyama S, Kamo Y, Ueki Y. Non-alcoholic steatohepatitis-like pattern in liver biopsy of rheumatoid arthritis patients with persistent transaminitis during low-dose methotrexate treatment. PLoS One 2018;13:e0203084. [PMID: 30142184 DOI: 10.1371/journal.pone.0203084] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 4.3] [Reference Citation Analysis]
318 Okanoue T, Umemura A, Yasui K, Itoh Y. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in Japan. J Gastroenterol Hepatol. 2011;26 Suppl 1:153-162. [PMID: 21199527 DOI: 10.1111/j.1440-1746.2010.06547.x] [Cited by in Crossref: 75] [Cited by in F6Publishing: 72] [Article Influence: 7.5] [Reference Citation Analysis]
319 Wong VW, Chan WK, Chitturi S, Chawla Y, Dan YY, Duseja A, Fan J, Goh KL, Hamaguchi M, Hashimoto E, Kim SU, Lesmana LA, Lin YC, Liu CJ, Ni YH, Sollano J, Wong SK, Wong GL, Chan HL, Farrell G. Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 1: Definition, risk factors and assessment. J Gastroenterol Hepatol. 2018;33:70-85. [PMID: 28670712 DOI: 10.1111/jgh.13857] [Cited by in Crossref: 165] [Cited by in F6Publishing: 134] [Article Influence: 82.5] [Reference Citation Analysis]
320 Reddy JK, Sambasiva Rao M. Lipid Metabolism and Liver Inflammation. II. Fatty liver disease and fatty acid oxidation. American Journal of Physiology-Gastrointestinal and Liver Physiology 2006;290:G852-8. [DOI: 10.1152/ajpgi.00521.2005] [Cited by in Crossref: 487] [Cited by in F6Publishing: 432] [Article Influence: 32.5] [Reference Citation Analysis]
321 Yang Y, Jiang Y, Wang Y, An W. Suppression of ABCA1 by unsaturated fatty acids leads to lipid accumulation in HepG2 cells. Biochimie 2010;92:958-63. [PMID: 20385201 DOI: 10.1016/j.biochi.2010.04.002] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 3.6] [Reference Citation Analysis]
322 Fukuda T, Hamaguchi M, Kojima T, Ohshima Y, Ohbora A, Kato T, Nakamura N, Fukui M. Association between serum γ-glutamyltranspeptidase and atherosclerosis: a population-based cross-sectional study. BMJ Open 2014;4:e005413. [PMID: 25280803 DOI: 10.1136/bmjopen-2014-005413] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
323 Soresi M, Noto D, Cefalù AB, Martini S, Vigna GB, Fonda M, Manzato E, Cattin L, Fellin R, Averna MR. Nonalcoholic fatty liver and metabolic syndrome in Italy: results from a multicentric study of the Italian Arteriosclerosis society. Acta Diabetol. 2013;50:241-249. [PMID: 22684314 DOI: 10.1007/s00592-012-0406-1] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 3.2] [Reference Citation Analysis]
324 Lee YJ, Cho S, Kim SR. A possible role of serum uric acid as a marker of metabolic syndrome. Intern Med J 2014;44:1210-6. [PMID: 25228498 DOI: 10.1111/imj.12588] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
325 Xing J, Guan X, Zhang Q, Chen S, Wu S, Sun X. Triglycerides Mediate Body Mass Index and Nonalcoholic Fatty Liver Disease: A Population-Based Study. Obes Facts 2021;14:190-6. [PMID: 33780962 DOI: 10.1159/000514848] [Reference Citation Analysis]
326 Okanoue T, Yasui K, Itoh Y. Non-Alcoholic Fatty Liver Disease in Japan. In: Farrell GC, Mccullough AJ, Day CP, editors. Non-Alcoholic Fatty Liver Disease. Oxford: Wiley-Blackwell; 2013. pp. 217-27. [DOI: 10.1002/9781118556153.ch19] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
327 Kew MC. Obesity as a cause of hepatocellular carcinoma. Annals of Hepatology 2015;14:299-303. [DOI: 10.1016/s1665-2681(19)31267-0] [Cited by in Crossref: 10] [Article Influence: 1.7] [Reference Citation Analysis]
328 Jeong SK, Kim YK, Park JW, Shin YJ, Kim DS. Impact of visceral fat on the metabolic syndrome and nonalcoholic fatty liver disease. J Korean Med Sci. 2008;23:789-795. [PMID: 18955783 DOI: 10.3346/jkms.2008.23.5.789] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
329 Virani SS, Alonso A, Aparicio HJ, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Cheng S, Delling FN, Elkind MSV, Evenson KR, Ferguson JF, Gupta DK, Khan SS, Kissela BM, Knutson KL, Lee CD, Lewis TT, Liu J, Loop MS, Lutsey PL, Ma J, Mackey J, Martin SS, Matchar DB, Mussolino ME, Navaneethan SD, Perak AM, Roth GA, Samad Z, Satou GM, Schroeder EB, Shah SH, Shay CM, Stokes A, VanWagner LB, Wang NY, Tsao CW;  American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2021 Update: A Report From the American Heart Association. Circulation. 2021;143:e254-e743. [PMID: 33501848 DOI: 10.1161/cir.0000000000000950] [Cited by in Crossref: 174] [Cited by in F6Publishing: 62] [Article Influence: 174.0] [Reference Citation Analysis]
330 Farrell GC, Wong VW, Chitturi S. NAFLD in Asia--as common and important as in the West. Nat Rev Gastroenterol Hepatol. 2013;10:307-318. [PMID: 23458891 DOI: 10.1038/nrgastro.2013.34] [Cited by in Crossref: 278] [Cited by in F6Publishing: 243] [Article Influence: 34.8] [Reference Citation Analysis]
331 Mehta R, Birerdinc A, Hossain N, Afendy A, Chandhoke V, Younossi Z, Baranova A. Validation of endogenous reference genes for qRT-PCR analysis of human visceral adipose samples. BMC Mol Biol 2010;11:39. [PMID: 20492695 DOI: 10.1186/1471-2199-11-39] [Cited by in Crossref: 75] [Cited by in F6Publishing: 65] [Article Influence: 6.8] [Reference Citation Analysis]
332 Imajo K, Honda Y, Kobayashi T, Nagai K, Ozaki A, Iwaki M, Kessoku T, Ogawa Y, Takahashi H, Saigusa Y, Yoneda M, Kirikoshi H, Utsunomiya D, Aishima S, Saito S, Nakajima A. Direct Comparison of US and MR Elastography for Staging Liver Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol 2020:S1542-3565(20)31673-6. [PMID: 33340780 DOI: 10.1016/j.cgh.2020.12.016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
333 Cicero AF, D’Addato S, Reggi A, Marchesini G, Borghi C. Gender difference in hepatic steatosis index and lipid accumulation product ability to predict incident metabolic syndrome in the historical cohort of the Brisighella Heart Study. Metab Syndr Relat Disord. 2013;11:412-416. [PMID: 23902132 DOI: 10.1089/met.2012.0147] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
334 Omagari K, Takamura R, Matsutake S, Ichimura M, Kato S, Morikawa S, Nagaoka S, Osabe M. Serum alanine aminotransferase concentration as a predictive factor for the development or regression of fatty liver. J Clin Biochem Nutr 2011;49:200-6. [PMID: 22128220 DOI: 10.3164/jcbn.11-27] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
335 Lee C, Kim J, Jung Y. Potential Therapeutic Application of Estrogen in Gender Disparity of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis. Cells 2019;8:E1259. [PMID: 31619023 DOI: 10.3390/cells8101259] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 10.0] [Reference Citation Analysis]
336 Piao L, Choi J, Kwon G, Ha H. Endogenous catalase delays high-fat diet-induced liver injury in mice. Korean J Physiol Pharmacol 2017;21:317-25. [PMID: 28461774 DOI: 10.4196/kjpp.2017.21.3.317] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 4.8] [Reference Citation Analysis]
337 Wong VW, Wong GL, Yeung DK, Lau TK, Chan CK, Chim AM, Abrigo JM, Chan RS, Woo J, Tse YK, Chu WC, Chan HL. Incidence of non-alcoholic fatty liver disease in Hong Kong: a population study with paired proton-magnetic resonance spectroscopy. J Hepatol. 2015;62:182-189. [PMID: 25195550 DOI: 10.1016/j.jhep.2014.08.041] [Cited by in Crossref: 94] [Cited by in F6Publishing: 83] [Article Influence: 13.4] [Reference Citation Analysis]
338 Lu Z, Ma H, Xu C, Shao Z, Cen C, Li Y. Serum Sialic Acid Level Is Significantly Associated with Nonalcoholic Fatty Liver Disease in a Nonobese Chinese Population: A Cross-Sectional Study. Biomed Res Int 2016;2016:5921589. [PMID: 27042666 DOI: 10.1155/2016/5921589] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
339 Kitae A, Hashimoto Y, Hamaguchi M, Obora A, Kojima T, Fukui M. The Triglyceride and Glucose Index Is a Predictor of Incident Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study. Can J Gastroenterol Hepatol 2019;2019:5121574. [PMID: 31687367 DOI: 10.1155/2019/5121574] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
340 Hassan K, Bhalla V, El Regal ME, A-Kader HH. Nonalcoholic fatty liver disease: a comprehensive review of a growing epidemic. World J Gastroenterol. 2014;20:12082-12101. [PMID: 25232245 DOI: 10.3748/wjg.v20.i34.12082] [Cited by in CrossRef: 104] [Cited by in F6Publishing: 81] [Article Influence: 17.3] [Reference Citation Analysis]
341 Burra P, Bizzaro D, Gonta A, Shalaby S, Gambato M, Morelli MC, Trapani S, Floreani A, Marra F, Brunetto MR, Taliani G, Villa E; Special Interest Group Gender in Hepatology of the Italian Association for the Study of the Liver (AISF). Clinical impact of sexual dimorphism in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Liver Int 2021;41:1713-33. [PMID: 33982400 DOI: 10.1111/liv.14943] [Reference Citation Analysis]
342 Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Chang AR, Cheng S, Delling FN, Djousse L, Elkind MSV, Ferguson JF, Fornage M, Khan SS, Kissela BM, Knutson KL, Kwan TW, Lackland DT, Lewis TT, Lichtman JH, Longenecker CT, Loop MS, Lutsey PL, Martin SS, Matsushita K, Moran AE, Mussolino ME, Perak AM, Rosamond WD, Roth GA, Sampson UKA, Satou GM, Schroeder EB, Shah SH, Shay CM, Spartano NL, Stokes A, Tirschwell DL, VanWagner LB, Tsao CW;  American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2020 Update: A Report From the American Heart Association. Circulation. 2020;141:e139-e596. [PMID: 31992061 DOI: 10.1161/cir.0000000000000757] [Cited by in Crossref: 1624] [Cited by in F6Publishing: 711] [Article Influence: 1624.0] [Reference Citation Analysis]
343 Wu S, Wu F, Ding Y, Hou J, Bi J, Zhang Z. Association of non-alcoholic fatty liver disease with major adverse cardiovascular events: A systematic review and meta-analysis. Sci Rep. 2016;6:33386. [PMID: 27633274 DOI: 10.1038/srep33386] [Cited by in Crossref: 110] [Cited by in F6Publishing: 100] [Article Influence: 22.0] [Reference Citation Analysis]
344 Wildman RP, Janssen I, Khan UI, Thurston R, Barinas-Mitchell E, El Khoudary SR, Everson-Rose SA, Kazlauskaite R, Matthews KA, Sutton-Tyrrell K. Subcutaneous adipose tissue in relation to subclinical atherosclerosis and cardiometabolic risk factors in midlife women. Am J Clin Nutr 2011;93:719-26. [PMID: 21346089 DOI: 10.3945/ajcn.110.007153] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 3.4] [Reference Citation Analysis]
345 Tvarijonaviciute A, Ceron JJ, Holden SL, Cuthbertson DJ, Biourge V, Morris PJ, German AJ. Obesity-related metabolic dysfunction in dogs: a comparison with human metabolic syndrome. BMC Vet Res 2012;8:147. [PMID: 22929809 DOI: 10.1186/1746-6148-8-147] [Cited by in Crossref: 72] [Cited by in F6Publishing: 59] [Article Influence: 8.0] [Reference Citation Analysis]
346 Abdelmalek MF, Diehl AM. Nonalcoholic fatty liver disease as a complication of insulin resistance. Med Clin North Am. 2007;91:1125-1149, ix. [PMID: 17964913 DOI: 10.1016/j.mcna.2007.06.001] [Cited by in Crossref: 113] [Cited by in F6Publishing: 98] [Article Influence: 8.1] [Reference Citation Analysis]
347 Mykhalchyshyn G, Kobyliak N, Bodnar P. Diagnostic accuracy of acyl-ghrelin and it association with non-alcoholic fatty liver disease in type 2 diabetic patients. J Diabetes Metab Disord. 2015;14:44. [PMID: 25995986 DOI: 10.1186/s40200-015-0170-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
348 Shiga T, Shimbo T, Yoshizawa A. Multicenter investigation of lifestyle-related diseases and visceral disorders in thalidomide embryopathy at around 50 years of age. Birth Defects Res A Clin Mol Teratol 2015;103:787-93. [PMID: 26033770 DOI: 10.1002/bdra.23363] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
349 Ritchlin CT, Giles JT, Ogdie A, Gomez-Reino JJ, Helliwell P, Young P, Wang C, Wu J, Romero AB, Woolcott J, Stockert L. Tofacitinib in Patients With Psoriatic Arthritis and Metabolic Syndrome: A Post hoc Analysis of Phase 3 Studies. ACR Open Rheumatol. 2020;2:543-554. [PMID: 32910531 DOI: 10.1002/acr2.11166] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
350 Corey KE, Chalasani N. Management of dyslipidemia as a cardiovascular risk factor in individuals with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2014;12:1077-84; quiz e59-60. [PMID: 23962548 DOI: 10.1016/j.cgh.2013.08.014] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
351 Fukuda T, Hamaguchi M, Kojima T, Mitsuhashi K, Hashimoto Y, Ohbora A, Kato T, Nakamura N, Fukui M. Transient remission of nonalcoholic fatty liver disease decreases the risk of incident type 2 diabetes mellitus in Japanese men. Eur J Gastroenterol Hepatol. 2016;28:1443-1449. [PMID: 27603300 DOI: 10.1097/meg.0000000000000736] [Cited by in Crossref: 25] [Cited by in F6Publishing: 7] [Article Influence: 6.3] [Reference Citation Analysis]
352 Hamabe A, Uto H, Imamura Y, Kusano K, Mawatari S, Kumagai K, Kure T, Tamai T, Moriuchi A, Sakiyama T. Impact of cigarette smoking on onset of nonalcoholic fatty liver disease over a 10-year period. J Gastroenterol. 2011;46:769-778. [PMID: 21302121 DOI: 10.1007/s00535-011-0376-z] [Cited by in Crossref: 77] [Cited by in F6Publishing: 69] [Article Influence: 7.7] [Reference Citation Analysis]
353 Katsuda S, Kawashiri M, Inazu A, Tada H, Tsuchida M, Kaneko Y, Nozue T, Nohara A, Okada T, Kobayashi J, Michishita I, Mabuchi H, Yamagishi M. Apolipoprotein B gene mutations and fatty liver in Japanese hypobetalipoproteinemia. Clinica Chimica Acta 2009;399:64-8. [DOI: 10.1016/j.cca.2008.09.021] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
354 de la Iglesia R, Lopez-Legarrea P, Abete I, Bondia-Pons I, Navas-Carretero S, Forga L, Martinez JA, Zulet MA. A new dietary strategy for long-term treatment of the metabolic syndrome is compared with the American Heart Association (AHA) guidelines: the MEtabolic Syndrome REduction in NAvarra (RESMENA) project. Br J Nutr 2014;111:643-52. [PMID: 23968597 DOI: 10.1017/S0007114513002778] [Cited by in Crossref: 42] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
355 Yang YM, Han CY, Kim YJ, Kim SG. AMPK-associated signaling to bridge the gap between fuel metabolism and hepatocyte viability. World J Gastroenterol. 2010;16:3731-3742. [PMID: 20698033 DOI: 10.3748/wjg.v16.i30.3731] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 31] [Article Influence: 2.8] [Reference Citation Analysis]
356 Hashimoto Y, Hamaguchi M, Fukuda T, Obora A, Kojima T, Fukui M. Weight gain since age of 20 as risk of metabolic syndrome even in non-overweight individuals. Endocrine 2017;58:253-61. [DOI: 10.1007/s12020-017-1411-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
357 Machado UF, Schaan BD, Seraphim PM. Transportadores de glicose na síndrome metabólica. Arq Bras Endocrinol Metab 2006;50:177-89. [DOI: 10.1590/s0004-27302006000200004] [Cited by in Crossref: 13] [Cited by in F6Publishing: 2] [Article Influence: 0.9] [Reference Citation Analysis]
358 Grundy SM. Gamma-glutamyl transferase: another biomarker for metabolic syndrome and cardiovascular risk. Arterioscler Thromb Vasc Biol. 2007;27:4-7. [PMID: 17185620 DOI: 10.1161/01.atv.0000253905.13219.4b] [Cited by in Crossref: 47] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
359 Askari F, Rashidkhani B, Hekmatdoost A. Cinnamon may have therapeutic benefits on lipid profile, liver enzymes, insulin resistance, and high-sensitivity C-reactive protein in nonalcoholic fatty liver disease patients. Nutr Res. 2014;34:143-148. [PMID: 24461315 DOI: 10.1016/j.nutres.2013.11.005] [Cited by in Crossref: 74] [Cited by in F6Publishing: 60] [Article Influence: 9.3] [Reference Citation Analysis]
360 Toshikuni N, Tsutsumi M, Arisawa T. Clinical differences between alcoholic liver disease and nonalcoholic fatty liver disease. World J Gastroenterol 2014;20:8393-406. [PMID: 25024597 DOI: 10.3748/wjg.v20.i26.8393] [Cited by in CrossRef: 55] [Cited by in F6Publishing: 49] [Article Influence: 9.2] [Reference Citation Analysis]
361 Chitturi S, Farrell GC, Hashimoto E, Saibara T, Lau GK, Sollano JD; Asia-Pacific Working Party on NAFLD. Non-alcoholic fatty liver disease in the Asia-Pacific region: definitions and overview of proposed guidelines. J Gastroenterol Hepatol. 2007;22:778-787. [PMID: 17565630 DOI: 10.1111/j.1440-1746.2007.05001.x] [Cited by in Crossref: 208] [Cited by in F6Publishing: 188] [Article Influence: 14.9] [Reference Citation Analysis]
362 Feagins LA, Flores A, Arriens C, Park C, Crook T, Reimold A, Brown G. Nonalcoholic fatty liver disease: a potential consequence of tumor necrosis factor-inhibitor therapy. Eur J Gastroenterol Hepatol. 2015;27:1154-1160. [PMID: 26148245 DOI: 10.1097/meg.0000000000000421] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.4] [Reference Citation Analysis]
363 Maruotti N, d’Onofrio F, Cantatore FP. Metabolic syndrome and chronic arthritis: effects of anti-TNF-α therapy. Clin Exp Med 2015;15:433-8. [DOI: 10.1007/s10238-014-0323-4] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
364 Kimura T, Deshpande GA, Urayama KY, Masuda K, Fukui T, Matsuyama Y. Association of weight gain since age 20 with non-alcoholic fatty liver disease in normal weight individuals. J Gastroenterol Hepatol 2015;30:909-17. [PMID: 25469977 DOI: 10.1111/jgh.12861] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
365 Vita T, Murphy DJ, Osborne MT, Bajaj NS, Keraliya A, Jacob S, Diaz Martinez AJ, Nodoushani A, Bravo P, Hainer J, Bibbo CF, Steigner ML, Taqueti VR, Skali H, Blankstein R, Di Carli MF, Dorbala S. Association between Nonalcoholic Fatty Liver Disease at CT and Coronary Microvascular Dysfunction at Myocardial Perfusion PET/CT. Radiology 2019;291:330-7. [PMID: 30835188 DOI: 10.1148/radiol.2019181793] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
366 Hashimoto Y, Tanaka M, Kimura T, Kitagawa N, Hamaguchi M, Asano M, Yamazaki M, Oda Y, Toda H, Nakamura N, Fukui M. Hemoglobin concentration and incident metabolic syndrome: a population-based large-scale cohort study. Endocrine 2015;50:390-6. [DOI: 10.1007/s12020-015-0587-9] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
367 Kong CY, Wang CL, Niu KJ, Qi W. Prevalence of metabolic syndrome in patients with rheumatoid arthritis in eastern China-A hospital based study. Int J Rheum Dis 2021;24:1121-6. [PMID: 34080783 DOI: 10.1111/1756-185X.14148] [Reference Citation Analysis]
368 Cheung KK, Luk AO, So WY, Ma RC, Kong AP, Chow FC, Chan JC. Testosterone level in men with type 2 diabetes mellitus and related metabolic effects: A review of current evidence. J Diabetes Investig 2015;6:112-23. [PMID: 25802717 DOI: 10.1111/jdi.12288] [Cited by in Crossref: 44] [Cited by in F6Publishing: 33] [Article Influence: 6.3] [Reference Citation Analysis]
369 Hashimoto Y, Hamaguchi M, Nakanishi N, Ohbora A, Kojima T, Fukui M. Urinary pH is a predictor of diabetes in men; a population based large scale cohort study. Diabetes Res Clin Pract. 2017;130:9-14. [PMID: 28551482 DOI: 10.1016/j.diabres.2017.04.023] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
370 Hamirani YS, Katz R, Nasir K, Zeb I, Blaha MJ, Blumenthal RS, Kronmal RN, Budoff MJ. Association between inflammatory markers and liver fat: The Multi-Ethnic Study of Atherosclerosis. J Clin Exp Cardiolog. 2014;5. [PMID: 25598995 DOI: 10.4172/2155-9880.1000344] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 3.4] [Reference Citation Analysis]
371 Li XD, Qiu BH, Su FC, Sun SX. Gender impacts on the correlations between nonalcoholic fatty liver disease and hypertension in a Chinese population aged 45-60 y. Clin Exp Hypertens 2016;38:639-43. [PMID: 27680771 DOI: 10.1080/10641963.2016.1182181] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
372 Kahali B, Liu YL, Daly AK, Day CP, Anstee QM, Speliotes EK. TM6SF2: catch-22 in the fight against nonalcoholic fatty liver disease and cardiovascular disease? Gastroenterology. 2015;148:679-684. [PMID: 25639710 DOI: 10.1053/j.gastro.2015.01.038] [Cited by in Crossref: 52] [Cited by in F6Publishing: 45] [Article Influence: 8.7] [Reference Citation Analysis]
373 Imajo K, Kessoku T, Honda Y, Hasegawa S, Tomeno W, Ogawa Y, Motosugi U, Saigusa Y, Yoneda M, Kirikoshi H, Yamanaka S, Utsunomiya D, Saito S, Nakajima A. MRI-Based Quantitative R2* Mapping at 3 Tesla Reflects Hepatic Iron Overload and Pathogenesis in Nonalcoholic Fatty Liver Disease Patients. J Magn Reson Imaging 2021. [PMID: 34184822 DOI: 10.1002/jmri.27810] [Reference Citation Analysis]
374 Ono M, Saibara T. Clinical features of nonalcoholic steatohepatitis in Japan: Evidence from the literature. J Gastroenterol 2006;41:725-32. [PMID: 16988759 DOI: 10.1007/s00535-006-1876-0] [Cited by in Crossref: 39] [Cited by in F6Publishing: 34] [Article Influence: 2.6] [Reference Citation Analysis]
375 Smits MM, Ioannou GN, Boyko EJ, Utzschneider KM. Non-alcoholic fatty liver disease as an independent manifestation of the metabolic syndrome: Results of a US national survey in three ethnic groups: Fatty liver and the metabolic syndrome. J Gastroenterol Hepatol 2013;28:664-70. [DOI: 10.1111/jgh.12106] [Cited by in Crossref: 92] [Cited by in F6Publishing: 81] [Article Influence: 11.5] [Reference Citation Analysis]
376 Kumanyika SK, Obarzanek E, Stettler N, Bell R, Field AE, Fortmann SP, Franklin BA, Gillman MW, Lewis CE, Poston WC 2nd, Stevens J, Hong Y; American Heart Association Council on Epidemiology and Prevention, Interdisciplinary Committee for Prevention. Population-based prevention of obesity: the need for comprehensive promotion of healthful eating, physical activity, and energy balance: a scientific statement from American Heart Association Council on Epidemiology and Prevention, Interdisciplinary Committee for Prevention (formerly the expert panel on population and prevention science). Circulation 2008;118:428-64. [PMID: 18591433 DOI: 10.1161/CIRCULATIONAHA.108.189702] [Cited by in Crossref: 415] [Cited by in F6Publishing: 174] [Article Influence: 31.9] [Reference Citation Analysis]
377 Liu L, Li C, Fu C, Li F. Dietary Niacin Supplementation Suppressed Hepatic Lipid Accumulation in Rabbits. Asian-Australas J Anim Sci 2016;29:1748-55. [PMID: 27004817 DOI: 10.5713/ajas.15.0824] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
378 Chiang C, Huang C, Chan W, Chen J, Leu H. The severity of non-alcoholic fatty liver disease correlates with high sensitivity C-reactive protein value and is independently associated with increased cardiovascular risk in healthy population. Clinical Biochemistry 2010;43:1399-404. [DOI: 10.1016/j.clinbiochem.2010.09.003] [Cited by in Crossref: 41] [Cited by in F6Publishing: 33] [Article Influence: 3.7] [Reference Citation Analysis]
379 Zorzi D, Laurent A, Pawlik TM, Lauwers GY, Vauthey JN, Abdalla EK. Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases. Br J Surg. 2007;94:274-286. [PMID: 17315288 DOI: 10.1002/bjs.5719] [Cited by in Crossref: 340] [Cited by in F6Publishing: 274] [Article Influence: 24.3] [Reference Citation Analysis]
380 Durazzo M, Belci P, Collo A, Prandi V, Pistone E, Martorana M, Gambino R, Bo S. Gender specific medicine in liver diseases: a point of view. World J Gastroenterol. 2014;20:2127-2135. [PMID: 24605011 DOI: 10.3748/wjg.v20.i9.2127] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 19] [Article Influence: 4.2] [Reference Citation Analysis]
381 Nishio T, Hatano E, Sakurai T, Taura K, Okuno M, Kasai Y, Seo S, Yasuchika K, Mori A, Kaido T, Uemoto S. Impact of Hepatic Steatosis on Disease-Free Survival in Patients with Non-B Non-C Hepatocellular Carcinoma Undergoing Hepatic Resection. Ann Surg Oncol 2015;22:2226-34. [PMID: 25395147 DOI: 10.1245/s10434-014-4181-9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 1.9] [Reference Citation Analysis]
382 Bhatnagar G, Sidhu HS, Vardhanabhuti V, Venkatanarasimha N, Cantin P, Dubbins P. The varied sonographic appearances of focal fatty liver disease: review and diagnostic algorithm. Clin Radiol 2012;67:372-9. [PMID: 22265856 DOI: 10.1016/j.crad.2011.10.020] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
383 Simeone JC, Bae JP, Hoogwerf BJ, Li Q, Haupt A, Ali AK, Boardman MK, Nordstrom BL. Clinical course of nonalcoholic fatty liver disease: an assessment of severity, progression, and outcomes. Clin Epidemiol 2017;9:679-88. [PMID: 29276410 DOI: 10.2147/CLEP.S144368] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
384 Hamaguchi M, Obora A, Okamura T, Hashimoto Y, Kojima T, Fukui M. Changes in metabolic complications in patients with alcoholic fatty liver disease monitored over two decades: NAGALA study. BMJ Open Gastroenterol 2020;7:e000359. [PMID: 32337056 DOI: 10.1136/bmjgast-2019-000359] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
385 Nagaoki Y, Hyogo H, Aikata H, Tanaka M, Naeshiro N, Nakahara T, Honda Y, Miyaki D, Kawaoka T, Takaki S, Hiramatsu A, Waki K, Imamura M, Kawakami Y, Takahashi S, Chayama K. Recent trend of clinical features in patients with hepatocellular carcinoma. Hepatol Res. 2012;42:368-375. [PMID: 22151896 DOI: 10.1111/j.1872-034x.2011.00929.x] [Cited by in Crossref: 63] [Cited by in F6Publishing: 40] [Article Influence: 6.3] [Reference Citation Analysis]
386 Wood MJ, Powell LW, Dixon JL, Ramm GA. Clinical cofactors and hepatic fibrosis in hereditary hemochromatosis: the role of diabetes mellitus. Hepatology. 2012;56:904-911. [PMID: 22422567 DOI: 10.1002/hep.25720] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 2.7] [Reference Citation Analysis]
387 Xu C, Wan X, Xu L, Weng H, Yan M, Miao M, Sun Y, Xu G, Dooley S, Li Y, Yu C. Xanthine oxidase in non-alcoholic fatty liver disease and hyperuricemia: One stone hits two birds. Journal of Hepatology 2015;62:1412-9. [DOI: 10.1016/j.jhep.2015.01.019] [Cited by in Crossref: 70] [Cited by in F6Publishing: 62] [Article Influence: 11.7] [Reference Citation Analysis]
388 Watanabe S, Hashimoto E, Ikejima K, Uto H, Ono M, Sumida Y, Seike M, Takei Y, Takehara T, Tokushige K, Nakajima A, Yoneda M, Saibara T, Shiota G, Sakaida I, Nakamuta M, Mizuta T, Tsubouchi H, Sugano K, Shimosegawa T. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. J Gastroenterol 2015;50:364-77. [DOI: 10.1007/s00535-015-1050-7] [Cited by in Crossref: 122] [Cited by in F6Publishing: 50] [Article Influence: 20.3] [Reference Citation Analysis]
389 Feitosa MF, Reiner AP, Wojczynski MK, Graff M, North KE, Carr JJ, Borecki IB. Sex-influenced association of nonalcoholic fatty liver disease with coronary heart disease. Atherosclerosis. 2013;227:420-424. [PMID: 23390892 DOI: 10.1016/j.atherosclerosis.2013.01.013] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
390 Eshraghian A, Nikeghbalian S, Geramizadeh B, Malek-Hosseini SA. Serum magnesium concentration is independently associated with non-alcoholic fatty liver and non-alcoholic steatohepatitis. United European Gastroenterol J. 2018;6:97-103. [PMID: 29435319 DOI: 10.1177/2050640617707863] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
391 Panchal SK, Ward L, Brown L. Ellagic acid attenuates high-carbohydrate, high-fat diet-induced metabolic syndrome in rats. Eur J Nutr. 2013;52:559-568. [PMID: 22538930 DOI: 10.1007/s00394-012-0358-9] [Cited by in Crossref: 89] [Cited by in F6Publishing: 76] [Article Influence: 9.9] [Reference Citation Analysis]
392 Jang S, Lee CH, Choi KM, Lee J, Choi JW, Kim KA, Park CM. Correlation of fatty liver and abdominal fat distribution using a simple fat computed tomography protocol. World J Gastroenterol. 2011;17:3335-3341. [PMID: 21876622 DOI: 10.3748/wjg.v17.i28.3335] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
393 Wang K, Shan S, Zheng H, Zhao X, Chen C, Liu C. Non-HDL-cholesterol to HDL-cholesterol ratio is a better predictor of new-onset non-alcoholic fatty liver disease than non-HDL-cholesterol: a cohort study. Lipids Health Dis 2018;17:196. [PMID: 30131058 DOI: 10.1186/s12944-018-0848-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
394 Sohn J, Kang DR, Kim HC, Cho J, Choi YJ, Kim C, Suh I. Elevation of Serum Aminotransferase Levels and Future Risk of Death from External Causes: A Prospective Cohort Study in Korea. Yonsei Med J 2015;56:1582-9. [PMID: 26446640 DOI: 10.3349/ymj.2015.56.6.1582] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
395 Xu X, Su L, Gao Y, Ding Y. The Prevalence of Nonalcoholic Fatty Liver Disease and Related Metabolic Comorbidities Was Associated with Age at Onset of Moderate to Severe Plaque Psoriasis: A Cross-Sectional Study. PLoS One 2017;12:e0169952. [PMID: 28099469 DOI: 10.1371/journal.pone.0169952] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
396 Zhou Y, Wei F, Fan Y. High serum uric acid and risk of nonalcoholic fatty liver disease: A systematic review and meta-analysis. Clin Biochem. 2016;49:636-642. [PMID: 26738417 DOI: 10.1016/j.clinbiochem.2015.12.010] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 5.8] [Reference Citation Analysis]
397 Chen QF, Zhou XD, Sun YJ, Fang DH, Zhao Q, Huang JH, Jin Y, Wu JS. Sex-influenced association of non-alcoholic fatty liver disease with colorectal adenomatous and hyperplastic polyps. World J Gastroenterol. 2017;23:5206-5215. [PMID: 28811715 DOI: 10.3748/wjg.v23.i28.5206] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
398 Fan JG. Impact of non-alcoholic fatty liver disease on accelerated metabolic complications. J Dig Dis 2008;9:63-7. [PMID: 18419637 DOI: 10.1111/j.1751-2980.2008.00323.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 2.1] [Reference Citation Analysis]
399 Lonardo A, Caldwell SH, Loria P. Clinical physiology of NAFLD: a critical overview of pathogenesis and treatment. Expert Review of Endocrinology & Metabolism 2014;5:403-23. [DOI: 10.1586/eem.10.5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
400 Okada Y, Yamaguchi K, Nakajima T, Nishikawa T, Jo M, Mitsumoto Y, Kimura H, Nishimura T, Tochiki N, Yasui K, Mitsuyoshi H, Minami M, Kagawa K, Okanoue T, Itoh Y. Rosuvastatin ameliorates high-fat and high-cholesterol diet-induced nonalcoholic steatohepatitis in rats. Liver Int 2013;33:301-11. [DOI: 10.1111/liv.12033] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 4.8] [Reference Citation Analysis]
401 Sumida Y, Yoneda M, Hyogo H, Yamaguchi K, Ono M, Fujii H, Eguchi Y, Suzuki Y, Imai S, Kanemasa K, Fujita K, Chayama K, Yasui K, Saibara T, Kawada N, Fujimoto K, Kohgo Y, Okanoue T; Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD). A simple clinical scoring system using ferritin, fasting insulin, and type IV collagen 7S for predicting steatohepatitis in nonalcoholic fatty liver disease. J Gastroenterol. 2011;46:257-268. [PMID: 20842510 DOI: 10.1007/s00535-010-0305-6] [Cited by in Crossref: 131] [Cited by in F6Publishing: 114] [Article Influence: 11.9] [Reference Citation Analysis]
402 Loomba R, Hwang SJ, O'Donnell CJ, Ellison RC, Vasan RS, D'Agostino RB Sr, Liang TJ, Fox CS. Parental obesity and offspring serum alanine and aspartate aminotransferase levels: the Framingham heart study. Gastroenterology 2008;134:953-9. [PMID: 18395076 DOI: 10.1053/j.gastro.2008.01.037] [Cited by in Crossref: 42] [Cited by in F6Publishing: 34] [Article Influence: 3.2] [Reference Citation Analysis]
403 Nakahara T, Hyogo H, Ono A, Nagaoki Y, Kawaoka T, Miki D, Tsuge M, Hiraga N, Hayes CN, Hiramatsu A, Imamura M, Kawakami Y, Aikata H, Ochi H, Abe-Chayama H, Furusho H, Shintani T, Kurihara H, Miyauchi M, Takata T, Arihiro K, Chayama K. Involvement of Porphyromonas gingivalis in the progression of non-alcoholic fatty liver disease. J Gastroenterol 2018;53:269-80. [PMID: 28741270 DOI: 10.1007/s00535-017-1368-4] [Cited by in Crossref: 33] [Cited by in F6Publishing: 25] [Article Influence: 8.3] [Reference Citation Analysis]
404 Nati M, Haddad D, Birkenfeld AL, Koch CA, Chavakis T, Chatzigeorgiou A. The role of immune cells in metabolism-related liver inflammation and development of non-alcoholic steatohepatitis (NASH). Rev Endocr Metab Disord. 2016;17:29-39. [PMID: 26847547 DOI: 10.1007/s11154-016-9339-2] [Cited by in Crossref: 64] [Cited by in F6Publishing: 62] [Article Influence: 16.0] [Reference Citation Analysis]
405 Wang Y, Wang H, Deng P, Tao T, Liu H, Wu S, Chen W, Qin J. Modeling Human Nonalcoholic Fatty Liver Disease (NAFLD) with an Organoids-on-a-Chip System. ACS Biomater Sci Eng 2020;6:5734-43. [DOI: 10.1021/acsbiomaterials.0c00682] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
406 St George A, Bauman A, Johnston A, Farrell G, Chey T, George J. Effect of a lifestyle intervention in patients with abnormal liver enzymes and metabolic risk factors. J Gastroenterol Hepatol. 2009;24:399-407. [PMID: 19067776 DOI: 10.1111/j.1440-1746.2008.05694.x] [Cited by in Crossref: 65] [Cited by in F6Publishing: 64] [Article Influence: 5.0] [Reference Citation Analysis]
407 Madan SA, John F, Pyrsopoulos N, Pitchumoni CS. Nonalcoholic fatty liver disease and carotid artery atherosclerosis in children and adults: a meta-analysis. Eur J Gastroenterol Hepatol. 2015;27:1237-1248. [PMID: 26193052 DOI: 10.1097/MEG.0000000000000429] [Cited by in Crossref: 34] [Cited by in F6Publishing: 20] [Article Influence: 6.8] [Reference Citation Analysis]
408 Baselga-escudero L, Souza-mello V, Pascual-serrano A, Rachid T, Voci A, Demori I, Grasselli E. Beneficial effects of the Mediterranean spices and aromas on non-alcoholic fatty liver disease. Trends in Food Science & Technology 2017;61:141-59. [DOI: 10.1016/j.tifs.2016.11.019] [Cited by in Crossref: 16] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
409 Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ;  American Gastroenterological Association;  American Association for the Study of Liver Diseases;  American College of Gastroenterologyh. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology. 2012;142:1592-1609. [PMID: 22656328 DOI: 10.1053/j.gastro.2012.04.001] [Cited by in Crossref: 1078] [Cited by in F6Publishing: 945] [Article Influence: 119.8] [Reference Citation Analysis]
410 Okamura T, Hashimoto Y, Hamaguchi M, Obora A, Kojima T, Fukui M. Creatinine-to-bodyweight ratio is a predictor of incident non-alcoholic fatty liver disease: A population-based longitudinal study. Hepatol Res 2020;50:57-66. [PMID: 31692179 DOI: 10.1111/hepr.13429] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
411 Shih KL, Su WW, Chang CC, Kor CT, Chou CT, Chen TY, Wu HM. Comparisons of parallel potential biomarkers of 1H-MRS-measured hepatic lipid content in patients with non-alcoholic fatty liver disease. Sci Rep 2016;6:24031. [PMID: 27079922 DOI: 10.1038/srep24031] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
412 Boutari C, Mantzoros CS. Adiponectin and leptin in the diagnosis and therapy of NAFLD. Metabolism 2020;103:154028. [PMID: 31785257 DOI: 10.1016/j.metabol.2019.154028] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 8.5] [Reference Citation Analysis]
413 Ballestri S, Nascimbeni F, Baldelli E, Marrazzo A, Romagnoli D, Lonardo A. NAFLD as a Sexual Dimorphic Disease: Role of Gender and Reproductive Status in the Development and Progression of Nonalcoholic Fatty Liver Disease and Inherent Cardiovascular Risk. Adv Ther. 2017;34:1291-1326. [PMID: 28526997 DOI: 10.1007/s12325-017-0556-1] [Cited by in Crossref: 197] [Cited by in F6Publishing: 158] [Article Influence: 49.3] [Reference Citation Analysis]
414 Nestel PJ, Mensink RP. Perspective: nonalcoholic fatty liver disease and cardiovascular risk. Curr Opin Lipidol. 2013;24:1-3. [PMID: 23298957 DOI: 10.1097/mol.0b013e32835c0834] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
415 Liu CJ. Prevalence and risk factors for non-alcoholic fatty liver disease in Asian people who are not obese. J Gastroenterol Hepatol. 2012;27:1555-1560. [PMID: 22741595 DOI: 10.1111/j.1440-1746.2012.07222.x] [Cited by in Crossref: 117] [Cited by in F6Publishing: 109] [Article Influence: 14.6] [Reference Citation Analysis]
416 Pilgrim CHC, Thomson BN, Banting S, Phillips WA, Michael M. The developing clinical problem of chemotherapy-induced hepatic injury: Chemotherapy-induced hepatic injury. ANZ Journal of Surgery 2012;82:23-9. [DOI: 10.1111/j.1445-2197.2011.05789.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
417 Sayki Arslan M, Turhan S, Dincer I, Mizrak D, Corapcioglu D, Idilman R. A potential link between endothelial function, cardiovascular risk, and metabolic syndrome in patients with Non-alcoholic fatty liver disease. Diabetol Metab Syndr 2014;6:109. [PMID: 25960770 DOI: 10.1186/1758-5996-6-109] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
418 van Werven JR, Marsman HA, Nederveen AJ, Smits NJ, ten Kate FJ, van Gulik TM, Stoker J. Assessment of hepatic steatosis in patients undergoing liver resection: comparison of US, CT, T1-weighted dual-echo MR imaging, and point-resolved 1H MR spectroscopy. Radiology 2010;256:159-68. [PMID: 20574093 DOI: 10.1148/radiol.10091790] [Cited by in Crossref: 183] [Cited by in F6Publishing: 151] [Article Influence: 16.6] [Reference Citation Analysis]
419 Sourianarayanane A, Garg G, Smith TH, Butt MI, McCullough AJ, Shen B. Risk factors of non-alcoholic fatty liver disease in patients with inflammatory bowel disease. J Crohns Colitis. 2013;7:e279-e285. [PMID: 23158500 DOI: 10.1016/j.crohns.2012.10.015] [Cited by in Crossref: 57] [Cited by in F6Publishing: 46] [Article Influence: 6.3] [Reference Citation Analysis]
420 Okajima A, Sumida Y, Taketani H, Hara T, Seko Y, Ishiba H, Nishimura T, Umemura A, Nishikawa T, Yamaguchi K, Moriguchi M, Mitsuyoshi H, Yasui K, Minami M, Itoh Y. Liver stiffness measurement to platelet ratio index predicts the stage of liver fibrosis in non-alcoholic fatty liver disease. Hepatol Res 2017;47:721-30. [PMID: 27539017 DOI: 10.1111/hepr.12793] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
421 Zhang Y, Zhang T, Zhang C, Tang F, Zhong N, Li H, Song X, Lin H, Liu Y, Xue F. Identification of reciprocal causality between non-alcoholic fatty liver disease and metabolic syndrome by a simplified Bayesian network in a Chinese population. BMJ Open. 2015;5:e008204. [PMID: 26395497 DOI: 10.1136/bmjopen-2015-008204] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 5.7] [Reference Citation Analysis]
422 Rivera DS, Lindsay CB, Codocedo JF, Carreño LE, Cabrera D, Arrese MA, Vio CP, Bozinovic F, Inestrosa NC. Long-Term, Fructose-Induced Metabolic Syndrome-Like Condition Is Associated with Higher Metabolism, Reduced Synaptic Plasticity and Cognitive Impairment in Octodon degus. Mol Neurobiol 2018;55:9169-87. [DOI: 10.1007/s12035-018-0969-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
423 Nakao H, Yoneda M. The intertwisted correlations among non-alcoholic fatty liver disease, atherosclerosis, and metabolic syndrome. J Gastroenterol 2009;44:1162-4. [DOI: 10.1007/s00535-009-0140-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
424 Xu C, Xu L, Yu C, Miao M, Li Y. Association between thyroid function and nonalcoholic fatty liver disease in euthyroid elderly Chinese. Clin Endocrinol (Oxf). 2011;75:240-246. [PMID: 21521285 DOI: 10.1111/j.1365-2265.2011.04016.x] [Cited by in Crossref: 51] [Cited by in F6Publishing: 45] [Article Influence: 5.1] [Reference Citation Analysis]
425 Gupta AK, Bray GA, Greenway FL, Martin CK, Johnson WD, Smith SR. Pioglitazone, but not metformin, reduces liver fat in Type-2 diabetes mellitus independent of weight changes. J Diabetes Complications 2010;24:289-96. [PMID: 19577936 DOI: 10.1016/j.jdiacomp.2009.05.004] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 2.1] [Reference Citation Analysis]
426 Shields WW, Thompson KE, Grice GA, Harrison SA, Coyle WJ. The Effect of Metformin and Standard Therapy versus Standard Therapy alone in Nondiabetic Patients with Insulin Resistance and Nonalcoholic Steatohepatitis (NASH): A Pilot Trial. Therap Adv Gastroenterol. 2009;2:157-163. [PMID: 21180541 DOI: 10.1177/1756283x09105462] [Cited by in Crossref: 86] [Cited by in F6Publishing: 43] [Article Influence: 8.6] [Reference Citation Analysis]
427 Ambachew S, Endalamaw A, Worede A, Tegegne Y, Melku M, Biadgo B. The Prevalence of Metabolic Syndrome in Ethiopian Population: A Systematic Review and Meta-analysis. J Obes 2020;2020:2701309. [PMID: 33489358 DOI: 10.1155/2020/2701309] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
428 Farrell GC, Wong VW, Chitturi S. NAFLD in Asia--as common and important as in the West. Nat Rev Gastroenterol Hepatol. 2013;10:307-318. [PMID: 23458891 DOI: 10.1038/nrgastro.2013. 34] [Reference Citation Analysis]
429 Kado A, Tsutsumi T, Enooku K, Fujinaga H, Ikeuchi K, Okushin K, Moriya K, Yotsuyanagi H, Koike K. Noninvasive diagnostic criteria for nonalcoholic steatohepatitis based on gene expression levels in peripheral blood mononuclear cells. J Gastroenterol 2019;54:730-41. [PMID: 30830270 DOI: 10.1007/s00535-019-01565-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
430 Hamaguchi M, Kojima T. Favorable effect of modest alcohol consumption to fatty liver disease. World J Gastroenterol 2013;19:5393-4. [PMID: 23983447 DOI: 10.3748/wjg.v19.i32.5393] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
431 Kur P, Kolasa-Wołosiuk A, Misiakiewicz-Has K, Wiszniewska B. Sex Hormone-Dependent Physiology and Diseases of Liver. Int J Environ Res Public Health 2020;17:E2620. [PMID: 32290381 DOI: 10.3390/ijerph17082620] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 19.0] [Reference Citation Analysis]
432 Marchesini G, Moscatiello S, Di Domizio S, Forlani G. Obesity-associated liver disease. J Clin Endocrinol Metab. 2008;93:S74-S80. [PMID: 18987273 DOI: 10.1210/jc.2008-1399] [Cited by in Crossref: 176] [Cited by in F6Publishing: 152] [Article Influence: 14.7] [Reference Citation Analysis]
433 Wong VW, Chan RS, Wong GL, Cheung BH, Chu WC, Yeung DK, Chim AM, Lai JW, Li LS, Sea MM, Chan FK, Sung JJ, Woo J, Chan HL. Community-based lifestyle modification programme for non-alcoholic fatty liver disease: a randomized controlled trial. J Hepatol. 2013;59:536-542. [PMID: 23623998 DOI: 10.1016/j.jhep.2013.04.013] [Cited by in Crossref: 154] [Cited by in F6Publishing: 143] [Article Influence: 19.3] [Reference Citation Analysis]
434 Gianotti G, Cenni A, Bianchi G, Masetti M, Zappoli P, Muscari A, Zoli M. Diastolic dysfunction and cardiovascular risk in old subjects: possible association with NAFLD? Arch Gerontol Geriatr. 2014;58:188-195. [PMID: 24268461 DOI: 10.1016/j.archger.2013.10.012] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
435 Okamura T, Hashimoto Y, Hamaguchi M, Obora A, Kojima T, Fukui M. Visceral Adiposity Index is a predictor of incident colorectal cancer: a population-based longitudinal study. BMJ Open Gastroenterol 2020;7:e000400. [PMID: 32595114 DOI: 10.1136/bmjgast-2020-000400] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
436 Loria P, Adinolfi L, Bellentani S, Bugianesi E, Grieco A, Fargion S, Gasbarrini A, Loguercio C, Lonardo A, Marchesini G, Marra F, Persico M, Prati D, Baroni GS. Practice guidelines for the diagnosis and management of nonalcoholic fatty liver disease. Digestive and Liver Disease 2010;42:272-82. [DOI: 10.1016/j.dld.2010.01.021] [Cited by in Crossref: 150] [Cited by in F6Publishing: 139] [Article Influence: 13.6] [Reference Citation Analysis]
437 La Carrubba S, Todaro MC, Zito C, Antonini-Canterin F, Monte IP, Caso P, Colonna P, de Gregorio C, Pezzano A, Benedetto F, Salvo GD, Carerj S, Bello VD. Asymptomatic Left Ventricular Dysfunction and Metabolic Syndrome: Results from an Italian Multicenter Study. J Cardiovasc Echogr 2013;23:96-101. [PMID: 28465894 DOI: 10.4103/2211-4122.127410] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
438 Kan H, Hyogo H, Ochi H, Hotta K, Fukuhara T, Kobayashi T, Naeshiro N, Honda Y, Kawaoka T, Tsuge M. Influence of the rs738409 polymorphism in patatin-like phospholipase 3 on the treatment efficacy of non-alcoholic fatty liver disease with type 2 diabetes mellitus. Hepatol Res. 2016;46:E146-E153. [PMID: 26147768 DOI: 10.1111/hepr.12552] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
439 Zhou YJ, Li YY, Nie YQ, Huang CM, Cao CY. Natural course of nonalcoholic fatty liver disease in southern China: a prospective cohort study. J Dig Dis. 2012;13:153-160. [PMID: 22356310 DOI: 10.1111/j.1751-2980.2011.00571.x] [Cited by in Crossref: 48] [Cited by in F6Publishing: 49] [Article Influence: 5.3] [Reference Citation Analysis]
440 Roerecke M, Nanau R, Rehm J, Neuman M. Ethnicity matters: A Systematic Review and Meta-Analysis of the Non-Linear Relationship Between Alcohol Consumption and Prevalence and Incidence of Hepatic Steatosis. EBioMedicine. 2016;8:317-330. [PMID: 27428441 DOI: 10.1016/j.ebiom.2016.04.023] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
441 Hamaguchi M, Kojima T, Ohbora A, Takeda N, Fukui M, Kato T. Protective effect of alcohol consumption for fatty liver but not metabolic syndrome. World J Gastroenterol. 2012;18:156-167. [PMID: 22253522 DOI: 10.3748/wjg.v18.i2.156] [Cited by in CrossRef: 52] [Cited by in F6Publishing: 47] [Article Influence: 5.8] [Reference Citation Analysis]
442 Musso G, Gambino R, De Michieli F, Biroli G, Premoli A, Pagano G, Bo S, Durazzo M, Cassader M. Nitrosative stress predicts the presence and severity of nonalcoholic fatty liver at different stages of the development of insulin resistance and metabolic syndrome: possible role of vitamin A intake. The American Journal of Clinical Nutrition 2007;86:661-71. [DOI: 10.1093/ajcn/86.3.661] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 2.7] [Reference Citation Analysis]
443 Tobari M, Hashimoto E. Characteristic Features of Nonalcoholic Fatty Liver Disease in Japan with a Focus on the Roles of Age, Sex and Body Mass Index. Gut Liver 2020;14:537-45. [PMID: 31887811 DOI: 10.5009/gnl19236] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 13.0] [Reference Citation Analysis]
444 Amanullah I, Khan YH, Anwar I, Gulzar A, Mallhi TH, Raja AA. Effect of vitamin E in non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomised controlled trials. Postgrad Med J 2019;95:601-11. [PMID: 31434683 DOI: 10.1136/postgradmedj-2018-136364] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 13.0] [Reference Citation Analysis]
445 Brunt EM, Wong VW, Nobili V, Day CP, Sookoian S, Maher JJ, Bugianesi E, Sirlin CB, Neuschwander-tetri BA, Rinella ME. Nonalcoholic fatty liver disease. Nat Rev Dis Primers 2015;1. [DOI: 10.1038/nrdp.2015.80] [Cited by in Crossref: 302] [Cited by in F6Publishing: 258] [Article Influence: 50.3] [Reference Citation Analysis]
446 Barros RK, Cotrim HP, Daltro C, Alves E, de Freitas LA, Daltro C, Oliveira Y. Nonalcoholic steatohepatitis in morbid obese patients: coffee consumption vs. disease severity. Ann Hepatol 2016;15:350-5. [PMID: 27049488 DOI: 10.5604/16652681.1198804] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
447 Niriella MA, Pathmeswaran A, De Silva ST, Kasturiratna A, Perera R, Subasinghe CE, Kodisinghe K, Piyaratna C, Rishikesawan V, Dassanayaka AS, De Silva AP, Wickramasinghe R, Takeuchi F, Kato N, de Silva HJ. Incidence and risk factors for non-alcoholic fatty liver disease: A 7-year follow-up study among urban, adult Sri Lankans. Liver Int 2017;37:1715-22. [PMID: 28544258 DOI: 10.1111/liv.13478] [Cited by in Crossref: 19] [Cited by in F6Publishing: 11] [Article Influence: 4.8] [Reference Citation Analysis]
448 Okamura T, Hashimoto Y, Hamaguchi M, Obora A, Kojima T, Fukui M. Triglyceride-glucose index is a predictor of incident chronic kidney disease: a population-based longitudinal study. Clin Exp Nephrol 2019;23:948-55. [PMID: 30955189 DOI: 10.1007/s10157-019-01729-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
449 Das K, Das K, Mukherjee PS, Ghosh A, Ghosh S, Mridha AR, Dhibar T, Bhattacharya B, Bhattacharya D, Manna B. Nonobese population in a developing country has a high prevalence of nonalcoholic fatty liver and significant liver disease. Hepatology. 2010;51:1593-1602. [PMID: 20222092 DOI: 10.1002/hep.23567] [Cited by in Crossref: 250] [Cited by in F6Publishing: 215] [Article Influence: 22.7] [Reference Citation Analysis]
450 Wang L, Liu M, Ning D, Zhu H, Shan G, Wang D, Ping B, Yu Y, Yang H, Yan K, Pan H, Gong F. Low Serum ZAG Levels Correlate With Determinants of the Metabolic Syndrome in Chinese Subjects. Front Endocrinol (Lausanne) 2020;11:154. [PMID: 32265843 DOI: 10.3389/fendo.2020.00154] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
451 Sharma DL, Lakhani HV, Klug RL, Snoad B, El-Hamdani R, Shapiro JI, Sodhi K. Investigating Molecular Connections of Non-alcoholic Fatty Liver Disease with Associated Pathological Conditions in West Virginia for Biomarker Analysis. J Clin Cell Immunol 2017;8:523. [PMID: 29177105 DOI: 10.4172/2155-9899.1000523] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
452 Singh P, Goode T, Dean A, Awad SS, Darlington GJ. Elevated interferon gamma signaling contributes to impaired regeneration in the aged liver. J Gerontol A Biol Sci Med Sci. 2011;66:944-956. [PMID: 21719609 DOI: 10.1093/gerona/glr094] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
453 Yoshimura Y, Hamaguchi M, Hashimoto Y, Okamura T, Nakanishi N, Obora A, Kojima T, Fukui M. Obesity and metabolic abnormalities as risks of alcoholic fatty liver in men: NAGALA study. BMC Gastroenterol 2021;21:321. [PMID: 34372774 DOI: 10.1186/s12876-021-01893-4] [Reference Citation Analysis]
454 Tomita K, Teratani T, Yokoyama H, Suzuki T, Irie R, Ebinuma H, Saito H, Hokari R, Miura S, Hibi T. Plasma Free Myristic Acid Proportion Is a Predictor of Nonalcoholic Steatohepatitis. Dig Dis Sci 2011;56:3045-52. [DOI: 10.1007/s10620-011-1712-0] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.2] [Reference Citation Analysis]
455 Osaka T, Hashimoto Y, Hamaguchi M, Kojima T, Obora A, Fukui M. Nonalcoholic fatty liver disease remission in men through regular exercise. J Clin Biochem Nutr 2018;62:242-6. [PMID: 29892163 DOI: 10.3164/jcbn.17-115] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
456 Kimura T, Hashimoto Y, Tanaka M, Asano M, Yamazaki M, Oda Y, Toda H, Marunaka Y, Nakamura N, Fukui M. Sodium-chloride Difference and Metabolic Syndrome: A Population-based Large-scale Cohort Study. Intern Med 2016;55:3085-90. [PMID: 27803399 DOI: 10.2169/internalmedicine.55.7000] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 2.6] [Reference Citation Analysis]
457 Moriya A, Iwasaki Y, Ohguchi S, Kayashima E, Mitsumune T, Ikeda F, Ando M, Yamamoto K. Roles of alcohol drinking pattern in fatty liver in Japanese women. Hepatol Int 2013;7:859-68. [PMID: 26201923 DOI: 10.1007/s12072-013-9449-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
458 Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ. The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012;55:2005-23. [DOI: 10.1002/hep.25762] [Cited by in Crossref: 2057] [Cited by in F6Publishing: 1754] [Article Influence: 228.6] [Reference Citation Analysis]
459 Batallés SM, Villavicencio RL, Quaranta A, Burgos L, Trezzo S, Staffieri R, Pezzotto SM. [Variations of the hepatic SUV in relation to the body mass index in whole body PET-CT studies]. Rev Esp Med Nucl Imagen Mol 2013;32:26-32. [PMID: 23177341 DOI: 10.1016/j.remn.2012.02.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.1] [Reference Citation Analysis]
460 Utzschneider KM, Kahn SE. The Role of Insulin Resistance in Nonalcoholic Fatty Liver Disease. The Journal of Clinical Endocrinology & Metabolism 2006;91:4753-61. [DOI: 10.1210/jc.2006-0587] [Cited by in Crossref: 476] [Cited by in F6Publishing: 420] [Article Influence: 31.7] [Reference Citation Analysis]
461 Lautamäki R, Borra R, Iozzo P, Komu M, Lehtimäki T, Salmi M, Jalkanen S, Airaksinen KEJ, Knuuti J, Parkkola R, Nuutila P. Liver steatosis coexists with myocardial insulin resistance and coronary dysfunction in patients with type 2 diabetes. American Journal of Physiology-Endocrinology and Metabolism 2006;291:E282-90. [DOI: 10.1152/ajpendo.00604.2005] [Cited by in Crossref: 103] [Cited by in F6Publishing: 98] [Article Influence: 6.9] [Reference Citation Analysis]
462 Higashiura Y, Furuhashi M, Tanaka M, Takahashi S, Mori K, Miyamori D, Koyama M, Ohnishi H, Moniwa N, Numata K, Hisasue T, Hanawa N, Miura T. Elevated Fatty Liver Index Is Independently Associated With New Onset of Hypertension During a 10-Year Period in Both Male and Female Subjects. J Am Heart Assoc 2021;10:e021430. [PMID: 34259033 DOI: 10.1161/JAHA.121.021430] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
463 Sinn DH, Gwak GY, Park HN, Kim JE, Min YW, Kim KM, Kim YJ, Choi MS, Lee JH, Koh KC. Ultrasonographically detected non-alcoholic fatty liver disease is an independent predictor for identifying patients with insulin resistance in non-obese, non-diabetic middle-aged Asian adults. Am J Gastroenterol. 2012;107:561-567. [PMID: 22108448 DOI: 10.1038/ajg.2011.400] [Cited by in Crossref: 73] [Cited by in F6Publishing: 68] [Article Influence: 7.3] [Reference Citation Analysis]
464 Kogiso T, Moriyoshi Y, Nagahara H. Clinical significance of fatty liver associated with metabolic syndrome. Hepatology Research 2007;37:711-21. [DOI: 10.1111/j.1872-034x.2007.00116.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
465 Hsu CS, Kao JH. An update on non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in Asia. Expert Rev Gastroenterol Hepatol 2017;11:759-72. [PMID: 28613087 DOI: 10.1080/17474124.2017.1342535] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
466 Gwon SY, Ahn JY, Chung CH, Moon B, Ha TY. Lithospermum erythrorhizon suppresses high-fat diet-induced obesity, and acetylshikonin, a main compound of Lithospermum erythrorhizon, inhibits adipocyte differentiation. J Agric Food Chem 2012;60:9089-96. [PMID: 22900585 DOI: 10.1021/jf3017404] [Cited by in Crossref: 29] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
467 Matsushita K, Hamaguchi M, Hashimoto M, Yamazaki M, Yamazaki T, Asai K, Yamori M, Bessho K, Toda H, Hasegawa G, Nakamura N, Fukui M. The novel association between red complex of oral microbe and body mass index in healthy Japanese: a population based cross-sectional study. J Clin Biochem Nutr 2015;57:135-9. [PMID: 26388671 DOI: 10.3164/jcbn.15-19] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
468 Miyake T, Kumagi T, Hirooka M, Koizumi M, Furukawa S, Ueda T, Tokumoto Y, Ikeda Y, Abe M, Kitai K. Metabolic markers and ALT cutoff level for diagnosing nonalcoholic fatty liver disease: a community-based cross-sectional study. J Gastroenterol. 2012;47:696-703. [PMID: 22331365 DOI: 10.1007/s00535-012-0534-y] [Cited by in Crossref: 36] [Cited by in F6Publishing: 25] [Article Influence: 4.0] [Reference Citation Analysis]
469 Buday B, Pach PF, Literati-Nagy B, Vitai M, Kovacs G, Vecsei Z, Koranyi L, Lengyel C. Sex influenced association of directly measured insulin sensitivity and serum transaminase levels: Why alanine aminotransferase only predicts cardiovascular risk in men? Cardiovasc Diabetol 2015;14:55. [PMID: 25986611 DOI: 10.1186/s12933-015-0222-3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
470 Wainwright P, Byrne CD. Bidirectional Relationships and Disconnects between NAFLD and Features of the Metabolic Syndrome. Int J Mol Sci. 2016;17:367. [PMID: 26978356 DOI: 10.3390/ijms17030367] [Cited by in Crossref: 57] [Cited by in F6Publishing: 47] [Article Influence: 11.4] [Reference Citation Analysis]
471 Fujikawa Y, Tominaga K, Fujii H, Machida H, Okazaki H, Yamagami H, Tanigawa T, Watanabe K, Watanabe T, Fujiwara Y, Matsuura T, Kawada N, Arakawa T. High prevalence of gastroesophageal reflux symptoms in patients with non-alcoholic fatty liver disease associated with serum levels of triglyceride and cholesterol but not simple visceral obesity. Digestion 2012;86:228-37. [PMID: 22964626 DOI: 10.1159/000341418] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
472 Carmina E. Need for liver evaluation in polycystic ovary syndrome. J Hepatol. 2007;47:313-315. [PMID: 17624467 DOI: 10.1016/j.jhep.2007.06.009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
473 Ertelt A, Barton AK, Schmitz RR, Gehlen H. Metabolic syndrome: is equine disease comparable to what we know in humans? Endocr Connect 2014;3:R81-93. [PMID: 24894908 DOI: 10.1530/EC-14-0038] [Cited by in Crossref: 25] [Cited by in F6Publishing: 7] [Article Influence: 3.6] [Reference Citation Analysis]
474 Tanaka M, Okada H, Hashimoto Y, Kumagai M, Nishimura H, Oda Y, Fukui M. Relationship between nonalcoholic fatty liver disease and muscle quality as well as quantity evaluated by computed tomography. Liver Int 2019;40:120-30. [DOI: 10.1111/liv.14253] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
475 Rhee E, Lee W, Cho Y, Kim B, Sung K. Hyperinsulinemia and the Development of Nonalcoholic Fatty Liver Disease in Nondiabetic Adults. The American Journal of Medicine 2011;124:69-76. [DOI: 10.1016/j.amjmed.2010.08.012] [Cited by in Crossref: 38] [Cited by in F6Publishing: 25] [Article Influence: 3.8] [Reference Citation Analysis]
476 Hashimoto E, Tokushige K, Ludwig J. Diagnosis and classification of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: Current concepts and remaining challenges. Hepatol Res. 2015;45:20-28. [PMID: 24661406 DOI: 10.1111/hepr.12333] [Cited by in Crossref: 57] [Cited by in F6Publishing: 42] [Article Influence: 8.1] [Reference Citation Analysis]
477 Inoue MK, Nakatsu Y, Yamamotoya T, Hasei S, Kanamoto M, Naitou M, Matsunaga Y, Sakoda H, Fujishiro M, Ono H, Kushiyama A, Asano T. Pin1 Plays Essential Roles in NASH Development by Modulating Multiple Target Proteins. Cells 2019;8:E1545. [PMID: 31795496 DOI: 10.3390/cells8121545] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
478 Manne V, Saab S. Impact of Nutrition and Obesity on Chronic Liver Disease. Clinics in Liver Disease 2014;18:205-18. [DOI: 10.1016/j.cld.2013.09.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
479 Yatsuji S, Hashimoto E, Tobari M, Tokushige K, Shiratori K. Influence of age and gender in Japanese patients with non-alcoholic steatohepatitis. Hepatol Res. 2007;37:1034-1043. [PMID: 17610504 DOI: 10.1111/j.1872-034x.2007.00156.x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 19] [Article Influence: 3.1] [Reference Citation Analysis]
480 Auberval N, Dal S, Maillard E, Bietiger W, Peronet C, Pinget M, Schini-Kerth V, Sigrist S. Beneficial effects of a red wine polyphenol extract on high-fat diet-induced metabolic syndrome in rats. Eur J Nutr 2017;56:1467-75. [PMID: 26913853 DOI: 10.1007/s00394-016-1192-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
481 Ratziu V, Voiculescu M, Poynard T. Touching some firm ground in the epidemiology of NASH. J Hepatol. 2012;56:23-25. [PMID: 21875499 DOI: 10.1016/j.jhep.2011.08.002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
482 Bedogni G, Miglioli L, Masutti F, Castiglione A, Crocè LS, Tiribelli C, Bellentani S. Incidence and natural course of fatty liver in the general population: The Dionysos study. Hepatology 2007;46:1387-91. [DOI: 10.1002/hep.21827] [Cited by in Crossref: 146] [Cited by in F6Publishing: 125] [Article Influence: 10.4] [Reference Citation Analysis]
483 Ahn J, Lee H, Jang J, Kim S, Ha T. Anti-obesity effects of glabridin-rich supercritical carbon dioxide extract of licorice in high-fat-fed obese mice. Food and Chemical Toxicology 2013;51:439-45. [DOI: 10.1016/j.fct.2012.08.048] [Cited by in Crossref: 44] [Cited by in F6Publishing: 30] [Article Influence: 5.5] [Reference Citation Analysis]
484 Fukuda T, Hamaguchi M, Kojima T, Hashimoto Y, Ohbora A, Kato T, Nakamura N, Fukui M. The impact of non-alcoholic fatty liver disease on incident type 2 diabetes mellitus in non-overweight individuals. Liver Int 2016;36:275-83. [DOI: 10.1111/liv.12912] [Cited by in Crossref: 76] [Cited by in F6Publishing: 66] [Article Influence: 12.7] [Reference Citation Analysis]
485 Kogiso T, Moriyoshi Y, Shimizu S, Nagahara H, Shiratori K. High-sensitivity C-reactive protein as a serum predictor of nonalcoholic fatty liver disease based on the Akaike Information Criterion scoring system in the general Japanese population. J Gastroenterol. 2009;44:313-321. [PMID: 19271113 DOI: 10.1007/s00535-009-0002-5] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 2.1] [Reference Citation Analysis]
486 Banerjee A, Das D, Paul R, Roy S, Bhattacharjee A, Prasad SK, Banerjee O, Mukherjee S, Maji BK. Altered composition of high-lipid diet may generate reactive oxygen species by disturbing the balance of antioxidant and free radicals. J Basic Clin Physiol Pharmacol 2020;31:/j/jbcpp. [PMID: 32229664 DOI: 10.1515/jbcpp-2019-0141] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
487 Lee JI, Kim MC, Moon BS, Song YS, Han EN, Lee HS, Son Y, Kim J, Han EJ, Park HJ, Park SE, Park CY, Lee WY, Oh KW, Park SW, Rhee EJ. The Relationship between 10-Year Cardiovascular Risk Calculated Using the Pooled Cohort Equation and the Severity of Non-Alcoholic Fatty Liver Disease. Endocrinol Metab (Seoul) 2016;31:86-92. [PMID: 26754585 DOI: 10.3803/EnM.2016.31.1.86] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 3.2] [Reference Citation Analysis]
488 Federico A, Dallio M, Godos J, Loguercio C, Salomone F. Targeting gut-liver axis for the treatment of nonalcoholic steatohepatitis: translational and clinical evidence. Transl Res. 2016;167:116-124. [PMID: 26318867 DOI: 10.1016/j.trsl.2015.08.002] [Cited by in Crossref: 48] [Cited by in F6Publishing: 44] [Article Influence: 8.0] [Reference Citation Analysis]
489 Min YW, Yun HS, Chang WI, Kim JY, Kim YH, Son HJ, Kim JJ, Rhee JC, Chang DK. Influence of non-alcoholic fatty liver disease on the prognosis in patients with colorectal cancer. Clin Res Hepatol Gastroenterol 2012;36:78-83. [PMID: 22133576 DOI: 10.1016/j.clinre.2011.10.006] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
490 Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, George J, Bugianesi E. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15:11-20. [PMID: 28930295 DOI: 10.1038/nrgastro.2017.109] [Cited by in Crossref: 1421] [Cited by in F6Publishing: 1157] [Article Influence: 355.3] [Reference Citation Analysis]
491 Cook PA, Morleo M, Billington D, Sanderson-Shortt K, Jones C, Gabbay M, Sheron N, Bellis MA, Phillips-Howard PA, Gilmore IT. Evaluation of work-based screening for early signs of alcohol-related liver disease in hazardous and harmful drinkers: the PrevAIL study. BMC Public Health 2015;15:532. [PMID: 26041363 DOI: 10.1186/s12889-015-1860-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
492 Ganzetti G, Campanati A, Offidani A. Non-alcoholic fatty liver disease and psoriasis: So far, so near. World J Hepatol. 2015;7:315-326. [PMID: 25848461 DOI: 10.4254/wjh.v7.i3.315] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 4.8] [Reference Citation Analysis]
493 Nishioji K, Sumida Y, Kamaguchi M, Mochizuki N, Kobayashi M, Nishimura T, Yamaguchi K, Itoh Y. Prevalence of and risk factors for non-alcoholic fatty liver disease in a non-obese Japanese population, 2011-2012. J Gastroenterol. 2015;50:95-108. [PMID: 24619537 DOI: 10.1007/s00535-014-0948-9] [Cited by in Crossref: 79] [Cited by in F6Publishing: 66] [Article Influence: 11.3] [Reference Citation Analysis]
494 Davaatseren M, Hur HJ, Yang HJ, Hwang JT, Park JH, Kim HJ, Kim MJ, Kwon DY, Sung MJ. Taraxacum official (dandelion) leaf extract alleviates high-fat diet-induced nonalcoholic fatty liver. Food Chem Toxicol 2013;58:30-6. [PMID: 23603008 DOI: 10.1016/j.fct.2013.04.023] [Cited by in Crossref: 50] [Cited by in F6Publishing: 36] [Article Influence: 6.3] [Reference Citation Analysis]
495 Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011;34:274-285. [PMID: 21623852 DOI: 10.1111/j.1365-2036.2011.04724.x] [Cited by in Crossref: 1806] [Cited by in F6Publishing: 1565] [Article Influence: 180.6] [Reference Citation Analysis]
496 Perlemuter G, Bigorgne A, Cassard-Doulcier AM, Naveau S. Nonalcoholic fatty liver disease: from pathogenesis to patient care. Nat Clin Pract Endocrinol Metab 2007;3:458-69. [PMID: 17515890 DOI: 10.1038/ncpendmet0505] [Cited by in Crossref: 72] [Cited by in F6Publishing: 61] [Article Influence: 5.1] [Reference Citation Analysis]
497 Pluimakers VG, van Waas M, Neggers SJCMM, van den Heuvel-Eibrink MM. Metabolic syndrome as cardiovascular risk factor in childhood cancer survivors. Crit Rev Oncol Hematol 2019;133:129-41. [PMID: 30661649 DOI: 10.1016/j.critrevonc.2018.10.010] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 5.3] [Reference Citation Analysis]
498 Liang H, Wang Y. Berberine alleviates hepatic lipid accumulation by increasing ABCA1 through the protein kinase C δ pathway. Biochemical and Biophysical Research Communications 2018;498:473-80. [DOI: 10.1016/j.bbrc.2018.03.003] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 5.7] [Reference Citation Analysis]
499 Mazza A, Fruci B, Garinis GA, Giuliano S, Malaguarnera R, Belfiore A. The role of metformin in the management of NAFLD. Exp Diabetes Res. 2012;2012:716404. [PMID: 22194737 DOI: 10.1155/2012/716404] [Cited by in Crossref: 98] [Cited by in F6Publishing: 93] [Article Influence: 9.8] [Reference Citation Analysis]
500 Mahmud MH, Nordin AJ, Ahmad Saad FF, Azman AZ. Impacts of biological and procedural factors on semiquantification uptake value of liver in fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography imaging. Quant Imaging Med Surg 2015;5:700-7. [PMID: 26682140 DOI: 10.3978/j.issn.2223-4292.2015.05.02] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
501 Colak Y, Tuncer I, Senates E, Ozturk O, Doganay L, Yilmaz Y. Nonalcoholic Fatty Liver Disease: A Nutritional Approach. Metabolic Syndrome and Related Disorders 2012;10:161-6. [DOI: 10.1089/met.2011.0145] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
502 Okamura T, Hashimoto Y, Hamaguchi M, Obora A, Kojima T, Fukui M. Ectopic fat obesity presents the greatest risk for incident type 2 diabetes: a population-based longitudinal study. Int J Obes (Lond) 2019;43:139-48. [PMID: 29717276 DOI: 10.1038/s41366-018-0076-3] [Cited by in Crossref: 50] [Cited by in F6Publishing: 37] [Article Influence: 16.7] [Reference Citation Analysis]
503 Hajifathalian K, Mehta A, Ang B, Skaf D, Shah SL, Saumoy M, Dawod Q, Dawod E, Shukla A, Aronne L, Brown RS, Cohen DE, Dannenberg AJ, Fortune B, Kumar S, Sharaiha RZ. Improvement in insulin resistance and estimated hepatic steatosis and fibrosis after endoscopic sleeve gastroplasty. Gastrointest Endosc 2021;93:1110-8. [PMID: 32861753 DOI: 10.1016/j.gie.2020.08.023] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
504 Lee J, Yoon K, Ryu S, Chang Y, Kim HR. High-normal levels of hs-CRP predict the development of non-alcoholic fatty liver in healthy men. PLoS One 2017;12:e0172666. [PMID: 28234943 DOI: 10.1371/journal.pone.0172666] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 5.5] [Reference Citation Analysis]
505 Rector RS, Thyfault JP, Wei Y, Ibdah JA. Non-alcoholic fatty liver disease and the metabolic syndrome: an update. World J Gastroenterol. 2008;14:185-192. [PMID: 18186553 DOI: 10.3748/wjg.14.185] [Cited by in CrossRef: 197] [Cited by in F6Publishing: 181] [Article Influence: 15.2] [Reference Citation Analysis]
506 Kim M, Huda MN, O'Connor A, Albright J, Durbin-Johnson B, Bennett BJ. Hepatic transcriptional profile reveals the role of diet and genetic backgrounds on metabolic traits in female progenitor strains of the Collaborative Cross. Physiol Genomics 2021;53:173-92. [PMID: 33818129 DOI: 10.1152/physiolgenomics.00140.2020] [Reference Citation Analysis]
507 Sowers JR. The Cardiometabolic Syndrome and Liver Disease. J CardioMetab Syndrome 2008;3:5-6. [DOI: 10.1111/j.1559-4572.2008.08248.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
508 Hashimoto Y, Hamaguchi M, Fukuda T, Nakamura N, Ohbora A, Kojima T, Fukui M. BMI history and risk of incident fatty liver: a population-based large-scale cohort study. Eur J Gastroenterol Hepatol. 2016;28:1188-1193. [PMID: 27347789 DOI: 10.1097/meg.0000000000000682] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 3.8] [Reference Citation Analysis]
509 Shin W, Jung D, Shim J, Lee H. The association between non-alcoholic hepatic steatosis and mean platelet volume in an obese Korean population. Platelets 2011;22:442-6. [DOI: 10.3109/09537104.2010.540049] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 2.2] [Reference Citation Analysis]
510 Lee M, Kowdley KV. Alcohol's effect on other chronic liver diseases. Clin Liver Dis 2012;16:827-37. [PMID: 23101984 DOI: 10.1016/j.cld.2012.08.010] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
511 Wáng YXJ, Deng M, Lin J, Kwok AWL, Liu EKW, Chen W. Age- and Gender-Associated Liver Physiological T1rho Dynamics Demonstrated with a Clinically Applicable Single-Breathhold Acquisition. SLAS Technol 2018;23:179-87. [PMID: 29241024 DOI: 10.1177/2472630317747198] [Cited by in Crossref: 1] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
512 Macut D, Božić-Antić I, Bjekić-Macut J, Tziomalos K. MANAGEMENT OF ENDOCRINE DISEASE: Polycystic ovary syndrome and nonalcoholic fatty liver disease. Eur J Endocrinol 2017;177:R145-58. [PMID: 28694246 DOI: 10.1530/EJE-16-1063] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
513 Morris-Stiff G, Feldstein AE. Fibroblast growth factor 21 as a biomarker for NAFLD: integrating pathobiology into clinical practice. J Hepatol 2010;53:795-6. [PMID: 20800308 DOI: 10.1016/j.jhep.2010.07.003] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
514 Chen MJ, Ho HN. Hepatic manifestations of women with polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol 2016;37:119-28. [PMID: 27107966 DOI: 10.1016/j.bpobgyn.2016.03.003] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
515 Chang Y, Ryu S, Sung E, Jang Y. Higher concentrations of alanine aminotransferase within the reference interval predict nonalcoholic fatty liver disease. Clin Chem. 2007;53:686-692. [PMID: 17272484 DOI: 10.1373/clinchem.2006.081257] [Cited by in Crossref: 147] [Cited by in F6Publishing: 125] [Article Influence: 10.5] [Reference Citation Analysis]
516 Wang S, Zhang C, Zhang G, Yuan Z, Liu Y, Ding L, Sun X, Jia H, Xue F. Association between white blood cell count and non-alcoholic fatty liver disease in urban Han Chinese: a prospective cohort study. BMJ Open 2016;6:e010342. [PMID: 27251683 DOI: 10.1136/bmjopen-2015-010342] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 3.4] [Reference Citation Analysis]
517 Okamura T, Hashimoto Y, Hamaguchi M, Obora A, Kojima T, Fukui M. Triglyceride-glucose index (TyG index) is a predictor of incident colorectal cancer: a population-based longitudinal study. BMC Endocr Disord 2020;20:113. [PMID: 32709256 DOI: 10.1186/s12902-020-00581-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
518 Kinoshita M, Kubo S, Tanaka S, Takemura S, Nishioka T, Hamano G, Ito T, Tanaka S, Ohsawa M, Shibata T. The association between non-alcoholic steatohepatitis and intrahepatic cholangiocarcinoma: A hospital based case-control study: NASH and Intrahepatic Cholangiocarcinoma. J Surg Oncol 2016;113:779-83. [DOI: 10.1002/jso.24223] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 4.4] [Reference Citation Analysis]
519 Kohsari M, Moradinazar M, Rahimi Z, Pasdar Y, Shakiba E. Liver Enzymes and Their Association with Some Cardiometabolic Diseases: Evidence from a Large Kurdish Cohort. Biomed Res Int 2021;2021:5584452. [PMID: 34235221 DOI: 10.1155/2021/5584452] [Reference Citation Analysis]
520 Musso G, Cassader M, Bo S, De Michieli F, Gambino R. Sterol regulatory element-binding factor 2 (SREBF-2) predicts 7-year NAFLD incidence and severity of liver disease and lipoprotein and glucose dysmetabolism. Diabetes 2013;62:1109-20. [PMID: 23274901 DOI: 10.2337/db12-0858] [Cited by in Crossref: 44] [Cited by in F6Publishing: 42] [Article Influence: 4.9] [Reference Citation Analysis]
521 Zelber-Sagi S, Ratziu V, Oren R. Nutrition and physical activity in NAFLD: an overview of the epidemiological evidence. World J Gastroenterol. 2011;17:3377-3389. [PMID: 21876630 DOI: 10.3748/wjg.v17.i29.3377] [Cited by in CrossRef: 152] [Cited by in F6Publishing: 133] [Article Influence: 15.2] [Reference Citation Analysis]
522 Bhala N, George J. The Burden of Non-alcoholic Fatty Liver Disease (NAFLD) in the Asia Pacific Region. Curr Hepatology Rep 2015;14:77-86. [DOI: 10.1007/s11901-015-0264-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
523 Aliyari Ghasabeh M, Shaghaghi M, Khoshpouri P, pan L, Pandy A, Pandy P, Zhong X, Kannengiesser S, Kamel IR. Correlation between incidental fat deposition in the liver and pancreas in asymptomatic individuals. Abdom Radiol 2020;45:203-10. [DOI: 10.1007/s00261-019-02206-w] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
524 Singh AK, Kari JA. Metabolic syndrome and chronic kidney disease. Curr Opin Nephrol Hypertens 2013;22:198-203. [PMID: 23340215 DOI: 10.1097/MNH.0b013e32835dda78] [Cited by in Crossref: 68] [Cited by in F6Publishing: 34] [Article Influence: 8.5] [Reference Citation Analysis]
525 Kim KY, Park KI, Lee SG, Baek SY, Lee EH, Kim SC, Kim SH, Park SG, Yu SN, Oh TW, Kim JH, Kim KJ, Ahn SC, Kim YW. Deoxypodophyllotoxin in Anthriscus sylvestris alleviates fat accumulation in the liver via AMP-activated protein kinase, impeding SREBP-1c signal. Chem Biol Interact 2018;294:151-7. [PMID: 30148990 DOI: 10.1016/j.cbi.2018.08.025] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
526 Porter SA, Pedley A, Massaro JM, Vasan RS, Hoffmann U, Fox CS. Aminotransferase levels are associated with cardiometabolic risk above and beyond visceral fat and insulin resistance: the Framingham Heart Study. Arterioscler Thromb Vasc Biol 2013;33:139-46. [PMID: 23162012 DOI: 10.1161/ATVBAHA.112.300075] [Cited by in Crossref: 34] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
527 Kotronen A, Yki-järvinen H. Fatty Liver: A Novel Component of the Metabolic Syndrome. ATVB 2008;28:27-38. [DOI: 10.1161/atvbaha.107.147538] [Cited by in Crossref: 541] [Cited by in F6Publishing: 243] [Article Influence: 41.6] [Reference Citation Analysis]
528 Ferraz-Amaro I, González-Juanatey C, López-Mejias R, Riancho-Zarrabeitia L, González-Gay MA. Metabolic syndrome in rheumatoid arthritis. Mediators Inflamm 2013;2013:710928. [PMID: 23431244 DOI: 10.1155/2013/710928] [Cited by in Crossref: 49] [Cited by in F6Publishing: 40] [Article Influence: 6.1] [Reference Citation Analysis]
529 Xu C, Yu C, Xu L, Miao M, Li Y. High serum uric acid increases the risk for nonalcoholic Fatty liver disease: a prospective observational study. PLoS One. 2010;5:e11578. [PMID: 20644649 DOI: 10.1371/journal.pone.0011578] [Cited by in Crossref: 88] [Cited by in F6Publishing: 80] [Article Influence: 8.0] [Reference Citation Analysis]
530 Bazick J, Donithan M, Neuschwander-Tetri BA, Kleiner D, Brunt EM, Wilson L, Doo E, Lavine J, Tonascia J, Loomba R. Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD. Diabetes Care. 2015;38:1347-1355. [PMID: 25887357 DOI: 10.2337/dc14-1239] [Cited by in Crossref: 101] [Cited by in F6Publishing: 76] [Article Influence: 16.8] [Reference Citation Analysis]
531 Xiong J, Zhang H, Wang Y, Wang A, Bian J, Huang H, Zheng Y, Sang X, Xu Y, Lu X, Zhao H. Hepatitis B virus infection and the risk of nonalcoholic fatty liver disease: a meta-analysis. Oncotarget 2017;8:107295-302. [PMID: 29291029 DOI: 10.18632/oncotarget.22364] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
532 Kim HJ, Cho MH, Park JS, Nam JS, Kang ES, Ahn CW, Cha BS, Lee EJ, Lim SK, Kim KR. Visceral fat thickness predicts fatty liver in Koreans with type 2 diabetes mellitus. J Korean Med Sci. 2008;23:256-261. [PMID: 18437009 DOI: 10.3346/jkms.2008.23.2.256] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
533 Sayiner M, Koenig A, Henry L, Younossi ZM. Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in the United States and the Rest of the World. Clin Liver Dis. 2016;20:205-214. [PMID: 27063264 DOI: 10.1016/j.cld.2015.10.001] [Cited by in Crossref: 247] [Cited by in F6Publishing: 205] [Article Influence: 41.2] [Reference Citation Analysis]
534 Moriya A, Iwasaki Y, Ohguchi S, Kayashima E, Mitsumune T, Taniguchi H, Ikeda F, Shiratori Y, Yamamoto K. Alcohol consumption appears to protect against non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2011;33:378-388. [PMID: 21118396 DOI: 10.1111/j.1365-2036.2010.04520.x] [Cited by in Crossref: 67] [Cited by in F6Publishing: 62] [Article Influence: 6.1] [Reference Citation Analysis]
535 Hamaguchi M, Kojima T, Takeda N, Nagata C, Takeda J, Sarui H, Kawahito Y, Yoshida N, Suetsugu A, Kato T, Okuda J, Ida K, Yoshikawa T. Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease. World J Gastroenterol. 2007;13:1579-1584. [PMID: 17461452 DOI: 10.3748/wjg.v13.i10.1579] [Cited by in CrossRef: 337] [Cited by in F6Publishing: 314] [Article Influence: 24.1] [Reference Citation Analysis]
536 Okamoto M, Miyake T, Kitai K, Furukawa S, Yamamoto S, Senba H, Kanzaki S, Deguchi A, Koizumi M, Ishihara T, Miyaoka H, Yoshida O, Hirooka M, Kumagi T, Abe M, Matsuura B, Hiasa Y. Cigarette smoking is a risk factor for the onset of fatty liver disease in nondrinkers: A longitudinal cohort study. PLoS One 2018;13:e0195147. [PMID: 29664906 DOI: 10.1371/journal.pone.0195147] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
537 Kumar PA, Chitra PS, Reddy GB. Metabolic syndrome and associated chronic kidney diseases: nutritional interventions. Rev Endocr Metab Disord 2013;14:273-86. [PMID: 24036690 DOI: 10.1007/s11154-013-9268-2] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
538 Kim NH, Kim JH, Kim YJ, Yoo HJ, Kim HY, Seo JA, Kim NH, Choi KM, Baik SH, Choi DS, Kim SG. Clinical and metabolic factors associated with development and regression of nonalcoholic fatty liver disease in nonobese subjects. Liver Int. 2014;34:604-611. [PMID: 24382309 DOI: 10.1111/liv.12454] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 5.3] [Reference Citation Analysis]
539 Ozhan H, Aydin M, Yazici M, Yazgan O, Basar C, Gungor A, Onder E. Mean platelet volume in patients with non-alcoholic fatty liver disease. Platelets. 2010;21:29-32. [PMID: 19947902 DOI: 10.3109/09537100903391023] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 3.5] [Reference Citation Analysis]
540 Chitapanarux T, Tienboon P, Pojchamarnwiputh S, Leelarungrayub D. Open-labeled pilot study of cysteine-rich whey protein isolate supplementation for nonalcoholic steatohepatitis patients. Journal of Gastroenterology and Hepatology 2009;24:1045-50. [DOI: 10.1111/j.1440-1746.2009.05865.x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 2.3] [Reference Citation Analysis]
541 Salgado Júnior W, Donadelli CADM, dos Santos JS, Nonino CB. Influence of Roux-en-Y Gastric Bypass on the Hepatocellular Function and Bile Flow of Obese Patients Assessed by Scintigraphy with DISIDA. OBES SURG 2016;26:2718-23. [DOI: 10.1007/s11695-016-2176-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
542 Vauthey JN, Pawlik TM, Ribero D, Wu TT, Zorzi D, Hoff PM, Xiong HQ, Eng C, Lauwers GY, Mino-Kenudson M, Risio M, Muratore A, Capussotti L, Curley SA, Abdalla EK. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 2006;24:2065-72. [PMID: 16648507 DOI: 10.1200/JCO.2005.05.3074] [Cited by in Crossref: 932] [Cited by in F6Publishing: 301] [Article Influence: 62.1] [Reference Citation Analysis]
543 Hu X, Huang Y, Bao Z, Wang Y, Shi D, Liu F, Gao Z, Yu X. Prevalence and factors associated with nonalcoholic fatty liver disease in Shanghai work-units. BMC Gastroenterol. 2012;12:123. [PMID: 22978800 DOI: 10.1186/1471-230x-12-123] [Cited by in Crossref: 47] [Cited by in F6Publishing: 26] [Article Influence: 5.2] [Reference Citation Analysis]
544 Tsochatzis EA, Papatheodoridis GV. Is there any progress in the treatment of non-alcoholic fatty liver disease? World J Gastrointest Pharmacol Ther. 2011;2:1-5. [PMID: 21577310 DOI: 10.4292/wjgpt.v2.i1.1] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
545 Crum-Cianflone N, Collins G, Medina S, Asher D, Campin R, Bavaro M, Hale B, Hames C. Prevalence and factors associated with liver test abnormalities among human immunodeficiency virus-infected persons. Clin Gastroenterol Hepatol. 2010;8:183-191. [PMID: 19800985 DOI: 10.1016/j.cgh.2009.09.025] [Cited by in Crossref: 48] [Cited by in F6Publishing: 48] [Article Influence: 4.0] [Reference Citation Analysis]
546 Hamaguchi M, Kojima T, Ohbora A, Takeda N, Fukui M, Kato T. Aging is a risk factor of nonalcoholic fatty liver disease in premenopausal women. World J Gastroenterol. 2012;18:237-243. [PMID: 22294826 DOI: 22294826] [Reference Citation Analysis]
547 Targher G, Arcaro G. Non-alcoholic fatty liver disease and increased risk of cardiovascular disease. Atherosclerosis. 2007;191:235-240. [PMID: 16970951 DOI: 10.1016/j.atherosclerosis.2006.08.021] [Cited by in Crossref: 355] [Cited by in F6Publishing: 304] [Article Influence: 23.7] [Reference Citation Analysis]
548 Wu G, Li H, Fang Q, Zhang J, Zhang M, Zhang L, Wu L, Hou X, Lu J, Bao Y, Jia W. Complementary Role of Fibroblast Growth Factor 21 and Cytokeratin 18 in Monitoring the Different Stages of Nonalcoholic Fatty Liver Disease. Sci Rep 2017;7:5095. [PMID: 28698650 DOI: 10.1038/s41598-017-05257-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
549 Chitturi S, Wong VW, Farrell G. Nonalcoholic fatty liver in Asia: Firmly entrenched and rapidly gaining ground. J Gastroenterol Hepatol. 2011;26 Suppl 1:163-172. [PMID: 21199528 DOI: 10.1111/j.1440-1746.2010.06548.x] [Cited by in Crossref: 110] [Cited by in F6Publishing: 104] [Article Influence: 11.0] [Reference Citation Analysis]
550 Non LR, Escota GV, Powderly WG. HIV and its relationship to insulin resistance and lipid abnormalities. Transl Res 2017;183:41-56. [PMID: 28068521 DOI: 10.1016/j.trsl.2016.12.007] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 5.2] [Reference Citation Analysis]
551 Anty R, Gual P, Huet P, Marchand-brustel YL, Tran A. Les stéatopathies métaboliques : conséquences hépatiques du syndrome métabolique. Gastroentérologie Clinique et Biologique 2007;31:1127-34. [DOI: 10.1016/s0399-8320(07)78350-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
552 Deetman PE, Alkhalaf A, Landman GW, Groenier KH, Kootstra-ros JE, Navis G, Bilo HJ, Kleefstra N, Bakker SJ. Alanine aminotransferase and mortality in patients with type 2 diabetes (ZODIAC-38). Eur J Clin Invest 2015;45:807-14. [DOI: 10.1111/eci.12474] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
553 Entezari MR, Talenezhad N, Mirzavandi F, Rahimpour S, Mozaffari-Khosravi H, Fallahzadeh H, Hosseinzadeh M. Mediterranean dietary pattern and non-alcoholic fatty liver diseases: a case-control study. J Nutr Sci 2021;10:e55. [PMID: 34367629 DOI: 10.1017/jns.2021.43] [Reference Citation Analysis]
554 Dufresne M, Masson JF, Chaurand P. Sodium-Doped Gold-Assisted Laser Desorption Ionization for Enhanced Imaging Mass Spectrometry of Triacylglycerols from Thin Tissue Sections. Anal Chem 2016;88:6018-25. [PMID: 27145160 DOI: 10.1021/acs.analchem.6b01141] [Cited by in Crossref: 47] [Cited by in F6Publishing: 36] [Article Influence: 9.4] [Reference Citation Analysis]
555 Farrell GC, Chitturi S, Lau GK, Sollano JD; Asia-Pacific Working Party on NAFLD. Guidelines for the assessment and management of non-alcoholic fatty liver disease in the Asia-Pacific region: executive summary. J Gastroenterol Hepatol 2007;22:775-7. [PMID: 17565629 DOI: 10.1111/j.1440-1746.2007.05002.x] [Cited by in Crossref: 293] [Cited by in F6Publishing: 275] [Article Influence: 20.9] [Reference Citation Analysis]
556 Pais R, Charlotte F, Fedchuk L, Bedossa P, Lebray P, Poynard T, Ratziu V; LIDO Study Group. A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver. J Hepatol. 2013;59:550-556. [PMID: 23665288 DOI: 10.1016/j.jhep.2013.04.027] [Cited by in Crossref: 277] [Cited by in F6Publishing: 241] [Article Influence: 34.6] [Reference Citation Analysis]
557 Russel SM, Valle V, Spagni G, Hamilton S, Patel T, Abdukadyrov N, Dong Y, Gangemi A. Physiologic Mechanisms of Type II Diabetes Mellitus Remission Following Bariatric Surgery: a Meta-analysis and Clinical Implications. J Gastrointest Surg 2020;24:728-41. [PMID: 31898109 DOI: 10.1007/s11605-019-04508-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
558 Chartampilas E. Imaging of nonalcoholic fatty liver disease and its clinical utility. Hormones (Athens) 2018;17:69-81. [PMID: 29858854 DOI: 10.1007/s42000-018-0012-x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 4.7] [Reference Citation Analysis]
559 Siddiqui MS, Charlton M. Liver Transplantation for Alcoholic and Nonalcoholic Fatty Liver Disease: Pretransplant Selection and Posttransplant Management. Gastroenterology 2016;150:1849-62. [DOI: 10.1053/j.gastro.2016.02.077] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 3.2] [Reference Citation Analysis]
560 Misciagna G, del Pilar Díaz M, Caramia DV, Bonfiglio C, Franco I, Noviello MR, Chiloiro M, Abbrescia DI, Mirizzi A, Tanzi M, Caruso MG, Correale M, Reddavide R, Inguaggiato R, Cisternino AM, Osella AR. Effect of a low glycemic index Mediterranean diet on non-alcoholic fatty liver disease. A randomized controlled clinici trial. J Nutr Health Aging 2017;21:404-12. [DOI: 10.1007/s12603-016-0809-8] [Cited by in Crossref: 53] [Cited by in F6Publishing: 47] [Article Influence: 10.6] [Reference Citation Analysis]
561 Osaka T, Hashimoto Y, Okamura T, Fukuda T, Yamazaki M, Hamaguchi M, Fukui M. Reduction of Fat to Muscle Mass Ratio Is Associated with Improvement of Liver Stiffness in Diabetic Patients with Non-Alcoholic Fatty Liver Disease. J Clin Med 2019;8:E2175. [PMID: 31835362 DOI: 10.3390/jcm8122175] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
562 Salvi P, Ruffini R, Agnoletti D, Magnani E, Pagliarani G, Comandini G, Praticò A, Borghi C, Benetos A, Pazzi P. Increased arterial stiffness in nonalcoholic fatty liver disease: the Cardio-GOOSE study. J Hypertens. 2010;28:1699-1707. [PMID: 20467324 DOI: 10.1097/hjh.0b013e32833a7de6] [Cited by in Crossref: 75] [Cited by in F6Publishing: 27] [Article Influence: 6.8] [Reference Citation Analysis]
563 Lee YJ, Yu JH, Kim W, Kim J. New mechanisms contributing to hepatic steatosis: glucose, insulin, and lipid signaling. Animal Cells and Systems 2014;18:77-82. [DOI: 10.1080/19768354.2014.906502] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
564 Armstrong MJ, Houlihan DD, Bentham L, Shaw JC, Cramb R, Olliff S, Gill PS, Neuberger JM, Lilford RJ, Newsome PN. Presence and severity of non-alcoholic fatty liver disease in a large prospective primary care cohort. J Hepatol 2012;56:234-40. [PMID: 21703178 DOI: 10.1016/j.jhep.2011.03.020] [Cited by in Crossref: 170] [Cited by in F6Publishing: 138] [Article Influence: 17.0] [Reference Citation Analysis]
565 Hajifathalian K, Torabi Sagvand B, McCullough AJ. Effect of Alcohol Consumption on Survival in Nonalcoholic Fatty Liver Disease: A National Prospective Cohort Study. Hepatology 2019;70:511-21. [PMID: 30125379 DOI: 10.1002/hep.30226] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 13.3] [Reference Citation Analysis]
566 Suzuki T, Voeks J, Zakai NA, Jenny NS, Brown TM, Safford MM, LeWinter M, Howard G, Cushman M. Metabolic syndrome, C-reactive protein, and mortality in U.S. Blacks and Whites: the Reasons for Geographic and Racial Differences in Stroke (REGARDS) study. Diabetes Care 2014;37:2284-90. [PMID: 24879838 DOI: 10.2337/dc13-2059] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 3.4] [Reference Citation Analysis]
567 Li Y, Yatsuya H, Yamagishi K, Wakai K, Tamakoshi A, Iso H, Mori M, Sakauchi F, Motohashi Y, Tsuji I, Nakamura Y, Mikami H, Kurosawa M, Hoshiyama Y, Tanabe N, Tamakoshi K, Tokudome S, Suzuki K, Hashimoto S, Kikuchi S, Wada Y, Kawamura T, Watanabe Y, Ozasa K, Miki T, Date C, Sakata K, Kurozawa Y, Yoshimura T, Fujino Y, Shibata A, Okamoto N, Shio H. Body mass index and weight change during adulthood are associated with increased mortality from liver cancer: the JACC Study. J Epidemiol 2013;23:219-26. [PMID: 23604063 DOI: 10.2188/jea.je20120199] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
568 Nishikawa K, Hashimoto M, Itoh Y, Hiroi S, Kusai A, Hirata F, Sakamoto T, Iwaya K. Detection of changes in the structure and distribution map of triacylglycerol in fatty liver model by MALDI-SpiralTOF. FEBS Open Bio 2014;4:179-84. [PMID: 24649399 DOI: 10.1016/j.fob.2014.02.005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
569 Kessoku T, Ogawa Y, Yoneda M, Imajo K, Sumida Y, Eguchi Y, Fujii H, Hyogo H, Ono M, Suzuki Y, Kawaguchi T, Chayama K, Tanaka S, Fujimoto K, Anzai K, Saibara T, Sata M, Itoh Y, Nakajima A, Okanoue T;  Japan Study Group of NAFLD (JSG-NAFLD). Simple scoring system for predicting cirrhosis in nonalcoholic fatty liver disease. World J Gastroenterol. 2014;20:10108-10114. [PMID: 25110437 DOI: 10.3748/wjg.v20.i29.10108] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
570 Pan JJ, Qu HQ, Rentfro A, McCormick JB, Fisher-Hoch SP, Fallon MB. Prevalence of metabolic syndrome and risks of abnormal serum alanine aminotransferase in Hispanics: a population-based study. PLoS One. 2011;6:e21515. [PMID: 21720553 DOI: 10.1371/journal.pone.0021515] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 2.5] [Reference Citation Analysis]
571 Smith GI, Shankaran M, Yoshino M, Schweitzer GG, Chondronikola M, Beals JW, Okunade AL, Patterson BW, Nyangau E, Field T, Sirlin CB, Talukdar S, Hellerstein MK, Klein S. Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease. J Clin Invest 2020;130:1453-60. [PMID: 31805015 DOI: 10.1172/JCI134165] [Cited by in Crossref: 85] [Cited by in F6Publishing: 46] [Article Influence: 85.0] [Reference Citation Analysis]
572 Murayama K, Okada M, Tanaka K, Inadomi C, Yoshioka W, Kubotsu Y, Yada T, Isoda H, Kuwashiro T, Oeda S, Akiyama T, Oza N, Hyogo H, Ono M, Kawaguchi T, Torimura T, Anzai K, Eguchi Y, Takahashi H. Prediction of Nonalcoholic Fatty Liver Disease Using Noninvasive and Non-Imaging Procedures in Japanese Health Checkup Examinees. Diagnostics (Basel) 2021;11:132. [PMID: 33467114 DOI: 10.3390/diagnostics11010132] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
573 Mao J, Liu W, Wang Y. Apolipoprotein A-I expression suppresses COX-2 expression by reducing reactive oxygen species in hepatocytes. Biochemical and Biophysical Research Communications 2014;454:359-63. [DOI: 10.1016/j.bbrc.2014.10.094] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
574 Mahady SE, George J. The future liver of the Asia pacific: fatter and firmer from more fructose and fortune? J Clin Exp Hepatol 2013;3:106-13. [PMID: 25755484 DOI: 10.1016/j.jceh.2012.10.011] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
575 Saida T, Fukushima W, Ohfuji S, Kondo K, Matsunaga I, Hirota Y. Effect modification of body mass index and body fat percentage on fatty liver disease in a Japanese population. J Gastroenterol Hepatol 2014;29:128-36. [PMID: 23980616 DOI: 10.1111/jgh.12377] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
576 Silva MA, Ataide Tda R, Oliveira SL, Sant'ana AE, Cabral Júnior CR, Balwani Mdo C, de Oliveira FG, Santos MC. [Hepatoprotective effect of diheptanoin and tritreptanoin chronic consumption against steatosis in rats]. Arq Bras Endocrinol Metabol 2008;52:1145-55. [PMID: 19082303 DOI: 10.1590/s0004-27302008000700011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
577 Iwase H, Tanaka M, Kobayashi Y, Wada S, Kuwahata M, Kido Y, Hamaguchi M, Asano M, Yamazaki M, Hasegawa G, Nakamura N, Fukui M. Lower vegetable protein intake and higher dietary acid load associated with lower carbohydrate intake are risk factors for metabolic syndrome in patients with type 2 diabetes: Post-hoc analysis of a cross-sectional study. J Diabetes Investig 2015;6:465-72. [PMID: 26221526 DOI: 10.1111/jdi.12326] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
578 Bellentani S, Marino M. Epidemiology and natural history of non-alcoholic fatty liver disease (NAFLD). Ann Hepatol. 2009;8 Suppl 1:S4-S8. [PMID: 19381118 DOI: 10.1016/s1665-2681(19)31820-4] [Cited by in Crossref: 188] [Article Influence: 15.7] [Reference Citation Analysis]
579 Tung TH, Chang TH, Chiu WH, Lin TH, Shih HC, Chang MH, Liu JH. Clinical correlation of nonalcoholic fatty liver disease in a Chinese taxi drivers population in Taiwan: Experience at a teaching hospital. BMC Res Notes 2011;4:315. [PMID: 21878129 DOI: 10.1186/1756-0500-4-315] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
580 Hashimoto Y, Hamaguchi M, Tanaka M, Obora A, Kojima T, Fukui M. Metabolically healthy obesity without fatty liver and risk of incident type 2 diabetes: A meta-analysis of prospective cohort studies. Obes Res Clin Pract. 2018;12:4-15. [PMID: 29307656 DOI: 10.1016/j.orcp.2017.12.003] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
581 Chen CH, Nien CK, Yang CC, Yeh YH. Association between nonalcoholic fatty liver disease and coronary artery calcification. Dig Dis Sci. 2010;55:1752-1760. [PMID: 19688595 DOI: 10.1007/s10620-009-0935-9] [Cited by in Crossref: 65] [Cited by in F6Publishing: 61] [Article Influence: 5.4] [Reference Citation Analysis]
582 Gelb B, Feng S. Management of the liver transplant patient. Expert Rev Gastroenterol Hepatol 2009;3:631-47. [PMID: 19929584 DOI: 10.1586/egh.09.58] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
583 Yi M, Chen RP, Yang R, Chen H. Increased prevalence and risk of non-alcoholic fatty liver disease in overweight and obese patients with Type 2 diabetes in South China. Diabet Med 2017;34:505-13. [PMID: 27334577 DOI: 10.1111/dme.13174] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 3.6] [Reference Citation Analysis]
584 Chao HW, Chao SW, Lin H, Ku HC, Cheng CF. Homeostasis of Glucose and Lipid in Non-Alcoholic Fatty Liver Disease. Int J Mol Sci 2019;20:E298. [PMID: 30642126 DOI: 10.3390/ijms20020298] [Cited by in Crossref: 34] [Cited by in F6Publishing: 26] [Article Influence: 17.0] [Reference Citation Analysis]
585 Phisalprapa P, Supakankunti S, Charatcharoenwitthaya P, Apisarnthanarak P, Charoensak A, Washirasaksiri C, Srivanichakorn W, Chaiyakunapruk N. Cost-effectiveness analysis of ultrasonography screening for nonalcoholic fatty liver disease in metabolic syndrome patients. Medicine (Baltimore) 2017;96:e6585. [PMID: 28445256 DOI: 10.1097/MD.0000000000006585] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 2.8] [Reference Citation Analysis]
586 Regnell SE, Peterson P, Trinh L, Broberg P, Leander P, Lernmark Å, Månsson S, Elding Larsson H. Magnetic resonance imaging reveals altered distribution of hepatic fat in children with type 1 diabetes compared to controls. Metabolism 2015;64:872-8. [PMID: 25982699 DOI: 10.1016/j.metabol.2015.04.002] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 3.5] [Reference Citation Analysis]
587 Imajo K, Kessoku T, Honda Y, Tomeno W, Ogawa Y, Mawatari H, Fujita K, Yoneda M, Taguri M, Hyogo H, Sumida Y, Ono M, Eguchi Y, Inoue T, Yamanaka T, Wada K, Saito S, Nakajima A. Magnetic Resonance Imaging More Accurately Classifies Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease Than Transient Elastography. Gastroenterology 2016; 150: 626-637. e7. [PMID: 26677985 DOI: 10.1053/j.gastro.2015.11.048] [Cited by in Crossref: 360] [Cited by in F6Publishing: 295] [Article Influence: 60.0] [Reference Citation Analysis]
588 Gutierrez-grobe Y, Ponciano-rodríguez G, Ramos MH, Uribe M, Méndez-sánchez N. Prevalence of non alcoholic fatty liver disease in premenopausal, posmenopausal and polycystic ovary syndrome women. The role of estrogens. Annals of Hepatology 2010;9:402-9. [DOI: 10.1016/s1665-2681(19)31616-3] [Cited by in Crossref: 119] [Article Influence: 10.8] [Reference Citation Analysis]
589 Tsunoda K, Kai Y, Uchida K, Kuchiki T, Nagamatsu T. Physical activity and risk of fatty liver in people with different levels of alcohol consumption: a prospective cohort study. BMJ Open 2014;4:e005824. [PMID: 25095878 DOI: 10.1136/bmjopen-2014-005824] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
590 Mccullough AJ. Epidemiology of the metabolic syndrome in the USA: The metabolic syndrome. Journal of Digestive Diseases 2011;12:333-40. [DOI: 10.1111/j.1751-2980.2010.00469.x] [Cited by in Crossref: 87] [Cited by in F6Publishing: 77] [Article Influence: 8.7] [Reference Citation Analysis]
591 Vallet-Pichard A, Parlati L, Pol S. [Epidemiology of non-alcoholic steatohepatitis. Extent/burden of the problem and its impact on public health]. Presse Med 2019;48:1459-67. [PMID: 31757728 DOI: 10.1016/j.lpm.2019.08.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
592 Garinis GA, Fruci B, Mazza A, De Siena M, Abenavoli S, Gulletta E, Ventura V, Greco M, Abenavoli L, Belfiore A. Metformin versus dietary treatment in nonalcoholic hepatic steatosis: a randomized study. Int J Obes 2010;34:1255-64. [DOI: 10.1038/ijo.2010.40] [Cited by in Crossref: 71] [Cited by in F6Publishing: 70] [Article Influence: 6.5] [Reference Citation Analysis]
593 Maurovich-Horvat P, Tárnoki DL, Tárnoki ÁD, Horváth T, Jermendy ÁL, Kolossváry M, Szilveszter B, Voros V, Kovács A, Molnár AÁ, Littvay L, Lamb HJ, Voros S, Jermendy G, Merkely B. Rationale, Design, and Methodological Aspects of the BUDAPEST-GLOBAL Study (Burden of Atherosclerotic Plaques Study in Twins-Genetic Loci and the Burden of Atherosclerotic Lesions). Clin Cardiol 2015;38:699-707. [PMID: 26492817 DOI: 10.1002/clc.22482] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 2.2] [Reference Citation Analysis]
594 Almoznino G, Kessler Baruch O, Kedem R, Protter NE, Shay B, Yavnai N, Zur D, Mijiritsky E, Abramovitz I. SOS Teeth: First Priority Teeth with Advanced Caries and Its Associations with Metabolic Syndrome among a National Representative Sample of Young and Middle-Aged Adults. J Clin Med 2020;9:E3170. [PMID: 33007919 DOI: 10.3390/jcm9103170] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
595 Pereira K, Salsamendi J, Casillas J. The Global Nonalcoholic Fatty Liver Disease Epidemic: What a Radiologist Needs to Know. J Clin Imaging Sci 2015;5:32. [PMID: 26167390 DOI: 10.4103/2156-7514.157860] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
596 Tang JT, Mao YM. Development of new drugs for the treatment of nonalcoholic steatohepatitis. J Dig Dis 2020;21:3-11. [PMID: 31682309 DOI: 10.1111/1751-2980.12830] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
597 Cai X, Zhu Q, Cao Y, Liu S, Wang M, Wu T, Hong J, Ahmat A, Aierken X, Li N. A Prediction Model Based on Noninvasive Indicators to Predict the 8-Year Incidence of Type 2 Diabetes in Patients with Nonalcoholic Fatty Liver Disease: A Population-Based Retrospective Cohort Study. Biomed Res Int 2021;2021:5527460. [PMID: 34095297 DOI: 10.1155/2021/5527460] [Reference Citation Analysis]
598 Speliotes EK, Butler JL, Palmer CD, Voight BF, Hirschhorn JN. PNPLA3 variants specifically confer increased risk for histologic nonalcoholic fatty liver disease but not metabolic disease. Hepatology. 2010;52:904-912. [PMID: 20648472 DOI: 10.1002/hep.23768.] [Reference Citation Analysis]
599 Auberval N, Dal S, Bietiger W, Pinget M, Jeandidier N, Maillard-Pedracini E, Schini-Kerth V, Sigrist S. Metabolic and oxidative stress markers in Wistar rats after 2 months on a high-fat diet. Diabetol Metab Syndr 2014;6:130. [PMID: 25960774 DOI: 10.1186/1758-5996-6-130] [Cited by in Crossref: 27] [Cited by in F6Publishing: 18] [Article Influence: 3.9] [Reference Citation Analysis]
600 Chung GE, Yim JY, Kim D, Kwak M, Yang JI, Chung SJ, Yang SY, Kim JS. Associations between hemoglobin concentrations and the development of incidental metabolic syndrome or nonalcoholic fatty liver disease. Digestive and Liver Disease 2017;49:57-62. [DOI: 10.1016/j.dld.2016.10.004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
601 Vasunta RL, Kesäniemi YA, Ylitalo AS, Ukkola OH. High ambulatory blood pressure values associated with non-alcoholic fatty liver in middle-aged adults. J Hypertens. 2012;30:2015-2019. [PMID: 22940679 DOI: 10.1097/hjh.0b013e3283576faf] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
602 Wei J, Sun X, Chen Y, Li Y, Song L, Zhou Z, Xu B, Lin Y, Xu S. Perinatal exposure to bisphenol A exacerbates nonalcoholic steatohepatitis-like phenotype in male rat offspring fed on a high-fat diet. J Endocrinol. 2014;222:313-325. [PMID: 25112833 DOI: 10.1530/joe-14-0356] [Cited by in Crossref: 61] [Cited by in F6Publishing: 31] [Article Influence: 8.7] [Reference Citation Analysis]
603 Sao R, Aronow WS. Association of non-alcoholic fatty liver disease with cardiovascular disease and subclinical atherosclerosis. Arch Med Sci 2018;14:1233-44. [PMID: 30393477 DOI: 10.5114/aoms.2017.68821] [Cited by in Crossref: 19] [Cited by in F6Publishing: 10] [Article Influence: 4.8] [Reference Citation Analysis]
604 Gentilucci UV, Santini D, Vincenzi B, Fiori E, Picardi A, Tonini G. Chemotherapy-induced steatohepatitis in colorectal cancer patients. J Clin Oncol. 2006;24:5467; author reply 5467-5468. [PMID: 17135651 DOI: 10.1200/jco.2006.08.1828] [Cited by in Crossref: 17] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
605 Long MT, Pedley A, Massaro JM, Hoffmann U, Ma J, Loomba R, Chung RT, Benjamin EJ. A simple clinical model predicts incident hepatic steatosis in a community-based cohort: The Framingham Heart Study. Liver Int 2018;38:1495-503. [PMID: 29377504 DOI: 10.1111/liv.13709] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
606 Ishizuka K, Kon K, Lee-Okada HC, Arai K, Uchiyama A, Yamashina S, Yokomizo T, Ikejima K. Aging exacerbates high-fat diet-induced steatohepatitis through alteration in hepatic lipid metabolism in mice. J Gastroenterol Hepatol 2020;35:1437-48. [PMID: 32030821 DOI: 10.1111/jgh.15006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
607 Okamura K, Okuda T, Takamiya Y, Shirai K, Urata H. High Fib4 index in patients with suspected NASH is associated with elevation of chymase-dependent angiotensin II-forming activity in circulating mononuclear leucocytes. Heart Vessels 2019;34:1559-69. [PMID: 30919112 DOI: 10.1007/s00380-019-01391-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
608 Oh HJ, Kim TH, Sohn YW, Kim YS, Oh YR, Cho EY, Shim SY, Shin SR, Han AL, Yoon SJ. Association of serum alanine aminotransferase and γ-glutamyltransferase levels within the reference range with metabolic syndrome and nonalcoholic fatty liver disease. Korean J Hepatol. 2011;17:27-36. [PMID: 21494075 DOI: 10.3350/kjhep.2011.17.1.27] [Cited by in Crossref: 40] [Cited by in F6Publishing: 32] [Article Influence: 4.0] [Reference Citation Analysis]
609 Newsome P, Francque S, Harrison S, Ratziu V, Van Gaal L, Calanna S, Hansen M, Linder M, Sanyal A. Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity. Aliment Pharmacol Ther 2019;50:193-203. [PMID: 31246368 DOI: 10.1111/apt.15316] [Cited by in Crossref: 40] [Cited by in F6Publishing: 34] [Article Influence: 20.0] [Reference Citation Analysis]
610 Ma D, Liu W, Wang Y. ApoA-I or ABCA1 expression suppresses fatty acid synthesis by reducing 27-hydroxycholesterol levels. Biochimie 2014;103:101-8. [DOI: 10.1016/j.biochi.2014.04.010] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 3.1] [Reference Citation Analysis]
611 Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: A weighty connection. Hepatology 2010;51:1820-32. [DOI: 10.1002/hep.23594] [Cited by in Crossref: 871] [Cited by in F6Publishing: 776] [Article Influence: 79.2] [Reference Citation Analysis]
612 Hashimoto Y, Hamaguchi M, Fukuda T, Ohbora A, Kojima T, Fukui M. Fatty liver as a risk factor for progression from metabolically healthy to metabolically abnormal in non-overweight individuals. Endocrine 2017;57:89-97. [DOI: 10.1007/s12020-017-1313-6] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 7.0] [Reference Citation Analysis]
613 Marcuccilli M, Chonchol M. NAFLD and Chronic Kidney Disease. Int J Mol Sci. 2016;17:562. [PMID: 27089331 DOI: 10.3390/ijms17040562] [Cited by in Crossref: 64] [Cited by in F6Publishing: 49] [Article Influence: 12.8] [Reference Citation Analysis]